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Abstract 
 
 
Vaccinia virus is a 250-300nm enveloped DNA virus from the poxvirus family and is used as a 
vector for oncolytic viral gene therapy. No unique cell surface receptor has been identified for 
Vaccinia virus and the reasons for its tropism for cancer cells are unclear. Pancreatic 
adenocarcinoma (PDAC) is resistant to conventional chemotherapy and typically contains areas 
that are profoundly hypoxic.  
 
We have investigated the utility of Vaccinia virus as a vector for targeting hypoxic regions in 
pancreatic adenocarcinoma, as other viral vectors have been found to replicate poorly in 
hypoxia. We found that cytotoxicity was equivalent in normoxia and hypoxia in some PDAC 
cell lines but in others cytotoxicity was enhanced in hypoxia. This increase in cytotoxicity was 
only seen in cell lines where there was hypoxic induction of vascular endothelial growth factor 
(VEGF). Functional studies using over-expression and knockdown of VEGF in pancreatic 
cancer cell models showed that VEGF can augment viral transgene expression, cytotoxicity and 
replication in vitro and in vivo. We found that VEGF facilitates the internalisation of Vaccinia 
virus. These results show that VEGF is an additional factor involved in the tropism and 
pathogenesis of Vaccinia virus.   
 
We then constructed an oncolytic Vaccinia virus to target hypoxic cancer cells using the HIF-1α 
oxygen degradation domain, encephalomyocarditis virus internal ribosomal entry site and the 
VEGF 3‟ un-translated region to regulate luciferase expression in hypoxia. We have shown a 
dose-, time- and oxygen-dependent effect using this construct and propose this may be adapted 
to regulate therapeutic genes, or produce a conditionally replicating Vaccinia virus, in hypoxic 
conditions. 
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1 Introduction 
1.1 Pancreatic Ductal Adenocarcinoma 
1.1.1 Pancreatic Cancer Incidence & Epidemiology  
Pancreatic ductal adenocarcinoma (PDAC) remains a disease with a dismal prognosis. 
Worldwide it is the 14
th
 most common cancer but the fifth and sixth leading cause of cancer 
death in the USA and UK respectively. In the developed world incidence has risen three-fold 
since the 1920s, stabilising in the late 1970s. PDAC occurs at an incidence of 1.75:1 male to 
female ratio but this gender bias diminishes with increased age of onset. Approximately 30 
percent of cases of PDACs are attributable to smoking. Diet and occupational carcinogens have 
been implicated but findings are not conclusive. Chronic pancreatitis is a known risk factor with 
the chronic inflammatory condition predisposing to malignant transformation(1).  
 
1.1.2 Pathology and Molecular Biology 
PDAC has a well-defined chronology of pathological and molecular changes during disease 
progression (Figure 1.1). Pre invasive lesions consist of pancreatic intra-epithelial neoplasia 
(PanIN) 1-3, after which loss of the integrity of the basement membrane is a sign of invasive 
carcinoma. The K-Ras oncogene is mutated in 95% of sporadic PDACs (2). It is located on 
chromosome 12p13 and mutations results in a constitutively active form which signals via the 
Ras-Raf-MEK pathway. The ErbB family of growth factor receptors have also been shown to be 
over expressed in PDAC, in particular epidermal growth factor receptor (EGFR) family 
members. Signalling via EGFR1 is increased due to greater production of its two ligands 
epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α). This results in 
signalling via the Ras-Raf-MEK signalling pathway (transmitting proliferative signals),
 
the 
PI3K/Akt signalling pathway (mediating cell cycle progression
 
and survival) and the signal 
transducer and activator of transcription (STAT) family of proteins which mediates a variety of 
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features conducive
 
to cancer cell survival progression, including cell division,
 
motility, invasion 
and adhesion (3). Loss of p16 function occurs
 
in 80–95% of PDACs and results in abrogation of 
the pRB/p16 pathway, this means that p16 can no longer inhibit the formation of the cyclin D-
cyclin-dependent kinase4/6 (CDK4/CDK6) complex resulting in cell cycle progression (4).  
 
Later in the development of PDAC, loss of the tumour suppressor genes p53, DPC4 and 
BRCA2 is found (5). Smad4 mediates intercellular signalling for members of the TGFβ family 
of cytokines. There is a loss of heterozygosity of Smad4 in 70% of pancreatic cancers and a 
total loss of protein function in 50%. This mutation affects the tumour microenvironment and 
potentiates tumour invasion (6). Reactivation of the developmental signalling pathway through 
Notch and Hedgehog is found in PDAC and may be involved in a putative pancreatic cancer 
stem cell phenotype (7). In summary, a progression model for pancreatic cancer exists but the 
variety of molecular changes highlight the heterogeneity of PDAC. 
 
 
Figure 1.1: Progression model for pancreatic cancer.  
Normal duct epithelium progresses to infiltrating cancer (left to right) through a series of 
histologically defined precursors. (5) 
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1.1.3 Pancreatic Ductal Adenocarcinoma Management 
In the UK during 2004 there were 7398 new cases and 7238 deaths with outcomes being poor 
regardless of the therapeutic modality (8). Median survival for surgically resected patients is 11-
15 months, 6-10 months for locally advanced disease and 3-5 months for metastatic disease(7).  
 
Surgery remains the only curative therapy although only a minority (10-15%) of patients present 
early enough for resection. A Kausch-Whipple partial pancreatoduodenectomy or a pylorus-
preserving partial pancreatoduodenectomy are considered the standard surgical procedures for 
resectable disease. 
 
For adjuvant therapy of resectable disease, ESPAC-1 was the first study to show benefit for 
chemotherapy in this setting. ESPAC-1 demonstrated a 21% vs. 8% 5 year survival rate when 
patients received 5-florouracil (5-FU) and Leucovorin (LV) as opposed to observation (9). The 
CONKO-001 study showed a similar benefit for gemcitabine chemotherapy in the adjuvant 
setting (10). ESPAC-3 was designed to compare 5-FU/LV with gemcitabine in a head to head 
design. Both drug treatments improved 5 year survival in comparison to historical data, but no 
benefit was seen to favour either agent in the adjuvant setting (11).  The standard of care for 
locally advanced or metastatic disease involves gemcitabine monotherapy, which has shown 
greater efficacy and lower toxicity compared to the previous regime of 5-flourouracil (12). A 
meta-analysis of clinical trials of chemotherapy for advanced pancreatic cancer have shown a 
small but significant survival advantage with combination regimes of gemcitabine with 
capecitabine (an oral 5-FU analogue) or a platinum-based drug over gemcitabine alone (13). A 
phase III randomized trial has recently demonstrated a 7.4 vs. 6.0 month (P=0.026) benefit for 
gemcitabine and capecitabine versus gemcitabine alone (14). Despite this, median survival 
times are still measured in months and consequently trials of biological agents targeting the 
molecular pathways involved in pancreatic cancer continue to be investigated. The EGFR 
inhibitor, erlotinib, was licensed by the Federal Drug Administration (FDA) after showing a 
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6.24 vs. 5.91 month improvement in mean overall survival when given with gemcitabine over 
gemcitabine alone (15). The anti-VEGF monoclonal antibody bevacizumab and the anti-EGFR 
monoclonal antibody cetuximab did not improve median survival in phase III trials of patients 
with metastatic and locally advanced PDAC (16, 17). Given this, there is a great need to 
develop effective systemic therapy, and consequently multiple novel immunotherapy and gene 
therapy strategies are being investigated.    
 
The role of radiotherapy in the management of pancreatic cancer remains controversial. The 
ability to deliver high dose therapy is limited by the proximity of adjacent organs. More targeted 
radiotherapy techniques which allow greater dose delivery and account for organ motion may 
prove to be useful. These include 3D conformal radiotherapy and Intensity-Modulated 
Radiotherapy (IMRT) which improve targeting by using multiple lower energy beams to deliver 
a higher total dose at the point where the beams transect. Proton therapy uses ionised protons 
which, compared to conventional radiation therapy, allow more accurate tumour targeting and 
decreased deposition of energy in the normal tissue through which it passes before reaching the 
tumour. In addition incorporation of organ motion sensing during the breathing cycle into the 
treatment plan should allow delivery of greater radiotherapy doses without increased toxicity. In 
the adjuvant setting, combination chemoradiotherapy (5-FU and ~45Gy) has been widely used 
in some centres (18). Data from the Surveillance Epidemiology and End Results (SEER) 
registry suggest that there is a five-month improvement in overall survival with the addition of 
radiotherapy to treatment (17 month vs. 12 month median survival, P<0.0001) (19). However no 
benefit has been demonstrated in a phase III randomised trial and in the ESPAC-1 trial a 
detrimental effect was seen. Radiotherapy may still be useful in the adjuvant setting if 
combination regimes can be designed or dose delivery improved with advanced external beam 
technologies or radionucleotide strategies. For locally advanced pancreatic cancer, radiotherapy 
is beneficial when given in combination with 5-FU but there are limited data to support the 
addition of radiotherapy to gemcitabine (20). There is currently no role for radiotherapy in the 
metastatic setting except for palliation of symptoms. 
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There is clearly an unmet need in the treatment of PDAC both in the adjuvant and metastatic 
setting and virotherapy has emerged as a novel strategy to treat tumours resistant to 
conventional therapy (21). Vaccinia virus is a promising vector for gene delivery, viral 
oncolysis and cancer vaccines however, tumour hypoxia has been shown to reduce the efficacy 
of conventional therapy (22) and it is important also to investigate its effect on novel therapies. 
 
1.2 Hypoxia and Cancer 
Tissue hypoxia is the result of a mismatch of oxygen supply to cellular demand and can be 
multi-factorial in origin. Reduction in atmospheric oxygen concentration, decreased blood 
oxygen-carrying capacity, impaired perfusion of tissue vasculature and the distance over which 
molecular oxygen must diffuse from vessel to cell all limit the delivery of oxygen. The 
physiology and microenvironment of solid tumours are fundamentally different from normal 
tissue and are more prone to develop hypoxic regions because the disordered growth of tumours 
results in structural and functional distortions in the microcirculation which impairs the delivery 
of oxygen.  
 
Normal tissues can maintain cellular function at a range of pO2 from 10-80mmHg depending on 
the tissue type. In contrast, cancer cells can be exposed to pO2 <10mmHg with moderate 
hypoxia being defined as pO2 ≤1% (~7mmHg), extreme hypoxia as pO2 ≤0.1% and anoxia as the 
absence of molecular oxygen (23). Tumours can be exposed to both chronic and acute hypoxia. 
Chronic hypoxia occurs when tumour cells are beyond the limit of oxygen diffusion (~150µm) 
which results from tumour growth extending beyond that of tumour vasculature, and this is 
defined as diffusion-limited hypoxia. In contrast, fluctuations in tumour blood supply caused by 
transient occlusion by intravascular thrombus, tumour cells or vasoconstriction result in periods 
of acute or perfusion-limited hypoxia. Thomlinson and Gray first described areas of hypoxia in 
histological sections of adenocarcinoma of the lung in 1955 (24). Since this time, areas of 
hypoxia have been found in the majority of solid tumours including malignant brain tumours 
Chapter 1 
 
22 
 
(25), melanomas (26), soft tissue sarcomas (27), prostate cancer (28), cervical cancer (29), 
invasive breast cancer (30), non-small cell lung cancer (NSCLC) (31), PDAC (32) and head and 
neck squamous cell carcinoma (HNSCC) (33). However, these areas are often heterogeneously 
distributed and may be located adjacent to normoxic regions. 
 
1.2.1 Molecular Basis of Oxygen Sensing 
 
The transcription factor hypoxia-inducible factor 1 (HIF-1) is an important regulator of the 
cellular response to hypoxic conditions (34-36). HIF-1 is a heterodimer composed of a α and β 
subunit. HIF-1β is constitutively expressed and not regulated by hypoxia. The transcription and 
translation of the HIF-1α subunit is mainly independent of oxygenation status (37) but 
proteolytic degradation is profoundly affected (38). In addition, the rate of HIF-1α translation is 
responsive to growth factor and oncogenic stimulation (39). The proteolytic regulation of HIF-
1α is controlled via the oxygen-dependent degradation domain (ODD) (Figure 1.2). This region 
of HIF-1α contains two domains which are specifically hydroxylated at prolyl residues Pro402 
and Pro 564. This hydroxylation is achieved via the actions of three prolyl hydroxylase domain 
(PHD) enzymes which require the presence of dioxygen as a substrate for this reaction in 
addition to other cofactors (2-oxoglutarate, iron and ascorbate) (40). This hydroxylation allows 
HIF-1α to bind the von Hippel-Lindau tumour suppressor protein (pVHL) which then functions 
as the substrate recognition component of the ubiquitin E3 ligase complex leading to proteolytic 
degradation of the HIF-1α-pVHL complex (41). In addition an asparaginyl residue, present in an 
N-terminal transactivation domain (TAD) of HIF-1α, is hydroxylated in the presence of 
molecular oxygen by factor inhibiting HIF (FIH). This FIH-dependent asparaginyl 
hydroxylation inhibits interactions with p300 co-activator and limits gene transcription (42). 
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Stabilisation of the HIF-p300/CBP complex leads to transcription of target genes containing 
hypoxia response elements (HRE). HRE sequences are present in the promoter region of some 
genes, and they contain the core sequence 5‟-RCGTG-3‟ along with flanking regions that are 
recognised by HIF-1α and lead to the formation of the transcription complex (43). Consequently 
Figure 1.2: An overview of HIF-1α function and regulation.  
In the presence of oxygen (O2), prolyl hydroxylase (PHD) hydroxylates hypoxia-inducible 
transcription factor (HIF)-1α at the oxygen degradation domain. This allows it to interact with 
the von Hippel–Lindau (VHL) complex and it is this complex that mediates the ubiquitylation 
of HIF-1α . The ubiquitination targets HIF-1α  for proteosomal degradation. In the absence of 
oxygen, prolyl hydroxylase cannot modify HIF-1α, and the protein remains stable. Stabilised 
HIF-1α, with an un-hydroxylated trans-activating domain (TAD) is translocated to the nucleus, 
where it interacts with cofactors including HIF-1β to bind to hypoxia-responsive elements 
(HREs) and activate transcription of target genes 
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this results in the transcription of genes with HREs within their promoters and this cellular 
response to hypoxia causes increased transcription of a number of genes involved in 
proliferation, apoptosis, energy metabolism and pH regulation (22). Gene expression studies of 
the response of both normal, non-transformed cells and cancer cells after exposure to hypoxia 
were published by Chi et al. (44). They defined both a gene signature pattern for the hypoxic 
response common to all cell types, and a distinct gene set which was specific to epithelial cells 
versus mesenchymal cells. Genes induced by hypoxia in an epithelial model included immune 
regulatory genes (HLADRB1, HLADRB3), complement inhibitors (SERPING1), solute 
transporters (MDR1), chemokines (CXCR4), genomic integrity (RAD50, RAD54B) and p53 
target genes (caveolin, EGF-like transforming growth factor). Many of these have been 
implicated in the aetiology of cancer and the resistance to conventional therapy and are 
considered therapeutic targets. The “hypoxic signature” of Chi et al was shown to have 
independent prognostic significance for survival and progression-free survival in breast and 
ovarian cancer. 
 
1.2.2 Hypoxia, Local Invasion and Metastasis of Cancer 
Exposure of tumour cells to hypoxia results in a phenotypic change with increased local 
invasion, perifocal tumour spreading and an increased propensity to disseminate widely. In 
prostate cancer it has been shown to be independently predictive of shortened time to 
biochemical failure, a surrogate marker for disease progression (45). In vitro analysis of the 
LNCap prostate cancer cell line after exposure to hypoxia for 24 hours demonstrated increased 
phosphorylation of Akt/Protein Kinase B and reduced apoptotic potential (46). 
Immunohistochemical analysis of HIF-1α and extrinsic measures of hypoxia such as invasive 
microelectrode studies and the hypoxic marker pimonidazole (which is reduced and retained in 
hypoxic cells) can predict for increased invasion and a poor outcome in uterine cervical cancer 
(29, 47). Human papillomavirus, the causative agent in uterine cervical cancer, has been shown 
to stabilise HIF-1α and result in increased expression of the vascular endothelial growth factor 
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(VEGF) (48, 49). In NSCLC an endogenous marker of hypoxia, Carbonic Anhydrase IX, 
predicts for a poor outcome (31). Knockdown of HIF-1α in NSCLC cell lines, by lentiviral 
short-hairpin RNA, was found to reduce CXCR4 expression and result in reduced invasion and 
migration in response to its ligand CXCL12 (50). 
 
The transition of cancer cells from an epithelial to a mesenchymal phenotype is now considered 
central to cancer migration, invasion and metastasis and is accompanied by the classical 
molecular hallmarks such as a fibroblastoid phenotype, loss of E-cadherin, β-catenin nuclear 
translocation and expression of vimentin (51). These changes can be induced by reactive oxygen 
species generation (ROS) secondary to hypoxic stress or by hypoxic upregulation of HIF-1α, 
hepatocyte growth factor (HGF), activation of Notch signalling or NFkB pathways or epigenetic 
changes (52, 53). This concept has great importance since it has been shown that anti-
angiogenic strategies can elicit the malignant progression of tumours by causing hypoxia in 
tumours and promoting an epithelial to mesenchymal transition (54). 
 
1.2.3 Hypoxia and Chemotherapy Response 
Cytotoxic chemotherapies, as monotherapies or in combination, are central to modern cancer 
therapy however hypoxia reduces the efficacy of chemotherapy by multiple mechanisms. The 
cytotoxicity of some agents relies on the generation of superoxide radicals which results in 
DNA damage. Doxorubicin, mitomycin C, etoposide, cisplatin and docetaxel have all been 
shown to generate ROS. Although superoxide radicals can be generated from a number of 
molecules containing oxygen other than dioxygen a reduction in molecular oxygen availability 
has been shown to reduce efficacy (55, 56). Drug resistance can also result from hypoxia-
induced cellular senescence. Many chemotherapies are only active against the proliferating 
tumour fraction and senescent cells which survive multiple cycles of chemotherapy will result in 
tumour regrowth (57). Hypoxic tumours also have disordered vasculature with greater diffusible 
distances between vessel and tumour cells. Both these factors can lead to poor distribution and 
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penetration of chemotherapy agents (58). The multiple alterations in gene expression after 
exposure to hypoxia can reduce the efficacy of chemotherapy. For example, hypoxia can 
increase the frequency of dihydrofolate reductase gene amplification and antagonise 
methotrexate cytotoxicity (59) and increase efflux of multiple chemotherapies by expression of 
the multi drug resistance protein (MDR) 1 (44). 
 
1.2.4 Hypoxia and Radiotherapy 
The response of both normal and malignant cells to ionizing radiation is dependent upon 
adequate oxygenation, a relationship was first described in 1953 by Gray et al (60). They 
defined the concept of the oxygen enhancement ratio i.e. the additional cytotoxicity induced by 
a given dose of radiation in normoxic vs. hypoxic cells in vitro. It was postulated that three 
times the amount of radiation was required to kill cells irradiated in the absence of oxygen. The 
magnitude of this effect at clinically relevant fractionation schedules (which are lower than 
those used in this original experiment) is not clear but the radio-resistance of hypoxic tumours 
has been well documented in a number of tumour types. Hypoxia has been shown to be 
independently predictive of a poor response to radiotherapy in cancer of the cervix (61), head 
and neck (33), prostate (62) and sarcoma (27, 63).  
 
There are multiple mechanisms of resistance to radiotherapy in hypoxia. Radiation leads to the 
generation of DNA radicals either by direct ionisation or by radiolysis of water molecules 
resulting in production of hydroxyl radicals which then react with DNA molecules. This 
damage is then fixed in the presence of oxygen. In hypoxic conditions, reducing species can 
accept electrons and repair this damaged before it is permanently fixed. The genetic 
mechanisms behind radio-resistance are less well characterised than the radiobiological effects. 
Studies using individual pathway analysis have shown that, as with resistance to chemotherapy, 
the activation of PI3K/Akt/NF-kappa B signalling is associated with resistance to radiation-
induced apoptosis (64). HIF-1α has also been used as a therapeutic target to restore 
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radiosensitivity. Knockdown of HIF-1α with siRNA in vivo using adenoviral gene transfer was 
found to cause a limited but significant improvement in radiosensitivity (65). 
 
1.2.5 Evidence for hypoxia in PDAC 
PDACs contain significant areas of hypoxia that have been measured intraoperatively using 
microelectrodes (32). Using intrinsic markers it has been shown that hypoxia and HIF-1α 
stabilisation is associated with a poor prognosis in PDAC (66, 67). In vitro, hypoxia is 
implicated in the resistance to gemcitabine, the current standard of care. Hypoxia causes 
resistance to the pro-apoptotic effects of gemcitabine by an increase in PI3K/Akt/NF-kappa B 
signalling (68).
 
 
1.3 Vascular Endothelial Growth Factor, Angiogenesis and Cancer 
Angiogenesis is the growth of new blood vessels from existing vessels and neoangiogenesis is 
essential for the growth of all tumours beyond 2 or 3mm (69). The process of angiogenesis is 
regulated by the balance of angiogenic growth factors and inhibitors, released from endothelial 
cells, monocytes, platelets, smooth muscle and tumour cells (70). When there is an excess of 
growth factors in comparison to inhibitors, as is frequently the case in tumours, neoangiogenesis 
within the local tumour environment is initiated.  
 
Proangiogenic growth factors released from tumours bind to receptors on both endothelial cells 
of nearby blood vessels and circulating, bone-marrow derived epithelial progenitor cells (EPC). 
This results in their activation, proliferation and co-ordinated growth via the interaction of 
integrins with extracellular matrix components. The endothelial cells then remodel and form 
tubes, which connect into loops through the tumours, forming completed blood vessels. 
Structural support cells such as smooth muscle cells follow, but these tumour blood vessels 
remain leaky and have a poorly formed basement membrane (71, 72). 
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Vascular endothelial growth factor-A (VEGF) is a diffusible mitogen that plays a critical role in 
angiogenesis by increasing blood vessel permeability, endothelial cell growth, proliferation, 
migration and differentiation (73-75). VEGF is a heparin-binding polypeptide growth factor that 
was identified and isolated in 1989 by Ferrara et al (76). They discovered a molecule that was 
secreted into the extracellular compartment and was mitogenic to endothelial cells. Further 
characterisation has discovered that this molecule exists in multiple isoforms (77) and that these 
isoforms differ in their molecular masses and their receptor binding (Figure 1.3). They have a 
variable pattern of binding to heparin or heparan-sulphate proteoglycans and to different VEGF 
receptors. The splice forms VEGF121, VEGF145 and VEGF165 are secreted, whereas VEGF189 is 
tightly bound to cell surface heparan-sulphate and VEGF206 is an integral membrane protein. In 
Figure 1.3: VEGF isoforms and their specificity for VEGFR1, VEGFR2, NRP1 and 
HSPGs.  
VEGFA isoforms/VEGFE and their binding to VEGF receptor 1, VEGF receptor 2, Neuropilin 
1 (NRP1) and heparan sulphate proteoglycans (HSPG) as relevant to this study. MAM Domain 
is a ~ 170 aa region important for NRP1 interaction with co-receptors. 
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contrast to the other forms, VEGF121 and VEGF145  do not bind to heparin or extracellular matrix 
proteoglycans. The signalling tyrosine kinase receptor FLT-1/VEGFR1 (fms-like tyrosine 
kinase-1) and KDR/VEGFR2 (kinase domain region/flk-1, foetal liver kinase-1) binds all 
isoforms of VEGFA but differ in their intracellular signalling. Signalling via VEGFR2 is 
responsible for most functions involved in angiogenesis. Neuropilin-1 acts predominantly as a 
co-receptor as it lacks the tyrosine kinase domain found in VEGFR1/2. Ligands for NRP1 
include VEGF165 and VEGFE, the Orf Virus VEGF homologue (78). 
 
Elevated expression of VEGF has been detected in a variety of human tumours and this is 
associated with poor survival and an increased risk of recurrence (74). Up-regulation of VEGF 
occurs in response to a microenvironment of low oxygen conditions via the hypoxia inducible 
transcription factor HIF-1α (79). The 5‟ VEGF gene promoter regions contain hypoxia response 
elements that allow binding of HIF-1α and increased gene transcription (80). VEGF then 
stimulates endothelial migration via the PI3K isoform p110 alpha and subsequent activation of 
the Small GTPase RhoA (81). Expression of VEGF in response to hypoxia is central to 
angiogenesis and has led to VEGF being defined as the prime hypoxia-inducible angiogenic 
factor. VEGF is also induced by a number of cytokine growth factors such as epidermal growth 
factor (EGF), platelet derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) 
(78). Mutations in Ras oncogenes, and p53 are also linked with increased VEGF expression, as 
are genetic alterations of the phosphatase and tensin homolog protein (PTEN) and the Von 
Hippel Lindau protein (pVHL) that increase HIF-1 activity in tumour cells, which may 
indirectly lead to increased levels of VEGF (82-87).  
 
Although there is no known homologue of VEGF in the Vaccinia virus genome, Orf virus the 
type species of the Parapoxvirus genus, produces a protein with a high degree of similarity to 
other VEGF family members (88, 89). VEGF-E has been shown to have 25-43% sequence 
homology with other VEGF proteins but notably contains all six cysteine residues of the 
cysteine-knot motif which are conserved in all VEGF family members. Unique among the 
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VEGF family, receptor binding is restricted to VEGFR-2 and NRP1 (90, 91). This viral protein 
induces endothelial cell proliferation, vascular permeability, angiogenesis and 
lymphangiogenesis in vitro. In vivo it is responsible for the characteristic pustular dermatitis 
seen in sheep, goats and humans where there is extensive vascular and epithelial proliferation 
(92). 
 
1.4 Viral Therapy for Cancer 
Despite advances in conventional chemotherapy the response rates of PDAC is poor and five 
year survival limited. With the increasing knowledge of the molecular genetics of pancreatic 
cancer, gene therapy is developing as a new option for this extremely aggressive disease. Gene 
therapy strategies to repair isolated genetic defects in cancers, such as restoring wild type p53 
status, showed promising in vitro results but have not been successful in clinical trials (93). The 
lack of efficacy of such single gene strategies is not unexpected given the complexity of genetic 
changes and abnormalities in signal transduction found in cancer cells. Given this lack of 
efficacy, the use or tumour-selective, replication-competent viruses or bacteria are being 
investigated as new agents for cancer therapy.  
 
The concept that viruses may have some role in the treatment of cancer is not new. There are 
many examples in the literature where an acute viral illness or recent vaccination has resulted in 
the regression of a malignancy (94). Previous smallpox vaccination has also been shown to 
reduce the risk of melanoma incidence many years after vaccination implicating tumour specific 
immunity as a mechanism of action (95). 
 
The central premise of viral oncolytic therapy is that the vector replicates specifically in cancer 
cells (Figure 1.4). Some viruses have an inherent tropism for cancer cells alternatively specific 
viral genes can be deleted which are essential for replication but are compensated for by 
abnormalities in cancer cells but not in normal tissue. These therapeutic effects can be mediated 
by multiple mechanisms in addition to cell lysis as a result of viral replication. These effects 
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include the expression of toxic proteins, local conversion of pro-drugs to active chemotherapy 
agents or re-sensitisation to conventional therapies and induction of host cell-mediated 
immunity.  
 
The ideal vector would be highly tumour-selective so that it can target cancer cells without 
affecting surrounding normal cells. The efficiency of viral therapy can be enhanced by the use 
of a bystander effect. This is defined as induction of cell death, limitation of cell growth, 
inhibition of angiogenesis or an immune mediated effect by enhancing the host immune 
response to cancer cells (96). The ability to harness the host immune response against tumour 
cells has the potential not only to enhance local cancer cell death, but also to treat distant 
metastases. 
  
Figure 1.4: Replication-selective oncolytic viruses.  
The premise of oncolytic viral therapy involves viral replication only in cancer cell due to an 
inherent tropism or deletion of critical viral genes rendering them tumour-specific. Viral 
replication leads to production of new infectious virions, lysis of infected cells and spread of 
virions to infect adjacent and potentially distant cancer cells. (Hawkins LK, Lemoine NR, Kirn D. 
Oncolytic biotherapy: a novel therapeutic plafform. The Lancet Oncology. 2002 January;3(1):17-26.) 
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Viruses have evolved over millions of years and gained the ability to evade our immune system, 
infect and replicate efficiently in and cause lysis of humans cells to facilitate viral spread (96). 
These vectors naturally induce oncolysis or stimulate apoptosis and are capable of expressing 
therapeutic genes at high transduction efficiencies and inducing tumour-specific, cell mediated 
immunity  (21).  
 
Many oncolytic viruses have been developed but there has been few successful clinical trials 
(97). Replication-selective oncolytic adenovirus is the most well-researched and Onyx 
015/dl1520, or H101 in China, was approved as the world's first oncolytic virotherapy for head 
and neck cancer therapy (98). However, to date clinical trials using oncolytic viral therapy for 
pancreatic cancer have been disappointing. Two phase I/II trials using Onyx 015 (dl 1520), an 
adenovirus serotype 5 (Ad5) vector, with a deletion in the p53-binding protein E1B55kD to 
improve tumour selectivity, have shown minimal response when injected into pancreatic cancers 
endoscopically or under CT guidance (99, 100). There are many reasons for the poor 
performance of adenoviral vectors in clinical trials to date. The complexity of cancer cell 
signalling abnormalities and the effect of viral gene deletions are major factors and results may 
improve with future generations of adenoviruses.  
 
Ultimately, for oncolytic viruses to become part of the cancer treatment paradigm the effect of 
the tumour microenvironment on viral delivery and pathogenesis will need to be considered.  
Studies looking more specifically at adenovirus biology under hypoxic conditions may partly 
explain its poor performance in clinical trials to date. Ad5, a group C adenovirus, shows 
attenuated viral replication in hypoxic conditions. Virus attachment and internalisation via 
Coxsackie/Adenovirus receptor (CAR) and αv integrin expression is unaffected by hypoxia as is 
mRNA expression of viral proteins E1A and Hexon. However translation of viral mRNA to 
protein is reduced, resulting in a 10-100-fold reduction in the yield of infectious virus particles 
(101, 102). In addition the group B adenoviruses type 3 and 11 are attenuated in hypoxia 
displaying reduced lytic potential and production of virus particles independent of viral receptor 
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status and viral gene expression (103). Consequently, adenoviruses may not be the ideal vectors 
for pancreatic cancer and investigation of other vectors is warranted.  
 
Vaccinia virus is an alternative viral vector with many attributes that make it an attractive vector 
for viral gene therapy. Townsley et al. found that exposure of cells to a low pH augmented viral 
uptake via an endosomal pathway. The tumour microenvironment is known to be hypoxic and 
genes involved in regulating intracellular pH are upregulated by HIF-1α (104). Given that 
pancreatic cancer has been shown to be one of the most hypoxic tumours (32) we have decided 
to investigate Vaccinia virus as an alternative vector for pancreatic cancer gene therapy and to 
characterise the effect of hypoxia on the viral life cycle. 
 
1.4.1 Vaccinia Virus 
Vaccinia virus is an enveloped, double-stranded DNA virus and a member of the genus 
Orthopoxvirus from the Poxviridae family. The true origin of Vaccinia virus remains unknown 
and it has no single natural host. In 1796, Edward Jenner created the first vaccine when he 
isolated cowpox virus from a milkmaid and used it to vaccinate others against smallpox. 
Vaccinia virus was probably derived from cowpox virus through multiple passages over time 
and became established as an effective smallpox vaccine (105). Vaccinia virus was used widely 
as the vaccine strain for the WHO smallpox eradication programme (106)  
 
1.4.2 Strains of Vaccinia virus 
Many strains exist, some of which have been sequenced (107). The Western Reserve (WR) 
strain of Vaccinia virus has been the most common strain used in laboratories for the 
construction of oncolytic Vaccinia viruses, based on its supposed superior lytic activity over 
other strains in vitro (108). However, this is not a vaccine strain and less is known of the safety 
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profile in humans. In addition, it has neurovirulence and is gonadotropic in murine models (109, 
110). 
 
Vaccine strains of Vaccinia virus such as the Lister, Wyeth, Modified Vaccinia virus Ankara 
(MVA), Copenhagen and its derivative New York Vaccinia virus (NYVAC) are less virulent 
than the WR strain and may offer a superior safety profile in vivo. The MVA, Copenhagen and 
NYVAC strains all require primary cells, such as chicken fibroblasts, for production (111). 
These are difficult to mass-produce and may be contaminated by other viruses. However, both 
the Lister and WR strains can be produced at a high yield in CV1 cells, a normal African Green 
Monkey Kidney Fibroblast Cells. This cell line can be easily stored and grown at high density in 
culture. Mass production of the Lister virus is therefore safer, easier and more cost-effective 
than other vaccine strains. The Lister strain was developed at the Elstree laboratories of the 
Lister Institute. This vaccine strain of Vaccinia virus was used safely as the smallpox vaccine 
throughout Europe, is highly attenuated and has recently been fully sequenced (112, 113). As a 
result the Lister strain is the Vaccinia strain used as the vector for oncolytic therapy in our 
laboratory.  
  
1.4.3 Structure of Vaccinia virus and nomenclature of virions. 
Vaccinia virus is a large DNA virus measuring 250-360nm in size and encodes over 200 
proteins from a genome of approximately 200 kilobases (114, 115). The study of this virus is 
complicated by the fact that there are four forms of infectious virus particles and controversy 
surrounding the exact structure of these.  The intracellular mature virus (IMV) is the initial 
particle formed in peri-nuclear viral factories and surrounded by a single lipoprotein membrane. 
The intracellular enveloped virus (IEV) which is a triple lipoprotein-enveloped virus produced 
after fusion with the trans-Golgi network or early endosomes. The cell-associated enveloped 
virus (CEV) is formed after the IEV fuses with the cell surface membrane and is retained at the 
cell surface membrane. The extracellular enveloped virus (EEV) is a double lipoprotein-
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enveloped virus released from the cell membrane (116). Each particle contains an inner viral 
core containing a number of virus-encoded proteins including RNA polymerases, enzymes for 
RNA capping, methylation, polyadenylation and some early viral mRNA (117). 
           
1.4.4 Overview of the Vaccinia virus life-cycle 
 
Vaccinia virus replication occurs exclusively in the cell cytoplasm. Infection is a highly co-
ordinated process from cell entry, viral mRNA transcription, protein translation, DNA 
replication, virion assembly through to release co-ordinated release of EEV/CEV or cell lysis 
and release of IMVs (Figure 1.5). 
 
 
 
 
Figure 1.5: Overview of the Vaccinia virus lifecycle.  
The Vaccinia virus lifecycle occurs in the cytoplasm of infected cells. Viral replication requires 
attachment and entry, temporal mRNA transcription, DNA replication, wrapping of viral cores 
with a cell-derived lipoprotein membrane and egress. (Moss B. Poxviridae: the viruses and their 
replication, Fields Virology. 4th Edition ed. Knie DM, Howley PM, editors. Philadelphia: Lippincott 
Williams and Wilkins; 2001.) 
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1.4.5 Viral Attachment and Internalisation 
Vaccinia virus has a wide tropism and can enter most mammalian cell lines (118). However, a 
unique receptor for Vaccinia virus has not been identified. This is in contrast to adenovirus 
where attachment is via the coxsackievirus and adenovirus receptor (CAR) for Ad5 and CD46 
for Group B adenoviruses (119, 120).  
 
Several proteins present in the outer membrane of Vaccinia virus have been shown to be 
important in IMV cell entry (121). H3L, A27L and D8L all interact with cell surface 
glycosaminoglycans (GAG) and are involved in virus binding (122-124). However, the presence 
of these viral proteins is not essential and their effect on viral replication is dependent on cell 
type. Carter et al found that pre-incubation of purified IMV with various GAGs, to saturate 
these viral proteins, did not significantly impair the infectivity of BSC-1 cells (125).  In 
contrast, Whitbeck et al found that heparin was able to inhibit IMV attachment in human HeLa 
cells, murine B78H1 and L cells but not BSC-1 and Vero cells (126). They also examined the 
effect of low pH on the rate of endosomal uptake of Vaccinia virus IMV. They used 
bafilomycin to inhibit the endosomal Na/H+ pump and thereby prevent acidification of the 
endosomal compartment. They found that they were able to reduce the entry of Vaccinia virus 
by 35-90%, depending upon the cell type. They concluded that Vaccinia virus may enter 
different cell types by different mechanisms and also use these different mechanisms 
simultaneously (both endocytosis and plasma membrane fusion) to enter a single cell type. This 
corroborates the findings of Townsley et al who showed that a low pH-dependent endosomal 
pathway was also responsible for the entry of Vaccinia virus IMV (127). Alternatively these 
findings may be the result of a mixture of IMVs and EEVs being used in the virus preparation. 
Vanderplasschen et al demonstrated that IMVs and EEVs enter cells via different mechanisms 
or receptors (128). They also suggested that only the EEV exhibits a low-pH-dependent entry 
mechanism where un-coating of the EEV occurs inside acidified endosomes (129). This would 
suggest that although EEVs represent only a small fraction (~2-5%) of standard preparations of 
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Vaccinia virus on a single sucrose gradient, they are responsible for a disproportionate amount 
of viral infection compared to IMVs. EEVs have an additional lipid layer making them more 
resistant to host immune inactivation. This improves infectivity after systemic delivery in vivo 
(130). In contrast, the comparative infectivity of IMV versus EEV particles in vitro has not been 
clearly demonstrated, partly due to the fragility of EEVs.  
 
The epidermal growth factor receptor (EGFR) was initially proposed as a cellular receptor for 
Vaccinia virus because receptor occupation was shown to inhibit Vaccinia virus (131, 132). 
This hypothesis stemmed from the discovery of the viral protein Vaccinia Growth Factor 
(VGF).  This is a polypeptide encoded in the viral genome with sequence homology to both the 
EGF and Transforming Growth Factor-α and is produced early after viral infection (133, 134). 
VGF is secreted extracellularly, induces auto-phosphorylation of the EGFR, and signals via 
MEK kinases resulting in cell survival and proliferation (135-137). The concept that EGFR is a 
receptor for Vaccinia virus has largely been disproved and there are no studies since the 
development of multi-channel fluorescence microscopy which show co-localisation of Vaccinia 
virus with the EGFR (138). The most likely conclusion is that VGF or EGF/TGF-α signalling 
via the EGFR stimulates cell signalling pathways that maintain cells in a more susceptible state 
for infection to maximise viral replication in epithelial tissues prior to the lytic step of the viral 
life cycle. A study by Vermeer et al used intact respiratory epithelium from cadaveric sources 
and monitored the effect of EGF on Vaccinia virus infection and respiratory epithelium 
morphology (139). In normal respiratory epithelium EGF is secreted via the apical membrane 
and acts on the basolaterally located receptors to stimulate cell proliferation and repair when 
epithelial integrity is lost. In the context of viral infection they showed that virally produced 
VGF or recombinant EGF was able to stimulate these basolateral receptors and maintain 
epithelial integrity, stimulate proliferation and consequently facilitate maximal viral replication 
at early time points after infection. Deletion of VGF now serves as one of the important 
strategies for improved tumour targeting of oncolytic Vaccinia virus. Mutant viruses with 
deletion in the VGF gene are attenuated but this deletion is compensated for in cancer cells with 
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constitutively active EGFR/Ras signalling pathways (140, 141). Due to concern about the use of 
smallpox in bioterrorist attacks this pathway has been targeted to reduce the lethality of 
respiratory inoculation. Vaccinia virus respiratory infection is used as a model of smallpox 
attack and Yang et al were able to show that pre-treatment with inhibitors of the ErbB1 receptor 
tyrosine kinase was able to reduce the lethality of a respiratory infection (142).  
 
Lipid-rich membrane domains defined as lipid rafts have been implicated in the entry of 
enveloped viruses (143). Vaccinia virus co-localises with GM-1, a marker of lipid rafts, and 
depletion of the sphingomyelin and cholesterol domains impairs the binding of Vaccinia virus to 
the cell membrane (144). 
 
1.4.6 Viral Internalisation and Movement. 
Macropinocytosis, used by the IMV for cell entry, is a transient growth factor-induced, actin-
dependent endocytic process that leads to internalisation of fluid and membrane into large 
vacuoles. It is associated with considerable cell-wide plasma membrane ruffling induced by the 
activation of actin and microfilaments connected to the plasma membrane. The ruffles take the 
form of lamellipodia, circular ruffles and plasma membrane blebs. These protrusions can fold 
back, forming fluid-filled cavities and undergo membrane fission forming closed vacuoles that 
are no longer connected with the plasma membrane. These macropinosomes have a diameter of 
0.5–10 µm, larger than other pinocytic vesicles. This causes a transient increase in cellular fluid 
uptake and is often termed fluid phase endocytosis (145). The arginine-rich HIV-Tat protein 
also uses this mechanism for cell entry. 
 
IMV can bind to filopodia and lamellapodia and move towards the cell body in a manner 
consistent with actin-based motility. Large transient plasma membrane blebs are formed when 
the IMV reaches the cell membrane. The formation of the structures appears to be stimulated by 
phosphatidylserine residues in the virus envelope. This mimics apoptotic bodies and induces a 
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macropinocytic response by the host cell. This requires Ras-related C3 botulinum toxin 
substrate 1 (Rac1), a member of the Rho family of GTPases and p21-activated kinase 1 (PAK1). 
The IMV induces phosphorylation of threonine 423 of PAK1 which is known to be essential for 
macropinocytosis (146). The stimulation of the cell entry mechanism allows virus cores to enter 
the cell. EEV entry does not require this co-ordinated entry mechanism and inhibition of 
molecules involved in this pathway does not reduce infectivity (147).  
 
After internalisation, virus trafficking switches to microtubule-dependent transport. The pre-
transcribed early viral mRNAs are released from the core on entry and are transported along 
with the intact viral core to the endoplasmic reticulum. Here these mRNAs are translated into 
proteins involved in core uncoating, release and then replication of viral DNA (148).  
 
1.4.7 Viral Gene Expression and DNA Replication 
The tropism of Vaccinia virus is determined both by the ability to enter cells but also to 
complete replication and form new virions.  Following the entry of Vaccinia virus into the cell 
cytoplasm and trafficking to endoplasmic reticulum-associated, peri-nuclear viral factories, 
RNA polymerase and transcription factors already present in the virus facilitate early viral gene 
expression (114). Early Vaccinia virus mRNA is detected within 20 minutes of infection and 
peaks at 1.5 hours. Early mRNA transcripts produce further enzymes required for DNA 
transcription including thymidine kinase and ribonucleotide reductase, which synthesise any 
extra deoxyribonucleotides required for DNA replication. Soon after Vaccinia virus entry, all 
host protein synthesis is shut down following the expression of D9 and D10 Vaccinia proteins 
which destabilise cellular mRNA (149-151). This enhances viral replication by alleviating 
competition for nucleotides and protein synthesis machinery from cellular mRNAs, as 
depletions of pyrimidine nucleotide pools has been shown to limit Vaccinia virus DNA 
replication (152-154).  Exposure of cancer cells to hypoxia is known to limit the availability of 
pyrimidine nucleotides (155). 
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Early transcription occurs exclusively under the control of viral transcription factors but host 
proteins  contribute to the efficiency of intermediate and late gene transcription (118). 
Intermediate mRNA is seen from 1 hour after infection and peaks at 2 hours, resulting in the 
production of late transcription factors. Late mRNA is seen from 2 hours until 48 hours and 
encodes the structural proteins and enzymes required for viral assembly. New virions are coated 
with a single lipid layer containing viral proteins to form the IMV. This represents the majority 
of infectious viral particles as completion of the lytic viral life cycle will results in the release of 
these particles and allow infection of adjacent cells (116). Vaccinia proteins expressed on the 
surface of infected cells may mediate cell lysis by binding complement or natural killer (NK) 
cells although this is not completely characterised (156). 
 
In order for viral replication to be efficient the virus must enter the cell and have sufficient time 
to replicate before virus-induced apoptosis or cell lysis occurs. The requirement of Akt 
activation to inhibit virus-induced apoptosis is a mechanism that is used by a number of viruses 
to facilitate maximal replication (157). Myxoma virus, a member of the poxvirus family, 
requires the presence of phosphorylated Akt or the induction of this phosphorylation on 
infection in order for viral replication to occur. An ankyrin-repeat viral protein, MT5 is 
responsible for phosphorylation of Akt (158). Soares et al were able to show that Vaccinia 
virus-induced Akt phosphorylation resulting in reduced virus-induced apoptosis as measured by 
caspase-3 and TUNEL assays (159). This was inhibited in the presence of LY294002, an 
inhibitor of PI3K/Akt. 
 
1.4.8 Virus Egress 
The majority of IMV are released on cell lysis. However some IMV are wrapped in a double 
layer of Golgi- or endosome-derived intracellular membrane to form IEV (160). These use 
microtubules to traffic to the cell surface where a single layer of the outer lipid membrane fuses 
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with the cell plasma membrane creating CEV (161). CEV induce the formation of actin tails at 
the cell surface, which facilitate their spread to surrounding cells. EEVs, which mediate long-
range viral spread, are CEVs released from the cell membrane.  
 
The molecular mechanisms of this transition have been clarified; the IEV binds via the 
unphosphorylated viral protein A36R to Kinesin which mediates the microtubule-dependent 
transport to the cell surface. When present at the membrane as a CEV the B5R protein 
stimulates Src or Abl family-mediated phosphorylation of A36R which causes recruitment of 
cell actin polymerization machinery including adaptor proteins Nck and Grb2, the scaffold 
protein N-WASP and the Arp2/3 nucleation complex. This results in a switch to actin-based 
motility and protrusion of actin tails from the cell membrane and can be inhibited using 
inhibitors of the Src or Abl families (162, 163).  The release of EEV requires Abl but not Src 
family tyrosine kinase phosphorylation and can inhibited using STI-571 (Gleevec – an Bcr-Abl 
kinase inhibitor used in the treatment of chronic myeloid leukaemia) and reduces viral 
dissemination five-fold (163).  
 
The replication of Vaccinia virus is fast, efficient and does not require the host transcriptional 
machinery. However the viral lifecycle is still regulated by interaction of viral proteins and 
intracellular signalling pathways. Selective modification of this can significantly affect viral 
pathogenesis. A greater understanding of the signalling pathways that facilitate Vaccinia virus 
infection could allow improvements in oncolytic viral therapy and present strategies to alter 
poxvirus pathogenesis.  
 
1.4.9 Inherent tumour selectivity of systemically delivered Vaccinia virus 
One of the greatest barriers to the clinical application of viral gene therapy is specific and 
efficient gene delivery. This can to some extent be achieved by direct delivery of the virus to 
primary tumours and metastases by intratumoural injection. However, for many tumours this is 
Chapter 1 
 
42 
 
not feasible or metastases are too small to be detectable and systemically delivered agents are 
required.  
 
Wild-type Lister strain of Vaccinia virus has been shown to display inherent tumour specificity 
following intravenous delivery in both human tumour xenografts in nude mice and murine 
tumours in immunocompetent mice (164). This inherent specificity of Vaccinia virus for cancer 
cells is due to several factors; live in vivo imaging of systemically administered Vaccinia virus 
expressing the green fluorescence protein (GFP) confirmed that viral replication initially took 
place immediately surrounding tumour capillaries. These vessels differ from normal capillaries 
as they do not have an intact basement membrane and are leaky due to large gaps between 
endothelial cells (165). This may allow the large Vaccinia virus virions to enter the 
extravascular space. In support of this hypothesis, hyperthermia (to induce capillary dilation) 
improves the dissemination of Vaccinia virus (117). Additional factors include the constitutive 
activation of cell signalling pathways found in cancer cells, such as the EGFR pathway. In 
addition there are a range of host immunological factors, notably the loss of the interferon-
gamma antiviral response, that contribute to the tropism of Vaccinia virus for cancer cells (166). 
 
1.4.10 Current Status of Oncolytic Vaccinia Virus for Cancer Therapy 
At present, there are three oncolytic Vaccinia viruses in clinical trials. The leading vector is JX-
594, a Wyeth strain virus attenuated by deletion of the viral TK region and replacement with 
granulocyte/macrophage-colony stimulating factor (GM-CSF) to augment anti-tumour efficacy 
(167). A phase I trial of intratumoural injection of 22 heavily pre-treated patients 
(predominantly with hepatocellular carcinoma) was recently reported (168). All patients 
experienced grade I-III flu-like symptoms and four had transient, grade I-III, dose-related 
thrombocytopenia. Grade III hyperbilirubinemia was dose-limiting in two patients and the 
maximum tolerated dose was set at 1x10
9
 pfu. Only ten patients were evaluable for efficacy 
however, according to Response Evaluation Criteria in Solid Tumors (RECIST), three patients 
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had partial responses, six had stable disease, and one had progressive disease. These responses 
included patients who had been previously vaccinated for smallpox and had anti-Vaccinia 
antibodies before treatment. Secondly, viral replication was found in un-injected tumour cells 
distant to the site of initial injection showing that Vaccinia virus is capable of replication and 
spread to distant tumour sites. A phase II study is currently recruiting and a phase I study of this 
vector in patients with malignant melanoma has paused for interim analysis. Two other 
replicating Vaccinia viruses (see below) are in phase I clinical trials.  
 
GLV-1h68 is a Lister strain virus with deletions of the viral TK and haemagglutinin gene and a 
phase I trial in patients with solid tumours using intravenous administration is currently 
recruiting. The trial plans to assess viral replication in primary/secondary lesions, evidence of 
immune response and traditional efficacy and toxicity outcomes.  
 
JX-929 (vvDD-CDSR) is a Wyeth strain virus deleted for the viral TK and VGF genes, with 
two transgenes inserted in their place. The somatostatin receptor allows scintigraphic imaging 
and the cytosine deaminase transgene converts the pro-drug 5-fluorocytosine to the active 
metabolite 5-fluorouracil. A phase I study of intratumoural injection of this agent is currently 
recruiting (Data accessed www.clinicaltrials.gov 12
th
 June 2010). 
 
1.5 Hypoxia Targeting  
1.5.1 Overview 
Since the observations from pre-clinical data that hypoxia influences the phenotype of tumours 
and their response to therapies much has been done to target this issue. As the oxygen 
enhancement ratio demonstrates, hypoxia significantly reduces the efficacy the radiotherapy and 
consequently much of the work has focused on reversing this. Early clinical trials using 
hyperbaric oxygen chambers to increase the oxygen concentration of inspired air during 
radiotherapy showed benefit. A Medical Research Council study from 1978 showed a survival 
Chapter 1 
 
44 
 
benefit for hyperbaric oxygen therapy in combination with radiotherapy in cancer of the uterine 
cervix (169). However, patients must enter hyperbaric oxygen chambers prior to each dose of 
radiotherapy delivered. Consequently the logistics of delivering this kind of therapy make it an 
unfeasible solution.  
 
Radiotherapy techniques have improved from this period and other ways of improving tumour 
oxygenation are being studied. A combination of the hyperoxic gas carbogen,
 
to overcome 
diffusion-limited hypoxia, and the vasoactive agent
 
nicotinamide, to circumvent perfusion-
limited hypoxia have shown promise in phase II clinical trials using Accelerated Radiotherapy 
with Carbogen and Nicotinamide (ARCON) therapy (170). Phase III trial data should become 
available in the next few years and provide data to assess the efficacy of this approach. 
 
An alternative is the use of radio-sensitizing agents to improve radiotherapy efficacy. A meta-
analysis of their use has shown benefit in terms of local control and, in some tumour types, 
overall survival (171). The radio-sensitizing agent nimorazole is used in some centres in Europe 
for the management of supraglotic larynx and pharynx tumours after showing improved loco-
regional control in phase III trials (172). Tirapazamine, a bio-reductive drug which becomes 
toxic preferentially in hypoxic cells, had shown benefit in phase II trials. A recent phase III trial 
in head and neck cancer using this agent in combination with cisplatin and radiotherapy has not 
shown benefit. However, this study has been criticised for its lack of biomarkers for selection of 
hypoxic tumours and poor radiotherapy delivery in some trial centres. In addition the aetiology 
of the disease has changed to more radiosensitive human papillomavirus (HPV)-induced 
tumours since the phase I/II data were collected. 
 
An alternative approach to target hypoxia is to reduce hypoxia-induced gene transcription to 
reverse the phenotype that this causes. Some conventional chemotherapy agents have been 
shown to inhibit HIF function.  Intervention with gene silencing or chemical inhibition of HIF 
has shown benefit in vitro (173). Development of these therapies may prove beneficial in future. 
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1.5.2 Hypoxia-Targeting Viral Therapy 
Gene therapy strategies targeting hypoxia offer the potential of improved specificity and 
increased therapeutic ratios by restricting transgene expression to hypoxic regions. HIF-1 
when stabilised in hypoxic conditions will bind to hypoxia regulatory elements (HREs) and 
initiate transcription. Hypoxia-induced genes such as erythropoietin (Epo-1), inducible nitric 
oxide synthetase (iNOS) and VEGF all have promoter sequences which include a HRE. Using 
these HREs as cis-acting elements in either 5‟ or 3‟ flanking locations allows hypoxia-specific 
transgene expression and has been demonstrated both in vitro and in vivo using both viral and 
non-viral vectors (174, 175). Post et al inserted HREs as part of the promoter sequence for E1A 
to make a conditionally replicating adenovirus (176). Gene transfer using adeno-associated virus 
as a transfer vector in cardiovascular disease has been used in a dual vector system to target 
ischaemia. Tang et al then created a transactivating fusion protein in the first vector that 
contains an ODD sequence, which under hypoxic conditions was able to bind to the inducible 
promoter in the second vector and increase transcription of the luciferase reporter gene (177).  
 
Vaccinia virus encodes many of its own polymerases and therefore using HREs in a 
conventional hypoxia-targeting approach is not feasible. Given the advantages of Vaccinia as an 
oncolytic vector, in comparison to adenovirus or adeno-associated virus, a Vaccinia virus 
capable of targeting transgene expression or conditionally replicating in hypoxic conditions 
could be useful for cancer therapy.   
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1.6 Aims of Project 
 
 To study the feasibility of Vaccinia virus as a therapeutic vector targeting hypoxic PDACs. 
 To study the functional mechanisms by which hypoxia affects the potency of Vaccinia 
virus. 
 To construct a novel hypoxia-targeting Vaccinia virus with the potential for re-
sensitization of hypoxic tumours. 
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2. Materials & Methods 
2.1 Cell Lines 
All cell lines were maintained in their respective media at 37C in air supplemented with 5% 
carbon dioxide (CO2) or were cultured in hypoxic conditions as indicated. Repeated 
experiments were performed using cells of similar passage. All cells were grown in media 
containing 0.06 μg/L penicillin and 0.1 μg/L streptomycin obtained from Cancer Research UK 
Central Cell Services (CRUK CCS, Clare Hall, Herts, UK) or PAA Laboratories GmbH 
(Pasching, Austria) and were regularly tested for mycoplasma. 
 
2.1.1 Human cell lines 
2.1.1.1 Pancreatic cancer cell lines 
The pancreatic carcinoma cell lines Suit-2, CFPac1, MiaPaca2 and Panc1 were obtained from 
CRUK CCS and maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% foetal 
calf serum (FCS) (PAA Laboratories GmbH). 
 
2.1.1.2 Primary cell lines 
Normal human bronchial epithelial cells (NHBE) were obtained from Lonza (Lonza Group Ltd, 
Basel, Switzerland) and maintained in Bronchial Epithelial Growth Medium (BEGM) 
containing the following growth supplements: Bovine Pituitary Extract (BPE), 2 mL; 
Hydrocortisone, 0.5 mL; Human Epidermal Growth Factor (hEGF), 0.5 mL; Epinephrine, 0.5 
mL; Transferrin, 0.5 mL; Insulin, 0.5 mL; Retinoic Acid, 0.5 mL; Triiodothyronine, 0.5 mL; 
GA-1000, 0.5 mL from Lonza (Basel, Switzerland). Lonza obtained these cells from their 
patient donation programme following the acquisition of informed consent for use of cells in 
research and were free of mycoplasma, HIV, HBV and HCV.  
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2.1.1.3 Monkey cell line 
The immortalised non-transformed African Green Monkey kidney cell line CV1, was obtained 
from The American Tissue Culture Consortium (VA, USA) and cultured in DMEM with 10% 
FCS. 
 
2.2 Vaccinia Virus Production 
2.2.1 Wildtype Lister strain and recombinant thymidine kinase-deleted Vaccinia Virus 
The Lister vaccine strain of Vaccinia virus (VVLister) and recombinant thymidine kinase (TK)-
deleted Vaccinia viruses (VVL15) were a gift from Professor Istvan Fodor (Loma Linda 
University Campus, CA, USA). Fluorescently tagged Vaccinia virus-488 and VV-ODD were 
produced by Crispin Hiley (CH). Dr L Chard was involved in the design of VV-ODD and 
provided post-doctoral assistance during its construction. 
 
VVLister was used as the backbone for production of other engineered viruses. VVL15 was 
produced by an in vitro intracellular recombination technique previously described (178). 
VVL15 was constructed by the insertion of the firefly luciferase and the lacZ reporter genes into 
the thymidine kinase (TK) region of VVLister downstream of the early–late Vaccinia p7.5 
promoter.(179).  
 
2.2.2 Fluorescently labeled Vaccinia virus - VV-488 
Fluorescently tagged Lister strain Vaccinia virus (VV-488) was produced by CH following the 
protocol used by Warren et al to label the capsid of adenovirus (180). The Alexa Fluor® 488 
(Invitrogen Ltd, Paisley, UK) 5-sulfodicholorphenol ester (1mg) was resuspended in 100 µL of 
DMSO in a foil-wrapped Eppendorf tube. The Lister strain Vaccinia virus was diluted to 0.885 
x10
11
 pfu/mL in 0.1 M sodium bicarbonate buffer to 2 mL in a 15 mL tube. This was vortexed 
slowly whilst adding the dye solution. This was then continuously vortexed for 1 hour at room 
temperature in a foil-wrapped tube. After 1 hour, the 2 mL volume was injected into a 10 kDa 
MWCO Slide-A-Lyzer dialysis cassette (Pierce Biotechnology Inc, IL, USA). This was 
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dialyzed overnight at 4°C against a total of two changes of 0.1 M Tris-HCL, pH 7.8, 0.1 M 
MgCl2, 1.5 M NaCl, and 10% Sucrose and stored at -80°C in 10 µL aliquots prior to use. 
 
2.2.3 Hypoxia-targeting virus - VV-ODD 
The recombinant hypoxia-targeting Vaccinia virus VV-ODD was produced using intracellular 
homologous recombination as used for the construction of VVL15. The design and construction 
of VV-ODD are outlined in the results. 
 
2.2.4 Vaccinia virus mass production 
CV1 cells were cultured until 90% confluent and infected with 20 μL of purified virus to 
produce a primary expansion, and after this all further virus production was performed by Heike 
Muller. The primary expansion was harvested when significant cytopathic effect (CPE) was 
observed by cell detachment at 48-72 hours. A CF10 viral production factory (Nunc, NY, USA) 
was seeded with the cells from four 175 cm
2
 flasks of CV1 cells at 90% confluence. After 72 
hours, this was infected with the primary expansion in DMEM with 2% FCS until significant 
CPE was observed a further 72-96 hours later. 
 
Cells harvested from the CF-10 were centrifuged in Sorvall centrifuge bottles (Sorvall, MA, 
USA) at 3500 revolutions per minute (rpm) for 15 minutes at 4C. The cell pellet in each bottle 
was resuspended in 30 mL phosphate-buffered saline (PBS), transferred to a 50 mL tube and 
centrifuged in the same manner. The supernatant was again discarded and each pellet of cells 
resuspended in 7 mL of 10 mM Tris-HCl pH 9.0, then combined. Cell membranes were 
disrupted by three cycles of freezing in liquid nitrogen and thawing in a 37C water bath, prior 
to homogenisation by 60 strokes with a Dounce homogeniser. 
 
Cells were centrifuged at 900 rpm for 5 minutes at 4C and the supernatant removed and saved. 
The cell pellet was resuspended in 3 mL of 10 mM Tris-HCl pH 9.0 prior to a second 
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centrifuge. Both supernatants were combined and the pellet discarded. This was sonicated in an 
ultrasound ice bath for 20 seconds (Grant Instruments, Herts, England) and diluted to 30 mL 
with 10 mM Tris-HCl pH 9.0. 7.5 mL was carefully layered onto 17 mL of 36% sucrose (w/v) 
10 mM Tris-HCl pH 9.0 in each of four SW17 Beckman ultracentrifuge tubes (Beckman 
Coulter UK Ltd, Bucks, UK). After careful balancing by weight, these tubes were centrifuged at 
13,500 rpm for 80 minutes at 4C.  Each supernatant was discarded and purified viral pellets 
resuspended in 1 mL of 1 mM Tris-HCl pH 9.0 prior to combination and storage at -80 C. The 
viral titre was determined by TCID50 plaque assay. 
 
2.3 Hypoxia 
For this study, hypoxia is defined as 1% oxygen unless otherwise stated. This equates to an 
approximate oxygen tension of 7 mmHg. This was achieved using a hypoxic incubator 
maintained at 94% nitrogen, 5% CO2 and 1% Oxygen (Heto-Holten Cell Chamber 170, Surrey, 
United Kingdom). 
 
2.4 RNA techniques 
2.4.1 RNA extraction 
Cells were lysed directly in wells using 1 mL of TRIzol (Invitrogen) reagent per 10 cm
2
 of cells. 
Solutions were then pipetted into Eppendorf tubes and incubated for 5 minutes at 23 °C. 0.2 mL 
of chloroform per 1 mL of TRIzol was added to each Eppendorf. Tubes were shaken by hand 
and incubated for 2 minutes at 23°C. The reactions were centrifuged at 4°C in the Eppendorf 
5471 refrigerated bench top centrifuge for 15 minutes at 14,000 rpm and the aqueous phase was 
transferred to a fresh tube.  RNA was precipitated by mixing with 0.5 mL of isopropanol per 1 
mL of TRIzol and incubated for 10 minutes at 4 °C.   Samples were then centrifuged at 14,000 
rpm for 10 minutes and the supernatant removed. Pellets were then washed with 75% ethanol 
and centrifuged at 14,000 rpm for 5 minutes at 4 °C. Pellets were air-dried and resuspended in 
20 µL RNAse-free ddH2O. 
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2.4.2 Reverse Transcription (RT) Polymerase Chain Reaction (PCR) 
Purified total cellular and viral RNA (2 g) was added to 1 L random hexanucleotide primers 
(RHP) (50 ng/L) (Roche) or gene-specific primers (2.5 M) (Sigma), 1 µL of 10 mM dNTPs 
(Invitrogen) and made up to a total volume of 12 L with nuclease-free dH2O.  The reactions 
were incubated at 65 
o
C for 5 minutes and chilled on ice. Then 4 µL of 5X first-strand buffer, 2 
µL 0.1 M DTT and 1 µL of RNAseOUT (40 U/µL) were added to each sample. Samples were 
mixed and then incubated for 2 minutes at 42 
o
C for gene specific primers or 25 
o
C for random 
primers. 1 µL of SuperscriptII reverse transcriptase (Invitrogen) was added to each sample and 
incubated at 42 
o
C for 50 minutes for gene specific primers or 25 
o
C for 10 minutes for random 
primers. Superscript II reverse transcriptase was inactivated by heating to 70 
o
C for 15 minutes. 
The cDNA was stored at -20 
 o
C until required. 
 
2.5 DNA techniques 
2.5.1 Agarose gel electrophoresis 
Agarose gels (1%) were made using 1x TAE (40 mM Tris-acetate, 10 mM EDTA, pH 8.2) 
buffer and electrophoresis grade agarose powder (Invitrogen).  Ethidium bromide (EtBr) 
(Sigma) was added to the molten agarose at a final concentration of 0.5 g/mL before the gel 
was cast.  Samples for analysis were added to 6x blue/orange loading dye (Promega) and dH2O 
before being loaded into the wells.  For reference, a 1 kb DNA ladder (5 µL) (Promega) was 
also run.  Gels were run in 1x TAE buffer containing 0.5 g/mL EtBr.  Bands were visualised 
using a transilluminator and the GelDoc program (BioRAD). 
 
2.5.2 Low melting point (LMP) gel electrophoresis 
LMP agarose gels were used for purification of DNA.  LMP agarose (1%) gels were made using 
1x TAE buffer and electrophoresis grade LMP agarose powder (Invitrogen) (Appendix II).  
EtBr was added to the molten agarose at a final concentration of 0.5 g/mL before the gel was 
cast.  Gels were run in a 1x TAE buffer containing 0.5 g/mL EtBr.  The DNA bands were 
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observed under low intensity ultra violet (U.V.) light and the appropriate bands excised from the 
gel.  The DNA was purified from the gel using the GE GFX
TM
 PCR DNA and Gel Band 
purification kit, according to the manufacturer‟s protocol.  The DNA was eluted in 50 L dH2O 
and quantified by using a NanoDrop spectrophotometer to measure absorbance at 260 nm. 
 
2.5.3 DNA extraction 
DNA was extracted using the QIAamp DNA blood mini kit (QIAGEN Ltd, Crawley, UK) 
according to the manufacturers‟ instructions. Samples were lysed and DNA bound to a silica-gel 
membrane, while contaminants were washed away before the elution of purified DNA. Cell 
pellets samples were resuspended in 200 μL PBS. Viral standard samples consisted of 100 μL 
purified VVLister mixed with 100 μL PBS. 20 μL protein kinase K and 200 μL of lysis buffer 
AL were added to samples and mixed before incubating at 56 C for 10 minutes. 200 μL ethanol 
was added, samples transferred into spin columns containing a silica-gel membrane, centrifuged 
at 800 rpm for 1 minute and filtrates discarded. Columns were placed in Eppendorfs and 500 μL 
wash buffer AW1 added to the columns, which were centrifuged as above and filtrates again 
discarded. Columns were washed in the same manner with 500 μL wash buffer AW2. Columns 
were placed in fresh Eppendorfs, samples eluted from membranes with 70 μL of elution buffer 
AE (10 mM TrisCl; 0.5 mM EDTA; pH 9.0) and stored at -20 C. Sample DNA concentration 
and purity was determined using the Nanodrop

 ND-Spectrophotometer and Nanodrop

 v3.1.0 
software (NanoDrop Technologies, Delaware, USA). DNA was accepted as adequately pure 
where the ratio of absorbance at 260 and 280 nm was ~1.8. Concentration was measured until 
three measurements within 4 ng were obtained and then an average taken.    
 
2.5.4 Restriction digests 
For analytical digests, 1 g of plasmid DNA was added to an appropriate amount of each 
restriction enzyme (Promega/NEB), 2 L of the supplied 10x enzyme buffer, 0.5 µL of bovine 
serum albumin as required and the reactions made up to 20 L with dH2O.  Digests were 
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incubated for 2 hours at 37 
o
C and the sample mixed with 4 L of blue/orange 6x loading dye 
and analysed by electrophoresis. 
 
For preparative digests, 5 g of the plasmid DNA and an appropriate amount of restriction 
enzyme were used in a 50 L volume digest.  Digests were incubated for 2 hours at 37 oC and 5 
L of the digest was analysed on a 1% agarose gel. 
 
2.5.5 DNA polymerase I (Klenow fragment) 
DNA polymerase I (Klenow fragment) was used for blunt end repair of DNA. 1 µL Klenow or 
(5 U/µL) (Promega) was added directly to 50 L of preparative restriction digests, with 1.5 L 
10 mM dNTPs (from PCR nucleotide mix, Promega). The reaction was incubated at room 
temperature for 30 minutes. 
 
2.5.6 Calf Intestinal Alkaline Phosphatase (CIAP) treatment 
To remove 5‟ phosphate groups, the DNA was incubated for 30 minutes at 37 oC with 0.5 µL 
CIAP (1 U/µL) (Promega) and 5 L 10x dephosphorylation buffer (Promega). 
 
2.5.7 PCR 
PCRs were performed using the primers listed in the appropriate results chapters. 50 µL 
reactions were used, containing 100 ng of template DNA, 10 pmol of each primer (forward and 
reverse), 5 µL 10x PCR reaction buffer, 2 µL of MgSO4 (25 mM), 1 µL 10 mM PCR nucleotide 
mix and 1 U of KOD Hot Start DNA Polymerase. PCR cycles were performed using the 
program detailed in Table 2.1.  The PCR products were analysed on a 1% agarose gel before the 
fragments were purified using LMP electrophoresis. Purified products were stored at -20 
o
C 
until required. 
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Table 2.1: Details of PCR cycles. 
*1 
The annealing temperature was adjusted according to 
the melting temperature (Tm) of the primers. 
 
Step Temperature Time 
1   Initial Denaturation 94 oC 2 minutes 
2   Denaturation 94 oC 20 seconds 
3   Annealing
*1 56 oC 30 seconds 
4   Elongation 72 oC 90 seconds/kb  
      Go to 2, repeat 30 times  
5   Final Elongation 72 oC 7 minutes 
6   Hold  4 oC 1 hour 
 
2.5.8 Quantitative real-time PCR 
2.5.8.1 Primers and probes 
Primers and probes for VVLister Vaccinia Late Transcription Factor were designed manually 
using Primer Express
®
 v3.0 software (Applied Biosystems, New Jersey, USA) and constructed 
by Sigma-Aldrich and Applied Biosystems respectively. Primers and probes were chosen for 
optimum PCR efficiency with minimal secondary structures with probe length 17-20 bp, Tm 
(Melting temperature) 68-70 C, GC content 40-60% with repeats minimised. Primers were 
chosen to be 20-26 bp in length either side of the probe with Tm 58-60 C and GC content 40-
60%. Sequences were confirmed as unique within the Vaccinia virus and human genomes and 
are presented in the relevant results section. 
 
2.5.8.2 Quantitative PCR (qPCR) 
All samples were diluted to a concentration of 8 ng/µL of DNA. Samples, no template control 
(RNAse free water) and nine 10-fold serial dilutions of standards (5x10
8
 to 5 viral genome 
copies diluted in 5μL RNAse free water) were tested in triplicate in each plate by qPCR. A 
25μL reaction volume consisted of 5μL sample or standard and 20μL of Master mix (0.9 μM 
forward primer, 0.9 μM reverse primer, 0.2 μM probe in TaqMan® Universal PCR Master Mix). 
Reactions were performed in MicroAmp optical 96-well reaction plates sealed with optical 
adhesive covers and amplified using the 7500 Real-time PCR System (1 cycle of 48 C for 30 
minutes, 95 C for 10 minutes then 40 cycles of 95 C for 15 seconds, 60 C for 1 minute). 
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Cycle thresholds (CT) were determined using 7500 System SBS software (All Applied 
Biosystems, New Jersey, USA). 
 
Standard and sample triplicates were accepted for analysis if their standard deviation was <0.3. 
Standard curves were created using mean cycle thresholds in Prism® and sample genome copy 
number determined accordingly. Standard curves were accepted as valid where R
2
  0.99 with a 
slope of –3.30 to -3.32. Results were expressed in total genome copy number per sample. As the 
concentration of DNA used was constant the copy number represents the ratio of viral DNA to 
cellular DNA in any given sample. The mean of the qPCR triplicate was summed with the 
corresponding biological duplicate and presented as an average.  
 
Reverse Transcriptase Quantitative PCR (rt-qPCR) for Vaccinia virus mRNA was performed as 
a two-step reaction with cDNA being produced as outlined. A multiplex reaction consisted of 
40ng of template and a mastermix, as outlined above, with the inclusion of 1.25 μL of 20x 
eukaryotic 18S rRNA endogenous control (VIC/MGB Probe, Primer; Applied Biosystems) for 
each reaction. The comparative CT was used to compare the relative expression of VLTF 
mRNA to 18S overtime. A validation experiment was performed to confirm comparative 
efficiency of the target and reference amplification. 
 
2.5.9 Annealing of oligonucleotides 
5‟ phosphorylated oligonucleotides (Sigma) were annealed for ligation into plasmid vectors.  
The details of these are given in the appropriate results chapters. 100 pmol of each of the 
forward and reverse primer were added to 18 L dH2O.  The oligonucleotides were boiled at 
100 
o
C for 2 minutes before being allowed to cool down to room temperature.  0.2 L of the 
annealed oligonucleotides was used in subsequent ligation reactions. 
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2.5.10 Ligations 
Ligations were carried out using 25-30 ng of vector and a quantified amount of purified insert at 
a ratio of 1:3.  To this, 2 L of 10x DNA ligase buffer (Promega) and 0.5 µL of T4 DNA ligase 
(3 U/µL) (Promega) were added and the reactions made up to 20 L with dH2O.  The ligations 
were incubated at 16 
o
C overnight and then transformed into One Shot Top10 competent cells 
(Invitrogen). „No insert‟ controls were performed for each vector used. 
 
2.5.11 Transformation of competent cells 
5 µL of each ligation reaction was added to 50 μL thawed One Shot Top10 competent cells and 
the mixture incubated on ice for 20 minutes.  Each reaction was heat-shocked at 42 
o
C for 45 
seconds then placed on ice for 5 minutes. 250 µL of warm SOC was added to each vial and then 
shaken horizontally for 1 hour at 225 rpm. Transformed bacteria were plated out on Lysogeny 
Broth (LB) agar plates containing the appropriate antibiotics and incubated overnight at 37 
o
C. 
 
For midi preparations, the transformed cells were added to 50 mL LB media containing the 
appropriate antibiotic and incubated overnight at 37 
o
C in the shaker.  Preparations were then 
pelleted by centrifugation at 8,000 rpm for 6 minutes and stored at -20 
o
C until purified. 
 
2.5.12 Mini-preparation of plasmid DNA 
Single colonies were picked from the LB agar plates and grown up overnight at 37 
o
C in 5 mL 
LB media containing an appropriate antibiotic. 1 mL of the overnight culture was centrifuged 
for 2 minutes at 14,000 rpm and the supernatant removed.  The plasmid DNA was purified from 
the pelleted bacterial cells using the Qiagen Miniprep DNA purification system as described by 
the manufacturer.  DNA was eluted in 50 L dH2O and 5 L of the sample was analysed by 
restriction analysis and agarose gel electrophoresis. 
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2.5.13 Midi-preparation of plasmid DNA 
For medium scale preparation of plasmid DNA, a 50 mL culture of transformed bacteria was 
grown overnight in LB broth containing the appropriate antibiotic.  Cultures were transferred 
into 50 mL falcon tubes and centrifuged at 6000 rpm for 10 minutes.  The supernatant was 
removed and the pellet used for purification of plasmid DNA. 
 
Midi-prep DNA was obtained using the Qiagen Hi-Speed Plasmid Midi Prep Kit according to 
the manufacturer‟s protocol and the DNA eluted in 1 mL dH2O.  The DNA was then 
precipitated for 1 hour using 2.5 volumes 100% ethanol (EtOH) and 1/10th volume 3 M Sodium 
Acetate (NaOAC), before being washed once in 70% EtOH.  The DNA was quantified using the 
Nanodrop spectrophotometer. 
 
2.6 Protein techniques 
2.6.1 Immunoblotting 
2.6.1.1 Sample preparation for Western blot analysis 
Nuclear extracts were isolated using the NE-PER Nuclear and Cytoplasmic extraction reagents 
(Pierce, Rockford, IL, USA) according to the manufacturer‟s instructions.  
 
Whole cell extracts were collected by lysis of cells with NP40 cell lysis buffer (50 mM Tris 
pH7.4, 150 mM NaCl, 10 mM Ca
2+
, protease inhibitor cocktail (Roche Applied Science, 
Mannheim, Germany) and 1% Nonidet P40 (Sigma Chemicals Co., Poole, UK). Lysis buffer for 
analysis of phosphorylated proteins also contained phophatase inhibitor cocktail (Roche 
Applied Science, Mannheim, Germany). 
 
2.6.1.2 Protein quantification 
Protein concentrations were determined using the Beckman protein assay. 5 μL of samples were 
mixed with 200 μL Bio-Rad protein assay indicator (Bio-Rad, Munich, Germany) and 795 μL 
of distilled water in cuvettes (Fisher Scientific, Leicester, UK). Following calibration with a 
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blank sample (200 μL Biorad indicator and 800 μL distilled water), the absorbance at 595 nm 
was measured using a spectrophotometer (Beckman Coulter UK Ltd, Bucks, UK). The protein 
concentration of samples was determined from a standard curve of protein concentration against 
absorbance of known quantities (1, 2, 4, 8, 16, 32 and 64 μg) of bovine serum albumin (Sigma 
Chemicals Co., Poole, UK) at 595 nm.  
 
2.6.1.3 SDS-Polyacrylamide gel electrophoresis 
30 μg of samples were mixed with 5 μL of 5x loading buffer (50 mM Tris, 4% SDS, 10% 
Glycerol, 5% Mercaptoethanol and 0.01% Bromophenol Blue) and distilled water to give a final 
volume of 25 μL. Samples were heated to 95 C for 5 minutes and cooled on ice for 5 minute 
prior to loading into a denaturing 10% polyacrylamide gel in 1x Running buffer (3 g of Tris 
base, 14.4 g of glycine, 1 g of SDS diluted to 1 L of distilled water, pH 8.3) 10 μL of Rainbow 
molecular weight marker (Amersham Biosciences, Bucks, UK) was loaded alongside the 
protein samples. Electrophoresis took place at 120 V for 60-70 minutes. 
 
Proteins were sandwiched between blotting paper in the presence of transfer buffer (1% glycine 
and 10% methanol in distilled water) and transferred onto a Polyvinylidene Fluoride (PVDF) 
membrane (Immobilon-P, Millipore, Bedford, MA, USA) using a wet transfer system (Bio-Rad, 
CA, USA) at 100 V for 1 hour. 
 
Membranes were blocked with a 5% BSA (Sigma Chemicals Co., Poole, UK) in a solution of 
1% Tween
®
20 (Sigma Chemicals Co., Poole, UK) in PBS for thirty minutes at room 
temperature. The primary antibodies (Table 2.2) were diluted in the same blocking solution and 
incubated with the membrane at 4 
0
C overnight or at 37 ºC for 1 hour. Following removal of the 
primary antibody, membranes were washed three times for 10 minutes with TBST washing 
buffer (137 mM NaCl, 20 mM Tris, 0.1% Tween-20, pH 7.6). Secondary horseradish 
peroxidase (HRP)-conjugated antibodies were diluted in blocking solution and incubated with 
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membranes for 1 hour at room temperature. Three further TBST washes were performed 
following removal of the secondary antibody. 
 
Chemiluminescent detection was performed using ECL Plus Detection reagent (GE 
Healthcare, Bucks, UK) according to the manufacturer‟s instructions. The signals were 
visualised by exposing membranes to Fuji Medical film Super RX (Fuji, Japan) for 1-10 
minutes. 
 
Membranes were placed in blocking solution for a further 30 minutes prior to incubation with 
proliferating cell nuclear antigen (PCNA), Ku-70 or β-actin (loading controls) using the same 
protocol. 
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Table 2.2: Antibodies used for western blots 
 
Antibody 1º/ 2º Species Dilution Supplier 
VVLister coat 
protein 
1º Rabbit-pAb 1:1000 
MorphoSys UK Ltd, 
Bath, UK 
HIF-1α 1º Murine-mAb 1:750 
AbCam Plc, Cambridge, 
UK 
PCNA 1º Murine-mAb 1:1000 
Santa Cruz Biotech Inc, 
California, USA 
Ku-70 1º Murine-mAb 1:1000 
Santa Cruz Biotech Inc, 
California, USA 
β-Actin (C4) 1º Murine-mAb 1:3000 
Santa Cruz Biotech Inc, 
California, USA 
Anti-mouse HRP 2º Goat 1:2000 Autogen Bioclear 
Anti-rabbit HRP 2º Goat 1:2000 Autogen Bioclear 
Anti-goat HRP 2º Donkey  1:2000 Autogen Bioclear 
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2.6.2 Enzyme-Linked Immunosorbant Assay (ELISA) for VEGFA 
The Duoset® ELISA for human VEGFA (R and D Systems, Abingdon, UK) was used 
according to the manufacturers‟ instructions. 96-well microplates were coated with 100 μL/well 
of 1 μg/mL mouse anti-human VEGF antibody diluted in PBS. Plates were sealed overnight 
with plate sealers then aspirated and washed 3 times with 400 μL/well wash buffer (0.05% 
Tween 20® in PBS). Plates were blocked for 1 hour at 20 °C with 300 μL/well 1% bovine 
serum albumin (BSA; Sigma Chemicals Co., Poole, UK) in PBS and washed in the same 
manner.  
 
Standards (recombinant human VEGF) and samples were diluted in PBS supplemented with 
10% FCS. All samples were diluted 1:10. 100 μL of samples and seven 2-fold serial dilutions of 
standard (2000 pg/mL to 31.25 pg/mL) were added to 2 wells of each plate for 2 hours. Plates 
were washed, 100 μL/well of 100 ng/mL biotinylated goat anti-human VEGF added for 2 hours, 
100 μL/well of 1:200 Streptavidin-HRP added and the plate kept in the dark for a further 20 
minutes before washing. 100 μL/well of substrate solution (1:1 colour reagent A (H2O2) and 
colour reagent B (Tetramethylbenzidine)) was added and the plate kept in the dark for 20 
minutes before the addition of 50 μL/well of stop solution (2NH2SO4) (R&D Systems, UK). 
 
The OD of each well was determined using an Opsys MR 96-well plate absorbance reader 
(Dynex, VA, USA) at 450 nm and OD values at 540 nm subtracted to correct for optical plate 
imperfections. Mean OD values were used to create a standard curve using revelation software 
(Dynex, VA, USA), which was used to obtain human VEGF levels. 
 
2.6.3 ELISA for Chloramphenicol Acetyltransferase (CAT) 
A CAT Elisa kit (Roche) was used to quantify CAT levels in samples according to the 
manufactures instructions. Cells were lysed directly in wells with the lysis buffer provided. 200 
µL of CAT standard or cell lysate was added to capture antibody labelled microplate modules 
and left for 1 hour at 37 °C. Cells were then washed 3 times with 250 µL of washing buffer. 200 
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µL of Anti-CAT-digoxigenin solution was added to each well and left for 1 hour at 37 °C. Cells 
were washed 3 times with 250 µL of washing buffer. 200 µL of anti-digoxigenin-peroxidase 
solutions was added to each well and left for 1 hour at 37 °C. Cells were washed 3 times with 
250 µL of washing buffer. 200 µL of peroxidise substrate was then added to each well and left 
for 10 minutes at room temperature. Absorbance at 405 nm (using 490 nm as a reference) was 
determined using an Opsys MR 96-well plate absorbance reader (Dynex, VA, USA). Mean OD 
values were used to create a standard curve using revelation software (Dynex, VA, USA), which 
was used to obtain CAT levels. 
 
2.6.4 In vitro bioluminescence quantification 
Bioluminescence was originally measured using the IVIS camera (In Vivo Imaging System; 
Xenogen Corp., CA, USA). Media was aspirated and replaced with 150 μg/mL D-Luciferin 
(Xenogen Corp, CA, USA) in PBS at 37 C and luminescence measured after 2 minutes. Light 
emission was quantified as the sum of all detected photon counts within uniform-sized regions 
of interest (ROI) with each well manually defined during post-data acquisition image analysis. 
This was measured in photons per second per cm
2
 (p/s/cm
2
) using Living Image software 
(Xenogen Corp., CA, USA). 
 
During the course of this project a Perkin Elmer Victor II Multi-label plate-reader became 
available and was used for all luciferase reporter assays. Cells were lysed with passive lysis 
buffer (Promega), centrifuged at 6000 rpm for 3 minutes at 4 °C, kept on ice and used fresh for 
each assay. 20 µL of sample was added to each well of a white polystyrene plate (Corning Life 
Sciences) and warmed to 37 °C. 75 µL of luciferase reagent (Promega) was added to each well 
using the automated dispenser. Bioluminescence was measured for 1 second and samples were 
assayed in triplicate. 
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2.6.5 In vitro red fluorescent quantification 
The Perkin Elmer Victor II Multi-label plate-reader was used to measure fluorescence using an 
excitation wavelength of 560 nm and an emission wavelength of 620 nm. Cells were lysed with 
passive lysis buffer (Promega), centrifuged at 6000 rpm for 3 minutes at 4 °C, kept on ice and 
used fresh for each assay. 50 µL of each sample was added to each well of a white polystyrene 
plate (Corning Life Sciences) and the fluorescence quantified in triplicate for each sample. The 
autofluorescence of control cells was subtracted from the average for each sample. 
 
2.7 Tissue culture technique and viral assays 
2.7.1 siRNA gene silencing 
Gene silencing was performed using siGenome siRNA smartpools (Dharmacom, IL, USA). 
targeting four sequences unique to each gene. Sequences are shown in the relevant results 
chapter. Cells were seeded in antibiotic-free complete DMEM supplemented with 10% FCS at a 
density of 2x10
4
 cells per well in 24 well plates or 1x10
6
 cells per well in 6 well plates. Cells 
were then transfected 16 hours later with 25 nM of siRNA. The protocol for preparing siRNA 
transfection mix for one well of a 24 well plate was used as follows. A 5 μM siRNA solution in 
1X siRNA Buffer (Dharmacon) was prepared from the stock reconstituted 20 μM solution using 
RNase-free water. In separate tubes 5 μM siRNA solution and DharmaFECT transfection 
reagent 1 were diluted with serum-free medium. Tube 1 – 2.5 μL of 5 μM siRNA and 47.5 μL 
serum-free medium. Tube 2 – 2 μL DharmaFECT reagent 1 and 48 μL of serum-free medium. 
The contents of each tube were incubated for 5 minutes at room temperature. Tube 1 and Tube 2 
were combined and incubated for 20 minutes at room temperature. Sufficient antibiotic-free 
medium supplemented with 10% FCS was then added to make the final volume 500 µL. The 
culture medium was removed and replaced with 500 μL of medium containing siRNA. This 
protocol was then adapted for the volume of transfection medium required for each experiment. 
SiGenome RISC-free Control siRNA was used in place of as a negative control (Dharmacon, 
IL, USA). Minimal toxicity was noted on transfection of cells with DharmaFECT reagents. All 
reagents were purchased from Dhamacon, IL US. 
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2.7.2 Cytotoxicity of Vaccinia virus by MTS assay 
The potency of viruses was determined by CellTiter 96
®
 AQueous Non-Radioactive Cell 
Proliferation (MTS) assay (Promega). Cells were infected with nine serial dilutions of virus in 
96 well plates and the proportion of cells alive after 6 days at each viral concentration compared 
to a non-infected control following the addition of MTS reagents.  
 
Cells were cultured in 90 L of DMEM with 5% FCS in 96-well plates at a density of between 
1x10
3
 and 5x10
3
 cells per well, depending on the rate of cell growth, to ensure that mock-
infected wells were nearly confluent 6 days after infection. Plates included six replicates. Plates 
were incubated at 37 C in normoxia or hypoxia and 16 hours later, infected with 10 L of 9 
serial dilutions of viruses (range optimised for each cell line) diluted in media with 5% FCS or 
mock-infected with media with 5% FCS alone and returned to normoxic or hypoxic conditions. 
6 days following infection, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H tetrazolium) was added to PMS (phenazine methosulfate; Promega, WI, 
USA) according to the manufacturer‟s instructions in a ratio of 20 MTS: 1 PMS. 20 L was 
added to each well and plates incubated for 1 to 3 hours. Cell viability was determined by 
measuring the absorbance or optical density (OD) at 490 nm using an Opsys MR 96-well plate 
absorbance reader (Dynex, VA, USA). Cell viability was determined in infected cells in 
comparison to mock-infected cells (positive control) after correction for absorbance due to the 
media alone (negative control). All OD values in positive controls were greater than 1. The 
concentration of virus required to kill 50% of cells (half maximal effective concentration or 
EC50) was then calculated for each cell line (section 2.11.1) and a dose-response curve created 
by non-linear regression using Prism
®
 (GraphPad Software, CA, USA). Experiments were 
repeated in duplicate. 
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2.7.3 Viral replication assay 
Cells were seeded in 3 wells of a 6-well plate in 2 mL of media with 10% FCS at a density of 
2x10
5
 cells per well. One plate was seeded for each virus at time points 24, 48, 72, and 96 hours 
with a further control plate. All plates were incubated overnight at 37 C in normoxic or 
hypoxic conditions.  
 
Plates were infected by 2 mL of media with 2% FCS containing Vaccinia virus Lister strain at a 
multiplicity of infection (MOI) of 1 pfu/cell in human tumour cell lines. Cells and supernatant 
were harvested together by scraping from each individual well to give samples in triplicate at 
every time point. Samples were frozen in liquid nitrogen and thawed in a 37 C water bath three 
times. 
 
The titres of purified viruses and the replication of viruses in cell lines were determined by 
measuring the 50% tissue culture infective dose (TCID50) of samples titrated onto indicator 
cells. 1x10
4
 CV1 cells were seeded in 200 μL of DMEM with 10% FCS into 96 well plates and 
incubated at 37 C in air supplemented with 5% CO2. 16 to 18 hours later, plates were infected 
with purified virus or viral burst assay sample lysates diluted to 1x10
-5
 or 1x10
-3
 respectively in 
DMEM supplemented with 10% FCS. 20 μL was added with a multi-tip pipette to all 12 wells 
of the top row and mixed. Following a change of pipette tips, serial 1:10 dilutions were made to 
the next 7 consecutive rows of CV1 cells up to a dilution of 1x10
-11
 for purified virus or 1x10
-9
 
for burst assay sample lysates. Row H was left uninfected as a negative control. 
 
The CPE of viruses on CV1 cells were determined by light microscopy 10 days after infection. 
Each well was scored 0 (no CPE) or 1 (any CPE) to make a score for each row out of 12. These 
were used to calculate the TCID50 using the established Reed-Meunch accumulate method 
(section 2.11.2). TCID50 plates were performed in duplicate for each sample, with three 
Chapter 2 
 
66 
 
samples at each time point. Purified viral titres were converted to pfu/mL and viral burst titres to 
pfu/cell based on the number of cells present at viral infection. 
 
2.7.4 VVLister genome replication 
For the assessment of Vaccinia virus DNA replication MiaPaca2-VEGF-165 and MiaPaca2-
Vector Control cells were infected as for the viral replication assay indicated above. Cells were 
collected at 24, 48 and 72 hours post-infection, DNA extracted and qPCR performed as 
outlined.  
 
2.7.5 Quantification of EEV production 
Miapaca2-VEGFp165 and Miapaca2-Vector Control cell lines were seeded at a density of 2x10
5
 
cells per well in 3 wells of a 24 well plate. After incubation for 16 hours at 37 ºC cells were 
infected with Vaccinia virus Lister strain at an MOI = 1 pfu/cell. 24 hours later before any CPE 
was evident only the supernatant was collected from the infected wells. This was then used 
without freeze-thawing to infect CV1 cells in a standard viral titration assay as outlined below. 
This method was previously used by Reeves et al to assess the effect of bcr-abl inhibition of 
EEV release (163). 
 
2.7.6 Viral internalisation and attachment 
Suit-2 cells were transfected with VEGF siRNA or control RISC-free siRNA for 72 hours 
before use. Miapaca2-VEGFp165 and Miapaca2-Vector control were cultured in 100mm dishes 
overnight in DMEM supplemented with 10% FCS. Cells were then trypsinised and suspended at 
a density of 1.5x10
5
 cells in a 1.5 mL Eppendorf in 100 µL of serum-free DMEM and kept on 
ice. Each cell type and time point was performed in duplicate and sufficient samples were 
prepared to assess viral attachment to the cell membrane and then internalisation at time points 
indicated in the results. Cells were then infected with an MOI = 10 pfu/cell of wild type Lister 
strain Vaccinia virus in 100 µL of buffer and left on a roller at 4 °C for 1 hour.  For viral 
attachment samples cells were centrifuged at 3000 rpm for 5 minutes at 4 °C. The supernatant 
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was then removed and washed once with cold PBS supplemented with 1% BSA. This was 
repeated a second time to remove unattached virus before the cells were pelleted at -80 °C or 
used immediately for DNA extraction. The remaining samples were vortexed gently and placed 
in a normoxic incubator at 37 °C until the indicated time points, after which cells were 
centrifuged and washed in cold PBS supplemented with 1% BSA. Cells were then resuspended 
in PBS with Pronase  (Roche, UK) at a dilution of 1.0 mg/mL for 30 minutes on ice to remove 
any attached but uninternalised virus (128). Cells were then centrifuged and washed once in 
cold PBS before pelleting for storage or DNA extraction and subsequent qPCR. 
 
2.7.7 Immunofluorescence confocal microscopy 
2.7.7.1 Validation of specific labelling of Vaccinia virus-488 with Alexa Fluor-488 
Specificity of labelling of the viral envelope with Alexa Fluor-488 was performed by assessing 
co-localisation of the Alexa Fluor-488 probe with a Vaccinia virus-specific antibody. Suit-2 
cells were seeded at a density of 5x10
4
 in three wells of a chamber slide in 500 µL of DMEM 
with 10% FCS. After 16 hrs, two chambers were infected with a 1:100 dilution of labelled 
Vaccinia virus-488 for 1 hour in DMEM supplemented with 5% FCS and the third chamber was 
mock-infected. The medium was removed and cells washed with PBS. These were then fixed 
with methanol for 10 minutes at -20 ºC. Cells were rinsed slowly three times with PBS and 
blocked for 1 hour at room temperature in PBS with 1% BSA. Cells were incubated with 
primary anti-Vaccinia virus rabbit polyclonal antibody at a 1:500  dilution (Serotac, USA) in 
PBS with 1% BSA for 1 hour at room temperature in one virally infected chamber and one 
mock-infected chamber. In the remaining virally infected chamber isotype control IgG at 1:500 
(Santa Cruz, CA, USA) in PBS with 1% BSA was added for 1 hour at room temperature. Cells 
were rinsed slowly three times with PBS and incubated with secondary antibody Alexa Fluor 
546 donkey anti-rabbit IgG (Invitrogen, USA) at 1:1000 dilution in PBS with 1% BSA for 1 
hour at room temperature. This was rinsed slowly three times with PBS and once in dH2O. Cells 
were protected with a cover slip mounted using Vectashield Mounting Media with DAPI 
(VectorLabs, USA), dried for 1 hour at 37 °C and protected from light until use. A Zeiss LSM 
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510 META laser scanning microscope was used for fluorescent 2D image and Z stack image 
capture and the Zeiss Zxiovision LE software for image presentation (Carl Zeiss Microimaging 
GmbH, Germany). 
 
2.7.7.2 Assessment of viral attachment and internalisation using fluorescence confocal 
microscopy. 
To assess attachment and binding of Vaccinia virus-488 to Suit-2 cells with or without VEGF 
knockdown, Suit-2 cells were seeded at a density of 2x10
4
 cells per chamber in 500 µL of 
DMEM supplemented with 10% FCS. Cells were seeded in all four chambers on each slide and 
incubated overnight at 37 °C in normoxia. Sufficient chamber slides were seeded to assess viral 
attachment and the internalisation at the indicated time points. Cells were then transfected with 
100 nM concentration of SiGenome Smartpool hVEGF siRNA, Control RISC free siRNA, 
Dharmafect Reagent 1 only or DMEM only. After 72 hours cells were washed twice in cold 
PBS. Vaccinia virus-488 was diluted 1:170 in cold DMEM supplemented with 5% FCS. Cells 
were left to attach at 4 °C for 1 hour then washed x 3 with cold PBS. The first slide was fixed in 
methanol for 10 minutes at -20 °C. Warm DMEM was added to the remaining slides and left at 
37 °C for 5 minutes, 15 minutes and 30 minutes. These slides were fixed in 100% methanol for 
10 minutes and rinsed slowly three times with PBS. They were blocked for 1 hour at room 
temperature in PBS with 1% BSA and incubated with anti α-tubulin murine mAb at a 1:500 
dilution (Sigma, UK) at room temperature for 1 hour in PBS with 1% BSA. Cells were rinsed 
slowly three times with PBS. Cells were incubated with Alexa Fluor 546 rabbit anti-mouse IgG 
at a dilution of 1:1000 at room temp for 1 hour in PBS with 1% BSA then rinsed slowly three 
times with PBS. Slides were mounted and imaged as outlined previously. Ten representative 
images of each experiment condition were taken with 63x lens on Zeiss Confocal Microscope. 
The ratio of internalised particles per cell and the number of infected versus uninfected cells 
was counted and results then analysed with Graph Pad Software using the students T-test for 
statistical analysis. 
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2.7.8 In vivo bioluminescent imaging 
All imaging experiments were performed by CH at the Barts and The London School of 
Medicine and Dentistry Biological Services Unit (Charterhouse Square, London, UK) in 
accordance with the UK co-ordinating committee on cancer research guidelines and the Animals 
(Scientific Procedures) Act 1986 and the guidelines for the welfare and use of animals in cancer 
research (181). During all in vivo experiments, the general health of mice was assessed daily 
and animals sacrificed if signs of ill health were seen such as piloerection, hunched posture, 
20% loss of body weight, diarrhoea or dyspnoea. Animals were also sacrificed if tumours 
ulcerated, impeded vital functions such as locomotion and excretion or tumour size (maximum 
length x maximum breadth) reached 1.4 cm
2
.  
 
Miapaca2-VEGFp165, Miapaca2-VEGFp121 and Miapaca2-Vector Control were used to 
establish tumour xenografts in the flank of 4-5 week-old Balb/c nude mice (Harlan UK Ltd., 
Bicester, Oxon, UK). 5x10
6
 cells in 150 µL of sterile PBS were injected using a 22 G needle 
into the right flank of each animal and there were five mice per group of each cell type. When 
tumours reached 0.4-0.5 cm each mouse received 1x10
7
 pfu of VVL15 in 100 µL of PBS via 
intravenous (IV) tail vein injection. The biodistribution of VVL15 was determined 1, 2, 3, 5 and 
6 days following infection by measuring luciferase distribution by light emission with the IVIS 
camera according to the manufacturer‟s instructions. Mice were anaesthetised (2% isofluorane 
by inhalation in O2 1 L/min and NO 1 L/min) and received an intraperitoneal (IP) injection of 
150 mg/kg D-Luciferin at a concentration of 15 mg/mL (200 μL injection in 20 g mouse). Mice 
were placed on a stage pre-warmed to 37 °C in the light-free chamber housing the IVIS camera 
where anaesthesia was continued by nose-cone delivery.  
 
10 minutes following D-Luciferin injection, grey-scale whole-body photographic images were 
collected (field of view 15 cm; exposure 0.2 seconds; binning medium; f/stop 16) followed by 
acquisition and overlay of a colour image representing the spatial distribution of the detected 
photons emitted from the field (field of view 15 cm; exposure 0.5-120 seconds; binning 
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medium; f/stop 1). The length of bioluminescence imaging varied between 0.5 and 120 seconds 
in order to ensure that a non-saturated image was obtained. Tumours were defined as ROI and 
light emission quantified (p/s/cm
2
) using Living Image software. Results were analysed using 
Prism
®
. 
 
2.8 Histology and immunohistochemistry (IHC) 
All histology and IHC procedures were performed by Vipul Bhakta, Mohammed Ikram and 
Keyur Trivedi (Pathology Service, Barts CR-UK Centre, QMUL, London) and all slides 
reviewed by CH and YW. 
 
2.8.1 Sample processing 
Tumour xenografts and organs were collected from mice immediately after sacrifice and were 
fixed in 10% formaldehyde and then paraffin-embedded. Samples were cut into 4 μm sections 
using a Leica EG1160 microtome. Slides were stained with haematoxylin and eosin (H&E) 
according to standard protocols using a Leica autostainer XL. Further sections were cut for IHC, 
which was performed using the Ventana
®
 Discovery staining module (Ventana, Tucson, USA). 
This system used biotin-free secondary antibodies, which were already conjugated to 
streptavidin-HRP. These were visualised with a hydrogen peroxide (H2O2) substrate and 
3,3‟diaminobenzidine tetrahydrochloride (DAB) chromogen, which produced a dark brown 
product visible by light microscopy.  
 
Table 2.3: Primary Antibodies used for IHC 
 
Antibody against 1º/ 2º Species Optimised dilution Supplier 
VVLister coat 
protein 
1º Rabbit 1:200 (paraffin) 
 
MorphoSys UK Ltd, Bath, UK 
Pecam-1 (ab56299) 1º Rabbit 1:200 Abcam Ltd. Cambridge. UK. 
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2.8.2 IHC in paraffin-embedded sections for Vaccinia virus and Pecam-1. 
All staining was performed using the Ventana
®
 Discovery staining module (Ventana, Tucson, 
USA). Slides were deparaffinised using EZ Prep (Ventana) at 75 C for 8 minutes. Slides 
were heated to 95 C for 8 minutes in the presence of conditioning solution 1 (CC1; Tris-
EDTA-based buffer). A 1:200 dilution of primary antibody (Table 2.3) was applied to sections 
for 60 minutes at 37 C. Omnimap anti-Rabbit HRP was then applied 16 minutes. Sections were 
then incubated with 3,3'-Diaminobenzidine (DAB) and hydrogen peroxide for 8 minutes. 
Sections were counterstained with haematoxylin and bluing agent for two minutes. Sections 
were washed between each step. 
 
2.8.3 Quantification of Pecam-1 immunostaining 
Five tumours per group were used for analysis. Samples were collected and stained as described 
using a Pecam-1 mAb (Abcam, Cambridge, UK). Two sections were taken from the centre of 
each tumour 200 µm apart. The Zeiss Axioplan microscope (Carl Zeiss International, Gottingen, 
Germany) was used at 20x magnification to take sufficient images to cover the entire section. 
The edges of tumours, folding of sections or any images showing sample degradation were not 
included in the analysis. The images from each section were reconstructed into a montage using 
the Image J Software (National Institute of Health, Bethesda, USA) (182). Montages were then 
split into RGB channels. The blue channel was selected as giving greatest distinction between 
Pecam-1-positive staining and background. The threshold analysis tool was used to select 
vessels and any contaminating (non-vessel) stray pixels were excluded. Each montage was 
measured to give the area of Pecam-1-positive immuno-staining as a percentage of the total 
area. Measurements were combined for each group for analysis. 
 
2.9 Data handling and statistical analysis 
2.9.1 EC50 and variable slope non-linear regression 
EC50 = ((X where Y=top) – (X where Y= bottom))*0.5 
 
Chapter 2 
 
72 
 
Y= Bottom +   ____(Top-Bottom)____ 
(1+10
((LogEC50-X)*HillSlope)
) 
X = log[virus] ;Y =  %cells alive; Hillslope=steepness of curve 
Top/Bottom = Maximum/Minimum Y value (or cell death) 
 
2.9.2 TCID50 
The Reed-Muench method of TCID50 calculation is based on the adding the proportionate 
distance between CPE scores of rows above and below 6 out of 12 to the log of the viral dilution 
where CPE is 6 or less. Viral dilutions range from 10
-3
 to 10
-9
 for viral replication samples.  
This is converted to pfu/mL for purified viral titres:  
Since volume of sample inoculated into the first row = 0.02 mL 
 
2.9.3 Statistical analysis 
Data sets were initially confirmed as normally distributed or not using the D'Agostino and 
Pearson test of normality. Comparisons were then performed using two-tailed unpaired t-tests or 
a Mann-Whitney U test as appropriate. A repeated measures two way ANOVA with a 
bonferroni correction was used to compare bioluminescence for in-vivo time course 
experiments. 
 
TCID50/mL = (1/ TCID50)*(1/0.02) 
TCID50 PFU/mL = TCID50/mL*0.69  
This is then converted into PFU/cell for viral replication titres. 
TCID50 (PFU/cell)  =  ____TCID50 PFU/mL___ 
number of cells at infection 
log TCID50 = log (viral dilu
n
 at row above 50% CPE) – __(% CPE next above  50%)-50%_____ 
            (% CPE next >50%)-(% CPE next ≤ 50%) 
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3 Hypoxia and Vaccinia Virus 
Many tumours are known to contain areas of hypoxia due to poorly developed vasculature. 
Adenovirus, the most commonly used oncolytic vector has been shown to replicate poorly in 
hypoxia. We wanted to assess the effect of hypoxia on the life cycle VVLister to assess its 
potential as an oncolytic viral vector in hypoxia. 
 
3.1 Validation of Hypoxic Conditions 
Hypoxia-inducible factor 1 alpha (Hif-1α) is the key protein mediating the response of cells to a 
hypoxic microenvironment. In the presence of oxygen Hif-1α is hydroxylated at specific proline 
residues which results in its interaction with the Von Hippel–Lindau gene product and 
subsequent ubiquitination and degradation (41). In the absence of ambient oxygen this 
degradation does not occur and subsequent nuclear localisation results in the transcription of 
Hif-1α target genes and cellular adaptation to hypoxia. Vaccinia Virus is becoming an 
increasingly common vector for viral gene and oncolytic therapy. However its ability to 
replicate in hypoxia has not been reported to date. In this project, hypoxic conditions were 
simulated with the use of a hypoxic incubator (Cell Chamber 170, Heto-Holten, Surrey, UK) 
maintaining the ambient oxygen concentration at 1% pO2. To validate the response of Hif-1α in 
our in vitro system, immunoblotting for Hif-1α in nuclear extracts of three pancreatic cancer cell 
lines Suit2, MiaPaca-2 and CFPac1 was carried out. This demonstrated stabilisation of the Hif-
1α protein and nuclear localisation only when exposed to 1% pO2 (Figure 3.1). The predicted 
molecular weight of Hif-1α is 92 kDa but this antibody, H1alpha67, detects a protein of 
approximately 120 kDa and it is assumed that this is due to post-translational modification of 
the protein (183). This demonstrates that a hypoxic environment can be maintained using our 
incubator and this was used to simulate a hypoxic environment in all future experiments unless 
otherwise stated. The use of the term hypoxia refers to a pO2 of 1%, 5% pCO2 and 94% pN2 
unless otherwise stated.  
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Figure 3.1: Stabilisation and nuclear translocation of Hif-1α under hypoxic conditions. 
 Cell lines were incubated in normoxic conditions (20% pO2) or hypoxia (1% pO2) for 16 
hours before harvesting of nuclear extracts for immunoblotting. Lysates were probed for Hif-
1α and proliferating cell nuclear antigen (PCNA) expression as a loading control. pO2 = 
Oxygen Partial Pressure. 
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3.2 Viral Protein Production in Hypoxia 
 
Hypoxia has been shown to limit the total amount of protein synthesis (184). Consequently we 
investigated whether production of viral proteins in pancreatic cancer cell lines exposed to 
hypoxic conditions would be altered. CFPac1 and MiaPaca2 cell lines were infected with 
VVLister at an MOI=1 pfu/cell or mock infected and lysates were harvested at 24h, 48h and 72h 
post-infection. Using an anti-VVL polyclonal antibody similar levels of Vaccinia virus protein 
were detected at 72 hours when exposed to normoxia or hypoxia as shown in lanes 6 & 7 of 
Figure 3.2. This result confirms that viral proteins are translated efficiently in hypoxic 
conditions. 
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Figure 3.2: Western Blot of Vaccinia virus protein expression in MiaPaca2 and CFPac1 in 
normoxia and hypoxia.  
Cells were maintained in normoxic or hypoxic conditions before and after viral infection. Cells 
were infected with VVLister at an MOI of 1 pfu/cell or mock infected with vehicle buffer alone. 
Membranes were probed for Vaccinia virus proteins with an anti-Vaccinia polyclonal antibody. 
This antibody detects most reliably a viral protein ~35-37 kDa in size which is likely to represent 
the 37 kDa Vaccinia virus major envelope protein. Human proliferating cell nuclear antigen 
(PCNA) was used as a loading control. 
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3.3 Viral Replication in Hypoxia 
 
The ability of replication-competent, oncolytic viruses to infect, multiply, lyse and subsequently 
infect neighbouring cells is crucial for their anti-tumour efficacy. There has been concern that 
hypoxia may present a barrier to this (185). We investigated the replication of VVLister in 
pancreatic cancer cell lines Suit-2, Miapaca2 and CFpac1 when exposed to normoxia or hypoxia 
prior to and post viral infection. Cells and supernatant were collected at 24, 48, 72 and 96 hours 
post-infection. The number of pfu/cell produced for each cell line in different conditions was 
determined using a TCID50 assay as described in the Materials and Methods. Viral replication 
in Miapaca-2 and CFpac1 cells is unaffected at any point by hypoxic conditions (Figure 3.3). 
Suit-2 cells show a similar pattern at 24h and 48h producing a high titre of infectious viral 
particles in both hypoxia and normoxia. At 72 and 96 hours post-infection even higher titres are 
achieved when replication occurs in ambient oxygen concentrations (P=0.01 and P=0.04 
respectively). In summary high viral titres of VVLister (approximately 100 pfu/cell) were 
achievable in all pancreatic cancer cell lines tested in both normoxia and hypoxia.   
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Figure 3.3: Viral replication of VVLister in normoxic and hypoxic conditions in PDAC 
cell lines.  
Viral replication was measured by TCID50 (50% tissue culture infective dose) assay of viral 
burst assays. Cell lines were exposed to normoxic (solid line) or hypoxic conditions (dashed 
line) before and after infection with an MOI=1 of VVLister. Burst assay samples were collected 
at 24, 48, 72 and 96 hours post-infection. TCID50 assays were performed on CV1 green 
monkey kidney cells. Experiments were performed in triplicate for each cell line, time point and 
condition. Results are presented as mean ± SEM. 
* 
* 
Normoxia 
 
  Hypoxia (1% Oxygen) 
Time Post-Infection (hours) Time Post-Infection (hours) 
Time Post-Infection (hours) 
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3.4  Cytotoxicity of Wildtype Vaccinia Virus in Hypoxia 
 
Effective lysis of infected tumour cells is the ultimate aim of oncolytic therapy. We used the 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) assay to determine the EC50 (dose of virus required to kill 50% of cells) for four 
pancreatic cancer cell lines using wild type Vaccinia virus. Cells were infected and maintained 
in the indicated oxygen conditions for the duration of the experiment and cell viability was 
analysed at 6 days post-infection. EC50 values were calculated (Figure 3.4).  
 
In Suit2 the EC50 in normoxia was 1.5 pfu/cell and 1.8 pfu/cell in hypoxia (P = 0.48). In Panc1 
the EC50 in normoxia was 1.2 pfu/cell and 0.8 pfu/cell in hypoxia (P = 0.07). For these two cell 
lines there was no statistically significant effect of hypoxia on viral replication. In MiaPaca2 the 
EC50 in normoxia was 187.0 pfu/cell and 9.0 pfu/cell in hypoxia (P ≤ 0.0001). In CFPac1 the 
EC50 in normoxia was 3.7 pfu/cell and 1.1 pfu/cell in hypoxia (P ≤ 0.0001). These values 
represent a statistically significant increase in Vaccinia virus cytotoxicity in Miapaca2 and 
CFPac1 cell lines maintained under hypoxic conditions, with an approximately 20-fold and 3-
fold reduction in EC50 respectively. These data suggest that the Lister strain Vaccinia Virus is a 
good agent for oncolytic viral therapy where hypoxia is likely to be present in the tumour 
microenvironment and represent a proportion of the tumour burden. 
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Figure 3.4: Effect of hypoxia on cytotoxicity of VVLister.  
Pancreatic cancer cell lines were incubated in hypoxic or normoxic conditions for at least 16 
hours, then infected with serial dilutions of VVLister and maintained under the same oxygen 
tension. The infected cells were assayed with MTS reagent at day 6 post-infection at 37 °C with 
5% CO2 for 2 hours. Viable cells were determined as a percentage of the uninfected controls 
and non-linear regression analysis was used to draw dose–response curves. The dotted line 
represents hypoxic conditions; the solid line represents normoxic conditions. Each assay 
contained six replicates and results are presented as mean ± SEM of four independent 
experiments.  
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3.5 Cytotoxicity of Recombinant Vaccinia Virus VVL15 in Hypoxia 
 
VVL15 is a recombinant Vaccinia virus provided by Istvan Fodor (Loma Linda University 
Campus, CA, USA). VVL15 was made by insertion of the firefly luciferase (fLuc) and the lacZ 
reporter genes into the thymidine kinase (TK) region of VVLister. The firefly luciferase gene 
was placed under the control of the Vaccinia early/late promoter and lacZ under the control of 
the Vaccinia promoter p7.5. This virus is valuable for following transgene expression in vitro 
and in vivo. This virus was used in subsequent experiments so we wanted to verify if there was a 
similar effect of hypoxia on the cytotoxicity of this TK-deleted oncolytic virus in MiaPaca2 and 
CFPac1. 
 
MTS assays were carried out as described previously. The EC50 values for VVL15 in MiaPaca2 
were 183.8 pfu/cell and 7.7 pfu/cell in normoxia and hypoxia respectively (P ≤ 0.0001). The 
EC50 values for CFPac1 were 7.9 pfu/cell and 2.4 pfu/cell in normoxia and hypoxia 
respectively (P ≤ 0.0001) (Figure 3.5). Although there was some difference in the mean EC50 
values for recombinant VVL15 versus wildtype VVLister a similar trend was observed. Both 
viruses were more cytotoxic under hypoxic conditions.  
  
Chapter 3 
82 
 
  
10 - 6 10 - 5 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 10 3 10 4
-50
-25
0
25
50
75
100
125
150
CFPac1
Virus  (PFU/cell)
C
e
ll
 D
e
a
th
 (
%
 C
o
n
tr
o
l)
10 - 6 10 - 5 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 10 3 10 4 10 5
-50
-25
0
25
50
75
100
125
150
MiaPaca2
Virus  (PFU/cell)
C
e
ll
 D
e
a
th
 (
%
 C
o
n
tr
o
l)
MiaPaca2 CFPac1
1
10
100
1000
20% Oxygen
1% Oxygen***
***
E
C
5
0
 V
a
lu
e
 (
p
fu
/c
e
ll)
A
B
 
Figure 3.5: Effect of hypoxia on cytotoxicity of recombinant Vaccinia virus VVL15.  
Pancreatic cancer cell lines were maintained in hypoxic or normoxic conditions for at least 16 
hours, then infected with serial dilutions of VVLister and maintained under the same oxygen 
tension. The infected cells were assayed with MTS reagent at day 6 post-infection at 37 °C with 
5% CO2 for 2 hours. Viable cells were determined as a percentage of the uninfected controls 
and non-linear regression analysis was used to draw dose–response curves. The dotted line 
represents hypoxic conditions; the solid line represents normoxic conditions. Each assay 
contained six replicates and results are presented as mean ± SEM of four independent 
experiments. 
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3.6 Viral Transgene Expression in Hypoxia 
Many replicating viruses used for oncolytic therapy have additional therapeutic transgenes 
inserted into the viral genome to increase their cytopathic effect. Examples include pro-
apoptotic proteins, prodrug-converting enzymes and cytokines (186). One attraction of Vaccinia 
virus versus more conventional viral vectors such as adenovirus or adeno-associated virus is its 
large capacity for transgene insertion (187). Although we have seen that Vaccinia virus gene 
expression is unaffected by hypoxia it is important to determine the effect of hypoxia on 
transgene expression from replication-competent Vaccinia virus if this vector is to be of clinical 
use (184).  
 
We used VVL15 to investigate the effect of hypoxia on firefly luciferase gene expression. Suit2, 
MiaPaca2, CFPac1 and Panc1 were all infected with VVL15 at an MOI=1 pfu/cell and samples 
collected at 24, 48 and 72 hours post-infection. In previous studies on the effect of hypoxia on 
other viruses isolated readings or early time points were used (103, 188). We felt it would be 
more appropriate to assay multiple and later time points to reflect the transgene expression that 
would be of interest in translational applications. The level of luciferase expression was largely 
unaffected by hypoxia (Figure 3.6). Only two of the four cell lines tested showed a significant 
difference between normoxia and hypoxia at two isolated time points. There was a decrease at 
24 hours and increase at 48 hours in luciferase expression for CFPac1 and Panc1, respectively. 
However, this difference was not sustained at later time points. This result suggests that hypoxia 
does not compromise transgene expression from replication-competent Vaccinia virus. 
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Figure 3.6: The effect of hypoxia on transgene expression from VVL15.  
Cells were seeded at a density of 3x104 per well in a 24 well plate and then infected with 1 
pfu/cell of VVL15 24 hours later. Cells were lysed and luciferase activity was measured at 24, 
48 and 72 hours post-infection using a luminometer (Perkin Elmer Victor II) after addition of 
D-Luciferin. The dashed line represents hypoxic conditions; the solid line represents normoxic 
conditions. All experiments were performed in triplicate and results represent the data from 
three separate experiments. Results are presented as mean ± SEM (solid line and triangle 20% 
pO2, dashed line and triangle 1% pO2. Light units=photons/second. * = P≤0.05). 
 
Normoxia Hypoxia
Time Post-Infection (hours) Time Post-Infection (hours) 
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3.6.1 Viral Transgene Expression in Hypoxia at an Early Time Point 
The transcription of early poxvirus genes occurs inside the viral core at less than 4 hours post-
infection using the virally encoded early transcription machinery that is packaged into the virion 
upon assembly. Intermediate and late viral gene expression occurs after peri-nuclear viral 
factories have been established at 4-5 hours post-infection (148). 
 
We performed a luciferase assay to assess the effect of hypoxia on early viral gene expression in 
CFPac1 and MiaPaca2 (Figure 3.7). There was a statistically significant increase in early gene 
expression seen for both cell lines under hypoxic conditions (P = 0.0004 and P ≤ 0.0001 
respectively). Luciferase imaging was also performed with the IVIS imager to give a visual 
impression of Luciferase expression in normoxia and hypoxia using MiaPaca2 cell line imaged 
at 4 hours post-infection and a clear difference was noted (Figure 3.8). This suggests that 
hypoxia has an effect on the viral life cycle at an early time point prior to establishment of peri-
nuclear viral factories. Additional effects at later time points are also possible.  
 
As Vaccinia virus is an enveloped virus that contains cellular proteins accumulated in the virion 
during assembly it cannot be excluded that some of the effect on Luciferase expression is the 
result of luciferase being enveloped within the viral core during viral production in CV1 cells. 
Incorporating luciferase proteins inside infective virions has been used to study the effect of 
PI3K inhibitors on the cellular entry of Ebola Virus (189). If luciferase contained inside the 
infective virion is contributing to this finding it would suggest an effect of hypoxia on viral 
entry.  
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Figure 3.7: The effect of hypoxia on early transgene expression from VVL15.  
Cells were seeded at a density of 3e4 per well in a 24 well plate and then infected with 1 pfu 
per cell of VVL15 four hours later. Cells were lysed and luciferase activity was measured at 
four hours post-infection using a luminometer (Perkin Elmer Victor II) after addition of D-
Luciferin. All experiments were performed in triplicate and results represent the data from two 
separate experiments. An unpaired two-tailed students T-test was used to compare the mean 
bioluminescence. Results are presented as mean ± SEM. *** = P ≤ 0.001. 
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Figure 3.8: Representative images of bioluminescence from MiaPaca2 parental cell 
infected with VVL15 in normoxia and hypoxia.  
MiaPaca2 cells were seeded in 6 wells plates and allowed to adhere overnight. Cells were then 
infected with VVL15 at an MOI of 10 pfu/cell, 1 pfu/cell or mock infected (M). Cells were then 
exposed to normoxia or hypoxia for 4 hours and imaged for luciferase expression using the IVIS 
imaging system. Wells are outlined in red and the same colorimetric scale is used for both 
images.   
MOI
I 
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3.7 Summary of Vaccinia Virus and Hypoxia 
 
We have demonstrated that the replication, protein production and transgene expression of the 
Lister strain Vaccinia virus is not negatively affected by hypoxia. Importantly, for translational 
applications, we found that viral cytotoxicity was augmented in two of four PDAC cell lines. 
Transgene expression from the recombinant virus VVL15 was increased in hypoxia versus 
normoxia early after viral infection. This suggests that hypoxia has a positive effect on an early 
stage of viral infection in some PDAC cell lines in vitro. 
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4 Vaccinia Virus and VEGFA 
4.1 The Effect of VEGFA Expression in PDAC Cell Lines 
Vaccinia virus is a large virus and we hypothesised that the tropism of Vaccinia virus may be 
related to the increased permeability of blood vessels in tumours compared to normal tissue, 
allowing extravasation preferentially at tumours. VEGFA was initially discovered as a factor 
released by tumour cells that increased the permeability of blood vessels (73). To test this 
hypothesis, a cell line with a low endogenous level of VEGFA that could be engineered to 
overexpress VEGFA and used to establish an in vivo tumour model with increased vascular 
permeability was required. As in other solid tumours, it has been found that VEGF is over 
expressed in pancreatic cancer (190) and that this can be regulated by hypoxia as a 
transcriptional target of Hif-1 (191).  
 
To verify the endogenous level of VEGF production and the effect of hypoxia on VEGF 
secretion by the PDAC cell lines, an ELISA was performed on the supernatant of uninfected 
cells. MiaPaca2, Suit2, CFPac1 and Panc1 cells were seeded in six well plates, allowed to 
adhere overnight and then incubated in normoxia or hypoxia for a further 24 hours. Experiments 
were designed so that all cells were at approximately 70% confluent when supernatant was 
taken to perform a subsequent ELISA. Suit2 and Panc1 had a relatively high level of VEGF 
secretion (>2000 ng/mL) compared to CFPac1 and MiaPaca2 (~1000 ng/mL). However, only in 
MiaPaca2 and CFPac1 was statistically significant hypoxic induction of VEGF observed and 
interestingly it is only in these two cell lines was a significant increase of viral cytotoxicity in 
hypoxia was noted  (Figure 4.1).  
 
Consequently we hypothesised that VEGF plays a role in the Vaccinia virus life cycle and could 
be involved in the effect of hypoxia on early gene expression. Orf virus, a member of the 
poxvirus family, produces VEGFE a vascular endothelial growth factor that is critical to viral 
infection (92). Although no homologue to VEGFA or VEGFE has been found in the Vaccinia 
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Lister strain genome it is known that another growth factor, epidermal growth factor, is 
important for Vaccinia virus infection, so we wanted to investigate if VEGFA played a role in 
the Vaccinia virus life cycle (133).  
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Figure 4.1: ELISA to assess VEGFA concentration in the supernatant of PDAC cell 
lines exposed to normoxia and hypoxia.  
MiaPaca2, CFPac1, Panc1 and Suit2 were seeded in 6 well plates and exposed to the 
relevant oxygen conditions for 48 hours when the cells were all at approximately 70% 
confluence. Fresh supernatant was taken and used for a subsequent ELISA. Experiments 
were performed in duplicate and results represent the data from two separate experiments. 
An unpaired two tailed students T-test was performed to compare the mean VEGF levels. 
Results are presented as mean ± SEM. * = P ≤ 0.05. 
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4.2 Manipulating VEGFA in PDAC cell lines 
4.2.1 Silencing of VEGF Expression in Suit2 Cells 
 
To establish cell models we selected Suit2, with a high endogenous level of VEGFA, and used a 
pool of four siRNA sequences to silence gene expression. Suit2 cells were transfected with 
Control siRNA, VEGFA siRNA (25 nM) or mock transfected and supernatant collected at 24, 
48 and 72 hours later. An ELISA was used to detect the effectiveness of VEGF silencing and 
select the optimal time for viral infection. There was some off-target (or transfection reagent) 
effect on VEGFA expression in the control siRNA-transfected cells when compared to the 
parental cell line at 48 hours. However, at 72 after transfection there was a three-fold 
differential between control and VEGFA siRNA-treated cells and consequently 72 hours after 
siRNA transfection was selected as the optimal time point for viral infection (Figure 4.2). To 
further optimise the required concentration of siRNA and quantity of transfection reagent 
required for VEGFA gene silencing 25 & 50 nM of siRNA and 1 or 2 μL of transfrection 
reagent were used and VEGFA measured 72 hours later. A combination of 25 µM of siRNA and 
2 uL of transfection was selected as optimal for VEGFA silencing (Figure 4.3). The sequences 
used for gene silencing of VEGFA are presented in Table 4.1. 
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Table 4.1: Sequence of VEGFA siRNA smartpool 
GENE 
(Ref Seq) 
siRNA Target Sequence 
VEGFA 
(NM_001025366) 
 
1-GCAGAAUCAUCACGAAGUGUU 
2-GGAGUACCCUGAUGAGAUCUU 
3-GAUCAAACCUCACC AAGGCUU 
4-AGAAAGAUAGAGCAAGACAUU 
 
 
 
  
Chapter 4 
94 
 
 
 
 
  
24 48 72
0
500
1000
1500
2000
Parental Cell Line
Control siRNA
VEGF siRNA
Time (hours)
V
E
G
F
 p
g
/m
l
 
Figure 4.2: The effect of VEGFA siRNA in the Suit2 cell line.  
To optimise timing for infection in the VEGFA-silenced Suit2 cell line, cells were transfected 
with VEGFA siRNA or siGENOME RISC-free control siRNA. Cells were transfected in 6 
well plates using 50 nM of siRNA and 2 uL of transfection reagent per well. Supernatant was 
then collected for a VEGFA ELISA at 24, 48 and 72 hours. The untransfected parental cell 
line was also included for comparison. Experiments were performed in duplicate and results 
represent the data from two separate experiments. Results are presented as mean ± SEM. * = P 
≤ 0.05. 
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Figure 4.3: Optimisation of VEGFA siRNA in Suit2 cells.  
Cells were transfected with 50 or 25 nM of VEGFA or Control siRNA using either 1 or 2uL of 
transfection reagent per well of a six well plate. Supernatant was collected 72 hours later and a 
VEGFA specific ELISA was used to measure VEGFA concentration. The VEGF level of the 
parental cell line at 72 hours is shown for comparison. Experiments were performed in 
duplicate and results represent the data from two separate experiments. Results are presented 
as mean ± SEM. 
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4.2.2 Over-expression of VEGF in MiaPaca2 
 
In order to create a stable model, VEGFA- overexpressing and paired vector-control MiaPaca2 
cells were selected as they have a relatively low endogenous level of VEGFA. The sequence 
NM_001025368.1 corresponding to Homo sapiens VEGFA transcript 4 coding for VEGF 
isoform p165 was used. This was supplied from the manufacturer in the Vector pCMV6-XL4 
(Origene, Rockville MD, USA). The pCMV6-Neo vector was used for expression in eukaryotic 
cells (Origene, Rockville MD, USA). The Not1 restriction site was used to excise the VEGF 
sequence from the pCMV6-XL4 vector which was gel-purified and ligated into the pCMV-Neo 
eukaryotic expression vector creating the vector pCMV-Neo-VEGFp165. Restriction enzyme 
digestion with gel analysis and sequencing was performed to verify the integrity and orientation 
of the VEGF transcripts. MiaPaca2 cells were seeded at a density of 2x10
5
 cells per well in a 6 
well plate. The Effectene transfection reagent (Qiagen, Valencia, CA, USA) was used at a ratio 
of 1 ug of DNA to 10 µL of Effectene reagent to transfect MiaPaca2 cells with pCMV-Neo-
VEGFp165, pCMV-Neo control vector or no vector. Cells were cultured in the presence of 
G418 (Invitrogen) in DMEM supplemented with 10% FCS until cells in the untransfected wells 
were no longer viable. VEGF protein expression was then confirmed using Enzyme-linked 
immunosorbent assay (R&D Systems, Abingdon, UK). These cell lines will subsequently be 
referred to as Miapaca2-VEGF-165 and Miapaca2-Vector control. 
 
To quantify the level of VEGF over-expression the stable cell lines were seeded in 6 well plates 
and supernatant collected for a VEGFA ELISA 48 hours later. There was a three-fold increase 
in VEGF A expression in MiaPaca2-VEGF-165 compared to MiaPaca2-Vector-Control (Figure 
4.4). The stable cell line was assayed for VEGFA using an ELISA at regular intervals to 
confirm continued expression.  
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Figure 4.4: Quantification of VEGFA production in stable MiaPaca2 cell lines.  
MiaPaca2 cells were transfected with pCMV-Neo-VEGF-165 or pCMV-Neo to establish the 
stable cell lines MiaPaca2-VEGF-165 and MiaPaca2-Vector Control respectively. Cells were 
seeded in 6 well plates and incubated in normoxic conditions for 24 hours. Supernatant was 
then collected and assayed for VEGF expression using an ELISA. Experiments were 
performed in triplicate. An unpaired two-tailed students T-test was used to compare the mean 
level of VEGF. * = P ≤ 0.05. 
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4.3 The effect of VEGF expression on Vaccinia virus gene expression 
 
To investigate whether VEGF plays a role in the viral life cycle in vitro we used the Suit2 cell 
model to assess the effect of VEGF gene silencing on luciferase expression from VVL15. Suit2 
cells were seeded and allowed to adhere overnight, transfected with siRNA and infected 72 
hours later with VVL15 at an MOI = 1, 0.1 or 0.01 pfu/cell, or mock-transfected. At 24 and 48 
hours after infection, supernatant was removed, luciferin added and plates imaged immediately 
using the IVIS imaging system. VEGFA gene silencing resulted in a statistically significant log 
fold reduction of bioluminescence from VVL15. The bioluminescence from control siRNA-
treated cells was comparable to the parental cell line. A reproducible effect was seen at both 24 
and 48 hours and was consistent at all MOIs (Figure 4.5). A representative image taken at 48 
hours after infection is shown in Figure 4.6.  
To confirm these findings similar experiments were performed using MiaPaca2-VEGF-165 and 
MiaPaca2-Vector Control cell lines. Cells were seeded and allowed to adhere overnight and 
then infected with VVL15 at an MOI = 1 pfu/cell. Hypoxia affects bioluminescence from 
VVL15 as early as 4 hours post-infection. To see if hypoxic induction of VEGF may be 
implicated in VVL15 infection, cells were analysed for luciferase expression at 4, 24 and 48 
hours post-infection. There was a statistically significant increase in bioluminescence in 
MiaPaca2-VEGF-165 verses MiaPaca2-Vector Control. The over expression of VEGF results in 
a greater than three-fold increase in luciferase expression from VVL15 at 4 hours post-infection 
and greater than two-fold increase at 24 hours post-infection. By 48 hours post-infection this 
finding had diminished and there was no significant difference between MiaPaca2-VEGF-165 
and MiaPaca2-Vector Control (Figure 4.7).   
These findings suggest that VEGF has a positive effect on the Vaccinia virus life cycle and that 
the mechanism operates early in the process of infection. However it is possible that VEGF may 
mediate effects at multiple points in the viral life cycle. 
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Figure 4.5. The effect of VEGFA silencing on expression of the firefly luciferase 
reporter gene from VVL15.  
Suit2 cells were seeded in a 24 well plate. Cells were transfected with siRNA 24 hours later 
and then infected 72 hours after this with VVL15 at an MOI = 1, 0.1 or 0.01 or mock 
infected. Cells were lysed in the well and the substrate D-Luciferin was added. Plates were 
then imaged immediately using the IVIS imager and the baseline bioluminescence from 
mock infected cells was subtracted from infected wells. Cells were imaged at 24 and 48 
hours post-infection. Experiments were performed in triplicate and results represent the data 
from two separate experiments. Results are presented as mean ± SEM. *** = P ≤ 0.001, ** = 
P ≤ 0.01, * = P ≤ 0.05. 
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Figure 4.6: A representative image of the effect of VEGFA silencing on expression of the 
firefly luciferase reporter gene from VVL15.  
Suit2 cells were seeded in a 24 well plate. Cells were transfected with siRNA 24 hours later and 
then infected 72 hours after this with VVL15 at an MOI = 1, 0.1 or 0.01 or mock infected. Cells 
were lysed in the well and the substrate D-Luciferin was added. Plates were then imaged 
immediately using the IVIS imager and the baseline bioluminescence from mock-infected cells 
was subtracted from infected wells. Cells were imaged at 48 hours post-infection. The same 
colorimetric scale was used for all images. PCL = parental cell line, Mock = mock-transfected. 
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Figure 4.7: The effect of VEGF overexpression on the expression of the firefly 
luciferase reporter gene from VVL15.  
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control were seeded in a 24 well plate. Cells 
were infected 24 hours later with VVL15 at an MOI = 1 or mock infected. Cells were lysed 
in the well and the substrate D-Luciferin was added. Plates were then imaged immediately 
using the IVIS imager and the baseline bioluminescence from mock infected cells was 
subtracted from infected wells. Cells were imaged at 4, 24 and 48 hours post-infection. 
Experiments were performed in triplicate and results represent the data from two separate 
experiments. Results are presented as mean ± SEM. *** = P ≤ 0.001, ** = P ≤ 0.01. 
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4.4 The effect of VEGF expression on Vaccinia virus replication 
 
We have determined that VEGF has a positive effect on luciferase expression from VVL15, but 
it is unclear whether this translates into an increase in production of infective virions. The effect 
of VEGF expression on wildtype Lister strain Vaccinia virus was investigated using the Suit2 
and MiaPaca2 cell models. Suit2 cells were seeded in six well plates and allowed to adhere 
overnight. They were then transfected with VEGFA siRNA or Control siRNA and infected 72 
hours after this with VVLister at an MOI=1 pfu/cell. Cells and supernatant were collected at 24, 
48, 72 and 96 hours post-infection. CV1 green monkey kidney cells were used as indicator cells 
and infected with collected lysates in a TCID50 assay. There was a statistically significant 
reduction in infective virions produced in Suit2 cells after VEGF gene silencing at 48, 72 and 96 
hours post-infection (Figure 4.8). A small amount of supernatant was also collected from all 
cells for a VEGF ELISA to verify that VEGF gene silencing was not lost towards the latter time 
points of the viral replication assay. Although there is a re-emergence of VEGFA secretion at 96 
hours post-infection in the VEGF siRNA-treated Suit2 cells a large differential between Control 
siRNA and VEGF siRNA treated cells persists for the duration of the experiment (Figure 4.9).  
 
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control were also used to test the effect of VEGF 
overexpression on the replication of wildtype Lister strain Vaccinia virus. Cells were seeded in 
6 well plates, allowed to adhere overnight then infected with VVLister at an MOI=1pfu/cell. 
Lysates were collected at 24, 48, 72 and 96 hours post-infection and CV1 cells used as indicator 
cells to determine a viral titre using a TCID50 assay. A statistically significant increase in viral 
replication was seen in MiaPaca2-VEGF-165 versus MiaPaca2-Vector Control at 48 and 72 
hours post-infection (Figure 4.10). This difference was lost at 96 hours post-infection, similar to 
the loss of a statistically significant difference in gene expression at later time points in this 
model using VVL15. A small amount of supernatant was also used to verify persistent 
overexpression of VEGF during the viral replication assay and MiaPaca2-VEGF-165 produced 
40-50% more VEGFA throughout the experiment ( 
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Figure 4.11). 
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Figure 4.8: The effect of VEGFA gene silencing on VVLister replication.  
Viral replication of VVLister in Suit2 cell line transfected with VEGFA siRNA (dashed line) 
or siGENOME RISC-free control siRNA (solid line) measured by TCID50 (50% tissue 
culture infective dose) assay of viral burst assays. Cell lines were infected with a multiplicity 
of infection (MOI) 1 of VVLister and burst assay samples were collected at 24, 48, 72 and 
96 hours post-infection. TCID50 assays were performed on CV1 green monkey kidney cells. 
Experiments were performed in triplicate for each cell line, time point and condition. Results 
are presented as mean ± SEM. * = P ≤ 0.05. 
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Figure 4.9: Confirmation of VEGFA silencing in Suit2 cell line during viral replication 
assay.  
A sample of supernatant (50 µL) was taken from each viral burst assay before infection and 
then at 24, 48 and 96 hours post-infection. A VEGFA specific ELISA was used to quantify 
VEGF levels in the supernatant to ensure VEGF silencing had not been lost at later time 
points. Mean values are presented and experiments were performed in duplicate. 
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Figure 4.10: The effect of VEGFA over-expression on VVLister replication.  
Viral replication of VVLister (Lister vaccine strain of Vaccinia virus) in MiaPaca2-VEGF-165 
(solid line) and MiPaca2-Vector Control (dashed line) cells as measured by TCID50 assay of 
viral burst assays. Cell lines were infected with an MOI = 1 of VVLister and burst assay 
samples were collected at 24, 48, 72 and 96 hours post-infection. TCID50 assays were 
performed on CV1 green monkey kidney cells. Experiments were performed in triplicate for 
each cell line, time point and condition. Results are presented as mean ± SEM. ** = P ≤ 0.01, * 
= P ≤0.05. 
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Figure 4.11: Confirmation of VEGFA expression in MiaPAca2-VEGF-165 and MiaPaca2-
Vector Control cell lines during viral replication assay.  
A sample of supernatant (50 µL) was taken from each viral burst assay before infection and then 
at 24, 48 and 96 hours post-infection. A VEGFA specific ELISA was then used to quantify 
VEGF levels in the supernatant. Mean values are presented and experiments were performed in 
duplicate 
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4.5 The effect of VEGF on Vaccinia virus cytotoxicity in PDAC 
 
The presence of VEGF increases viral transgene expression and the production of infectious 
virions. The next question addressed was whether VEGF could affect the oncolytic ability of 
Vaccinia virus. MiaPaca2-VEGF-165 and MiaPaca2-Vector control cells were seeded in 96 well 
plates and infected with serial dilutions of wildtype Lister strain virus. An MTS assay was 
performed at 6 days post-infection to determine the percentage of viable cells remaining and a 
dose response curve was drawn in order to calculate an EC50 value (Figure 4. 12-A&B). The 
dose-response curve represents a composite of all experiments where as an EC50 value was 
calculated for each assay plate and the mean EC50 values for VVLister in MiaPaca2-VEGF-165 
and MiaPaca2-Vector Control cells compared. A highly statistically significant reduction in the 
EC50 value, therefore increase in viral cytotoxicity, was seen for MiaPaca-VEGF-165 
compared to MiaPaca2-Vector Control (26.5 vs. 122.4 pfu/cell, P<0.0001).  
 
As CFPac1 cells showed a significant increase in viral cytotoxicity in hypoxia, recombinant 
human VEGF (rhVEGFA) was used to stimulate CFPac1 cells and see if any effect was seen on 
viral cytotoxicity. Cells were seeded in a 96 well plate format, stimulated with rhVEGFA and 
infected with serial dilutions of VVLister. A dose of 2 ng/mL was selected as this was the level 
of VEGFA found in other pancreatic cancer cell lines and therefore deemed to be an appropriate 
concentration (Figure 4.1). An MTS assay was performed 6 days after viral infection and a 
statistically significant increase in viral cytotoxicity was found in CFPac1 cells treated with 
rhVEGF versus untreated cells with EC50 values of 0.13 and 0.26 pfu/cell respectively (P 
<0.001) (Figure 4.13). 
 
A 96 well plate format was more difficult to use with the Suit2 VEGF gene silencing cell model 
and results were not reproducible. Instead cells were seeded in 24 well plates and an MTS assay 
used to determine the percentage of cells killed at 3 days post-infection (Figure 4.15). A small 
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but statistically significant increase in the EC50 value was found in VEGF siRNA treated cells 
versus control siRNA treated cells (2.19 pfu/cell vs. 1.79 pfu/cell respectively). 
 
These data show that modulating VEGF levels prior to viral infection using overexpression, 
siRNA knockdown or addition of recombinant human VEGF affects viral potency and that 
increased cytotoxicity is associated with increased VEGF. 
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Figure 4. 12 : Effect of VEGF on the cytotoxicity of VVLister.  
 
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control cells were infected with serial dilutions 
of VVLister. The infected cells were assayed with MTS reagent at day 6 post-infection at 37 
°C with 5% CO2 for 2 hours. Viable cells were determined as a percentage of the uninfected 
controls and non-linear regression analysis was used to draw dose–response curves (A) and 
determine the EC50 value (B). Each plate contained six replicates, each assay used two 96 
well plates. Each assay was repeated four times making a total of eight 96 well plates. For 
clarity the dose response curve shown is calculated from a combination of all the 48 replicates. 
The EC50 value is presented as the geometric mean of the eight plates with the 95% 
confidence interval. An unpaired students T-test was performed to compare geometric means 
**** = P ≤ 0.0001. 
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Figure 4.13  : The effect of rhVEGF on the cytotoxicity of VVLister in CFPac1 cells.  
 
Cells were stimulated with 2 ng/mL of rhVEGFA-165 for 5 minutes prior to infection with 
VVLister. An MTS assay was then used to assess cell viability at 72 hours post-infection. 
Viable cells were determined as a percentage of the uninfected controls and non-linear 
regression analysis was used to draw dose–response curves and determine the EC50 value. 
Each plate contained six replicates, each assay used two 96 well plates. Each assay was 
repeated twice making a total of 24 replicates. The EC50 value is presented as the geometric 
mean of the four plates with the 95% confidence interval. An unpaired students T-test was 
performed to compare geometric means *** = P ≤ 0.001. 
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Figure 4.14: The effect of VEGF silencing on the cytotoxicity of VVLister.  
 
Suit2 cells were seeded in 24 well plates and transfected with VEGF siRNA or siGENOME 
RISC free control siRNA. Cells were infected with VVLister at 72hours after siRNA 
transfection. The infected cells were assayed with MTS reagent at day 3 post-infection at 37 
°C with 5% CO2 for 1 hour. Viable cells were determined as a percentage of the uninfected 
controls and non-linear regression analysis was used to draw dose–response curves and 
determine the EC50 value. Each plate contained three replicates, each assay used two 24 well 
plates. Each assay was repeated twice making a total of 12 replicates. The EC50 value is 
presented as the geometric mean of the four plates with the 95% confidence interval. An 
Mann-Whitney U Test was performed to compare geometric means as results were not 
normally distributed ** = P ≤ 0.01.  
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4.6 The effect of VEGF on viral replication in Normal Human Bronchial Epithelial cells. 
 
Pox viruses are known to enter via the respiratory epithelium and it has been shown that EGF 
maintains epithelial integrity to allow viral replication in this context (139). Since it has been 
published that respiratory epithelium expresses VEGF and its receptors we were interested to 
determine whether exogenous VEGF could increase the susceptibility of cells to wildtype 
Vaccinia virus infection (192-194). Normal human bronchial epithelial (NHBE) cells were 
seeded in growth media without bovine pituitary extract which might potentially contain VEGF.  
 
Viral replication in NHBE cells was performed using BEGM (without BPE and hEGF) or 
BEGM (without BPE and hEGF) supplemented with 10 ng/mL of rhVEGF (Peprotec, London, 
UK). Cells were infected with Lister strain Vaccinia virus at an MOI of 0.1 pfu/mL 10 minutes 
after the addition of rhVEGF. Collection and processing of samples was then performed as for 
other viral burst assays. 
 
Significantly higher levels of viral replication were seen at 72 hours in the NHBE cells infected 
in the presence of rhVEGF (Figure 4.15). Although results were not as marked compared to the 
effect seen in PDAC cells, this suggests that VEGF may play a more fundamental role in 
Vaccinia virus infection and is not restricted to the infection of transformed cell lines. 
  
Chapter 4 
113 
 
  
  
 
Figure 4.15: The effect of VEGF on the replication of VVLister in normal human 
bronchial epithelial (NHBE) cells as measured by TCID50 assay of viral burst assays.  
 
Cells were seeded in growth mediator without growth factors and were then stimulated with 
10 ng/mL of rhVEGFA-165 for 5 minutes prior to infection with VVLister. NHBE cells were 
infected with an MOI = 0.1 pfu/cell. Burst assay samples were collected at 24, 48 and 72 h 
post-infection. TCID50 assays were performed on CV1 green monkey kidney cells. 
Experiments were performed in triplicate for each cell line, time point and condition. Results 
are presented as mean ± SEM. * = P ≤ 0.05. 
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4.7 Characterization of proteases to cleave bound Vaccinia virus from infected cells using 
Real-Time Quantitative PCR 
 
The life cycle of Vaccinia virus begins with attachment to the cell membrane via an 
uncharacterized receptor followed by internalisation of the infectious viral particle. Attachment 
to the cell membrane is considered to be a passive process which can occur at 4 °C whereas 
internalisation is an active process requiring ATP and the co-ordination of complex actin 
dynamics occurring at 37 °C (121). DNA can be extracted from cells, after infection at 4 °C or 
after allowing internalisation to occur at 37 °C and the amount of viral DNA can be quantified 
as a surrogate for viral infection at these time points. However, in order to provide accurate 
results after returning cells to 37 °C for viral internalisation any virus particles which have not 
been internalised at the relevant time point need to be cleaved from the cell membrane so that 
only truly internalised particles are included for qPCR analysis. In a previous study using the 
International Health Department-J strain (IHD-J) of Vaccinia virus it has been demonstrated that 
trypsin is unable to cleave bound virus from infected cells where as pronase treatment was able 
to cleave 92% and 97% of bound IMV from rabbit kidney (RK13) and HeLa cells respectively 
(128). Subtilisin has been used to cleave adenovirus from infected cells (195) but no data exist 
for the Lister strain Vaccinia virus. Consequently it was necessary to identify a suitable protease 
that could be used in subsequent internalisation assays to cleave and remove attached but un-
internalised virus. 
 
CV1 cells were infected with VVLister at an MOI = 30 pfu/cell at 4 °C for 1 hour after which 
unattached virus was removed by washing. At this point DNA was either extracted for 
assessment of internalisation or cells were treated with pronase (0.5, 1.0, 1.5 mg/mL), Subtilisin 
(2 mg/mL) or trypsin (0.5%) for 30 minutes at 4 °C and DNA extracted for qPCR to quantify 
the efficacy of these proteases at removing bound virions from infected cells. The Vaccinia late 
transcription factor 1 (VLTF-1) primer and probe set used and are shown in Table 4.2. As found 
in previous studies, trypsin does not cleave attached virus from infected cells ( 
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Figure 4.16). Higher concentrations of trypsin were not used as this was the maximum that 
could be used without detaching cells during treatment. Both subtilisin and pronase are effective 
and are capable of removing 75% of bound virus after 30 minutes of treatment at the optimum 
concentrations. The remaining 25% may represent a proportion of virus that binds to cells in an 
alternative manner or could be removed if a more efficient protease was available. Although 
these results were not as impressive as published using the IHD-J they were considered 
sufficient for subsequent viral internalisations assays and a concentration of 1 mg/mL of 
pronase was used in all subsequent assays. 
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Table 4.2: Primers and probes used for qPCR, S = sense; AS = antisense. Vaccinia virus 
strain, Lister clone VACV107, complete genome (GenBank: DQ1211394.1) VLTF-1 
Primers and probe =112800-112872 bp. 
 
Gene Primer 
or Probe 
Sequence 
VVLister 
VLTF-1 
Probe 
(FAM) 
ATTTTAGAACAGAAATACCC 
Primers S 5‟-AACCATAGAAGCCAACGAATCC 
AS 5‟-TGAGACATACAAGGGTGGTGAAGT 
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Figure 4.16: Comparison of proteases used to cleave virus attached to cells at 4°C.  
 
CV1 cells were placed on ice and infected with VVLister at an MOI = 30 pfu/cell. Unattached 
virus was then removed and cells exposed to the relevant proteases for 30 minutes on ice. DNA 
was then extracted and 40 ng was used for qPCR using the VLTF-1 primer & probe set. 
Experiments were performed in biological duplicates and qPCR in triplicates. Results are 
presented as mean DNA copy number ± SEM. *** =  P ≤ 0.001. 
 
Chapter 4 
118 
 
4.8 The effect of VEGF on viral attachment and internalisation measured using Real-
Time Quantitative PCR 
 
To assess if VEGF has any effect on attachment or internalisation of Vaccinia virus a 
quantitative PCR assay was used to measure the proportion of viral DNA present in extracts 
from infected cells. MiaPaca2-VEGF-165 and MiaPaca2-Vector Control cells were infected 
with VVLister at an MOI = 10 pfu/cell for one hour at 4 °C. Cells were washed to remove 
uninternalised virus and DNA extracted immediately or cells returned to 37 °C for 5, 15 or 30 
minutes. Cells were then treated with pronase to remove un-internalised virus and DNA 
extracted. As seen in Figure 4.17 there is no significant difference in the attachment of Vaccinia 
virus in the presence of VEGF. However after allowing internalisation to resume there is a 
highly significant increase in viral internalisation in the MiaPaca2-VEGF-165 versus MiaPaca2-
Vector Control at 15 minutes (P = 0.0032) and 30 minutes (P < 0.0001). Suit2 cells were also 
used to investigate the effect of VEGF gene silencing on VVLister internalisation. Cells were 
infected with VVLister at 72 hours after siRNA treatment and virus was allowed to internalise 
for 30 minutes before pronase treatment and DNA extraction. There was a significant decrease 
in viral internalisation in the VEGF siRNA-treated Suit2 cells versus control siRNA treated 
cells (P = 0.0027) as shown in Figure 4.18. 
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Figure 4.17: The effect of VEGF over expression on Vaccinia virus attachment and 
internalisation as measured by quantitative PCR.  
 
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control cells were infected with Vaccinia virus at 
an MOI of 10 pfu/cell for 1 hour at 4°C. Cells were washed and then DNA extracted for 
attachment analysis or treated with pronase (1 mg/mL) for 30 minutes at 4°C DNA and then 
warmed to 37 °C. Cellular and viral DNA was then extracted 5, 15 and 30 minutes later to 
assess viral internalisation. Quantitative real-time PCR was then used to determine the genome 
copy number using the VLTF-1 primer and probe set. Experiments were performed in 
triplicate for each time point and results are the combination of two experiments. Results are 
presented as mean ± SEM. *** = P ≤ 0.001, ** = P ≤ 0.01. 
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Figure 4.18: The effect of VEGF gene silencing on Vaccinia virus internalisation as 
measured by quantitative PCR.  
Suit2 cells were transfected with VEGF siRNA or Control siRNA and then 72 hours later 
infected with Vaccinia virus at an MOI of 10 pfu/cell for 1 hour at 4 °C. Cells were washed and 
treated with pronase (1 mg/mL) for 30 minutes at 4 °C and then warmed to 37 °C. Cellular and 
viral DNA was then extracted 30 minutes later to assess viral internalisation. Quantitative real-
time PCR was then used to determine the genome copy number using the VLTF-1 primer and 
probe set. Experiments were performed in triplicate for each time point and results are the 
combination of two experiments. Results are presented as mean ± SEM. ** = P ≤ 0.01. 
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4.9 Development of fluorescently labelled Vaccinia virus VVL-488 
 
In order to confirm, using an alternative technique, that viral internalisation was affected by 
VEGF we first made a fluorescently labelled Vaccinia virus to investigate attachment and 
internalisation of viral particles. To directly visualise the process of viral infection wildtype 
Lister strain virus was coated with Alexa Fluor® 488 (Invitrogen, USA) 5-
sulphodicholorphenol ester which links the fluorescent marker to viral coat proteins. To verify 
the specificity and sensitivity of this technique CV1 cells were seeded onto a transwell on a 
microscope slide and infected with the Alexa Fluor labelled wild type Vaccinia virus (VVL-
488) or mock-infected as shown in Figure 4.19-A and C. Samples were then fixed and probed 
with anti-Vaccinia polyclonal antibody or its isotype control as shown in Figure 4.19-A/C and 
B. The images show efficient labelling of Vaccinia virus with Alexa Fluor-488 (green) and this 
appears to be specific as these foci co-localise with staining for anti-Vaccinia antibody (red) 
although not all infective virions that are detected with anti-Vaccinia antibody were labelled 
with Alexa Fluor-488. In addition the foci VVL-488 vary markedly in size. As these are all 
labelled specifically with anti-Vaccinia virus antibody, it appears likely that our virus 
preparation produces individual infective virions but also virions grouped in clumps perhaps 
due to incomplete disruption of host cell membranes during virus production. However, this 
difference in size does not seem to affect virus attachment in these or subsequent images.  
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Figure 4.19: Validation of labelling of wild type lister strain virus with Alexa Fluor-488.  
Split channels images: Top left=Dapi, Top right=488, Bottom left=546, Bottom right=combined 
image. Panel A - Split channel image of CV1 cells infected with VVL-488 (green) and stained 
with Vaccinia virus polyclonal rabbit IgG (red) and nuclear stain DAPI (blue). Panel B – Split 
channel image of CV1 cells infected with VVL-488 (green) and isotype control RbIgG (red). 
Panel C – Split channel image of mock-infected CVI cells counterstained with Vaccinia virus 
polyclonal rabbit (red). Images were taken at 64x magnification with Zeiss LSM 510 META 
laser scanning microscope.  
 
A 
 
B 
 
C 
 
Chapter 4 
123 
 
4.9.1 The effect of VEGF on attachment and internalisation of VVL-488 assessed using 
confocal fluorescent microscopy 
 
In order to assess visually if VEGF facilitates Vaccinia virus internalisation, the fluorescently 
labelled VVL-488 was used to infect Suit2 cells transfected with VEGF siRNA or Control 
siRNA. After returning cells to 37 °C previous experiments had indicated that 30 minutes was 
required before a difference was seen in viral internalisation, therefore images were taken at 30 
minutes. Suit2 cells were seeded into chamber microscope slides and later transfected with 
control or VEGF specific siRNA. Three days after siRNA transfection cells were infected with a 
1:200 dilution of VVL-488. Chamber slides were warmed to 37 °C and then fixed at 30 minutes 
post-infection for confocal microscopy. Images of VEGF siRNA treated cells (Figure 4.20) and 
a representative Z-stack image (Figure 4.21) show reduced attachment and internalisation of 
viral particles compared to control siRNA treated cells (Figure 4.22 & Figure 4.24). Membrane 
fusion and macropinocytosis have both been implicated in the internalisation of Vaccinia virus 
and although it is not possible to determine which GFP foci represent intact virions and which 
are viral membranes fused with cellular membranes VEGF siRNA cells are clearly less 
infectable at this time point. Quantification of attachment and internalisation was performed 
despite this caveat. Z-stack 3D representations of 10 fields of view were taken for the VEGF 
siRNA and control siRNA treated Suit2 cells. A clearly isolated GFP foci was counted as one 
virion and small or large foci counted equally. Two independent observers, who were blinded to 
sample group, scored images at the time of viral attachment and 30 minutes after internalisation 
was allowed to proceed at 37 °C. There was no significant difference in viral attachment but 
there was a significant (P = 0.023) increase in mean number of viral particles per cell after 30 
minutes at 37 °C (Figure 4.24). Taken together with the quantitative PCR data it is clear that 
VEGF facilitates Vaccinia virus entry in PDAC cell lines in vitro.  
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Figure 4.20: The effect of VEGF gene silencing on the internalisation of VV-488.  
The Representative split channel image of Suit-2 cells transfected with VEGF siRNA and 
imaged at thirty minutes after warming of cells to 37 ºC to allow internalisation of viral particles. 
Nuclear material is stained blue with DAPI, alpha- tubulin (red) and VVL-488 (green). Images 
were taken at 64x magnification with a Zeiss LSM 510 META laser scanning microscope and 
displayed at a resolution of 1024 x 1024 dpi.  
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Figure 4.21: The effect of VEGF gene silencing on the internalisation of VV-488 (Z 
stack).  
Representative Z stack image of Suit-2 cells transfected with VEGF siRNA and imaged at 
thirty minutes after warming of cells to 37 ºC to allow internalisation of viral particles. 
Nuclear material is stained blue with DAPI, alpha-tubulin (red) and VVL-488 (green). 
Images were taken at 100x magnification with a Zeiss LSM 510 META laser scanning 
microscope and displayed at a resolution of 1024 x 1024 dpi. Twenty-five images were taken 
to create each Z-stack. X, Y and Z dimensions are shown with viewpoint aligned through 
centre of cell as indicated by cross-hairs.  
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Figure 4.22: The effect of control siRNA on the internalisation of VV-488.  
Representative split channel image of Suit-2 cells transfected with siGENOME RISC-free 
control siRNA and imaged at thirty minutes after warming of cells to 37 ºC to allow 
internalisation of viral particles. Nuclear material is stained blue with DAPI, alpha-tubulin (red) 
and VVL-488 (green). Images were taken at 64x magnification with a Zeiss LSM 510 META 
laser scanning microscope and displayed at a resolution of 1024 x 1024 dpi. 
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Figure 4.23: The effect of control siRNA on the internalisation of VV-488 (Z stack).  
Representative Z stack image of Suit-2 cells transfected with Control siRNA and imaged at 
thirty minutes after warming of cells to 37 ºC to allow internalisation of viral particles. Nuclear 
material is stained blue with DAPI, alpha-tubulin (red) and VVL-488 (green). Images were 
taken at 100x magnification with a Zeiss LSM 510 META laser scanning microscope and 
displayed at a resolution of 1024 x 1024 dpi. Twenty-five images were taken to create each Z-
stack. X, Y and Z dimensions are shown with viewpoint aligned through centre of cell as 
indicated by cross-hairs. 
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Figure 4.24: Quantification of VVL-488 attachment & internalisation confocal images 
Z-stack 3D representations of 10 fields of view were taken for the VEGF siRNA and control 
siRNA treated Suit2 cells. A clearly isolated GFP foci was counted as one virion and small or 
large foci counted equally. This was because we were not able to differentiate individual 
virions from those that could represent virion in complex with cellular membrane following 
viral preparation. Two independent observers, who were blinded to sample group, scored 
images at the time of viral attachment and at 30 minutes after internalisation was allowed to 
proceed at 37 °C. Images were taken at 64 x magnification with a Zeiss LSM 510 META laser 
scanning microscope and displayed at a resolution of 1024 x 1024 dpi for counting. * = P  ≤ 
0.05 Two tailed students T-test.  
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4.10 The effect of VEGF on Vaccinia virus mRNA transcription 
 
The next step in the Vaccinia life cycle is gene transcription, so to assess if VEGF can affect 
viral mRNA transcription we used a reverse transcription real-time quantitative PCR assay. 
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control cells were infected for 1 hour with 
VVLister at an MOI = 10 pfu/cell. At 6 and 24 hours post-infection cells were harvested for 
RNA extraction. Quantitative PCR was then performed using the VLTF-1 primer and probe set 
(Table 4.2) and results were normalised to 18S RNA as detailed in the Material and Methods 
section of this thesis. The VTLF-1 primer and probe set were used firstly as no pre-transcribed 
early mRNA presents in viral particles would contaminate the assay and also as VTLF-1 mRNA 
would be transcribed only after the productions of early and intermediate mRNAs.  This should 
give a picture more reflective of total viral mRNA transcription as opposed to early viral mRNA 
production.  
 
A significant increase in mRNA production was noted in MiaPaca2-VEGF-165 compared to 
control at 6 hours after infection (Figure 4.25). However, given that VEGF facilitates Vaccinia 
virus internalisation in these cells a crude attempt was made to remove the effect of increased 
internalisation as a more rapid infection will undoubtedly result in greater mRNA transcription 
at early time points. The amount of mRNA present in MiaPaca2-VEGF-165 was normalised to 
the amount of virus internalised so that results were more comparable with MiaPaca2-Vector 
Control cells. When this was done there was no longer a significant affect of VEGF on viral 
mRNA transcription although a trend is present (Figure 4.26). On balance it is unlikely that 
VEGF has an effect of viral mRNA transcription other than accelerating the process by inducing 
earlier internalisation. 
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Figure 4.25: The effect of VEGF on Vaccinia virus mRNA expression.  
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control were infected for 1 hour with wild type 
Lister strain Vaccinia virus at an MOI = 10 pfu/cell. Cells were harvested at 6 and 24 hours for 
RNA extraction. RT-qPCR was performed for VLTF-1 and 18S and fold changes normalised to 
MiaPaca2-Vector Control at 6 hours post-infection. Relative quantification was used. * =  P 
≤0.05.  
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Figure 4.26: The effect of VEGF on Vaccinia virus mRNA expression.  
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control were infected for 1 hour with wild type 
Lister strain Vaccinia virus at an MOI = 10pfu/cell. Cells were then harvested at 6 and 24 
hours for RNA extraction. RT-qPCR was performed for VLTF-1 and 18S then fold changes 
normalised to MiaPaca2-Vector Control at 6 hours post-infection. To control for increased 
internalisation of Vaccinia virus in MiaPaca2-VEGF-165 these ratios were transformed 
adjusting for this (values multiplied by 0.66). Relative quantification was used.  
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4.11 The effect of VEGF on Vaccinia virus DNA replication measured using qPCR 
 
Replication of Vaccinia virus genomic DNA is required to in order to produce infective virions. 
To determine whether VEGF has any effect on DNA replication, MiaPaca2-VEGF-165 and 
MiaPaca2-Vector Control cells were infected with VVLister at an MOI = 1 pfu/cell. Cells were 
collected at 24, 48 and 72 hours post-infection and DNA extracted for Real-Time quantitative 
PCR using the VLTF-1 primer and probe set. Cells were not collected at 96 hours post-infection 
as significant cytopathic effect is seen at this time and DNA would be lost after cell lysis and 
release of virions. 
  
A significant increase was seen in DNA replication in MiaPaca2-VEGF-165 compared to 
control cells at 24 (P = 0.0033), 48 (P = 0.0016) and 72 hours (P = 0.003) paralleling the viral 
replication as measured using viral burst and TCID50 assay (Figure 4.27).   
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Figure 4.27: The effect of VEGF on the replication of Vaccinia virus genomic DNA.  
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control were infected for 1 hour with wild type 
lister strain Vaccinia virus at an MOI = 1 pfu/cell. Cellular and viral DNA was then extracted 
at 24, 48 and 72 hours. The VLTF -1 primer and probe set was used to perform qPCR on 40 
ng of DNA at each time point. ** = P  ≤ 0.01 Two tailed students T-test. 
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4.12 The effect of VEGF on Vaccinia virus EEV production measured using TCID50 
assay 
 
I have demonstrated that VEGF facilitates Vaccinia virus replication resulting in increased 
cytolysis and cytotoxicity. However EEV forms of Vaccinia are released without cytolysis early 
after infection and this process has been shown to be mediated in part by Abl-family tyrosine 
kinases (163). To assess whether VEGF affects the release of extracellular enveloped virus 
(EEV), MiaPaca2-VEGF-165 and MiaPaca2-Vector Control cells were infected with VVLister 
at an MOI = 1 pfu/cell. Supernatant was collected at 24 hours post-infection before any 
cytopathic effect was seen. Consequently any infective virions present in the supernatant 
represent EEV rather than the usual, predominant IMVs. This supernatant was then used in 
TCID50 assay to titrate the amount of EEV produced. As expected the amount of EEV 
produced was much lower than that of IMVs at this time point. There was no significant 
difference in the amount of EEV produced in the presence of increased VEGF (Figure 4.28). In 
summary our results show that VEGF facilitates the entry of oncolytic Vaccinia virus 
accelerating viral infection but does not directly affect other steps in the virus life cycle. 
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Figure 4.28: The effect of VEGF on the production of extracellular enveloped virus 
particles (EEV).  
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control were infected for 1 hour with wild type 
Lister strain Vaccinia virus at an MOI = 1 pfu/cell. Supernatant was then collected at 24 hours 
before any cytopathic effect and used to determine titre of EEVs by TCID50 on CV-1 
indicator cells. 
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4.13 The expression of VEGF receptors on PDAC cell lines Suit2, MiaPaca2, Panc1 and 
CFPac1 
 
To investigate the mechanism through which VEGF facilitates Vaccinia virus entry we firstly 
characterized the endogenous expression of VEGF receptors. There are many receptors that 
bind to VEGF ligands, but we restricted our analysis to those most implicated in VEGFA-165 
biology, namely VEGFR1(Flt-1), VEGFR2(Flk-1/KDR) and neuropilin 1(NRP1) (78). Cells 
were seeded and allowed to adhere overnight, then exposed to normoxia or hypoxia for a further 
24 hours. Protein was then extracted and probed for VEGFR1, VEGFR2, NRP1. Ku-70 was 
used as a loading control (Figure 4.29). Protein extract from human umbilical vein endothelial 
cells (HUVEC) was used as a positive control as they express all three receptors (196). The 
double bands of VEGFR1 and VEGFR2 represent differently glycosylated forms (197). NRP1 
was highly expressed in CFPac1 cells compared to HUVECs in both normoxia and hypoxia. It 
was also present at a lower level in Suit2 and Panc1 and there is a slight increase in receptor 
expression after exposure to hypoxia. There is a faint band present in extracts of MiaPaca2 cells 
in both normoxia and hypoxia which is more clearly visible on the original radiograph. Li et al 
looked at NRP1 mRNA expression in Panc-1 and MiaPaca2 cells and their results are consistent 
with these. The immunoblotting for VEGFR1 and VEGFR2 is less clear. There are faint bands 
visible for VEGFR1 in Panc1 and CFPac1 cells and faint bands for VEGFR2 in 
Suit2/CFPac1cells exposed to hypoxia and MiaPaca2 cells exposed to normoxia. The 
expression of VEGFR1/2 is therefore likely to be low and variable across cell lines and as a 
consequence Western blotting may not be a sufficiently sensitive technique. This is consistent 
with the work of Itakura et al who found evidence for VEGFR2 in some PDAC cell lines but 
immunoprecipitation of protein was required to detect receptors with immunoblotting (190), 
although Wey et al have published that pancreatic cancer cell lines do express VEGFR1 and 
that density of receptor increases as cell become more confluent (198). Their experiments were 
performed using a polyclonal antibody for VEGFR1.  
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Figure 4.29: Western blot to determine VEGF receptor status of four pancreatic cancer 
cell lines in normoxia and hypoxia.  
A reducing denaturing gel was used to separate 30ng of protein per well and transferred to a 
PVDF membrane. Membranes were then probed for VEGFR1, VEGFR2 and neuropilin 1 
(NRP1) and Ku-70 used as a loading control. Human umbilical vein endothelial cells 
(HUVEC) known to express all three receptors were used as a positive control. Molecular 
weights are expressed as kDa. N=normoxia H=hypoxia. 
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4.14 The effect of NRP1 gene silencing in Vaccinia virus transgene expression in Suit2 
and CFPac1 
 
As NRP1 is the most abundant VEGF receptor we found on PDAC cell lines NRP1 gene 
silencing was used to look for any effect on Vaccinia virus transgene expression. The sequences 
used for siRNA gene silencing are shown in Table 4.3. Firstly the efficiency and timing of gene 
silencing was optimised in CFPac1 cells. Shown in Figure 4.30, cells were either mock 
transfected (1), transfected with transfection reagent only (2), NRP1 siRNA (25 nM) (3) or 
Control siRNA (25 nM) (4) and protein harvested 48 and 72 hours later. A Western Blot was 
then performed and membranes were probed with NRP1 mAb which show almost complete 
abolition of NRP1 protein expression at both time points. Cells were viable and did not show 
any unusual morphology. The double band on immunoblotting represents the soluble (90 kDa) 
and membrane-bound (130 kDa) form of NRP1 (199). 
 
CFPac1 and Suit2 cells were then either mock-transfected with transfection reagent only, or 
transfected with NRP1 siRNA or control siRNA followed by infection 48 hours later with 
VVL15 expressing firefly luciferase. At 48 hours after infection, cells were lysed and samples 
measured for bioluminescence (using the Perkin Elmer Victor luminometer) and protein 
concentration. Bioluminescence is expressed per µg of protein in Suit2 (Figure 4.31) and 
CFPac1 (Figure 4.32) cells infected with VVL15 at an MOI = 0.1 pfu/cell. Unexpectedly there 
was a small but significant increase in viral transgene expression after NRP1 gene silencing 
compared to control siRNA in both Suit2 (P < 0.0001) and CFPac1 (P < 0.0001) cells. 
However, in CFPac1 the bioluminescence in the parental cell line is higher than in control 
siRNA or transfection-reagent treated cells suggesting a non-specific effect on viral transgene 
expression. 
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Table 4. 3: The siRNA sequences for NRP1 gene silencing 
GENE 
(Ref Seq) 
siRNA Target Sequence 
NRP1 
(NM_001024629) 
 
1-CGAUAAAUGUGGCGAUACU 
2-GGACAGAGACUGCAAGUAU 
3-GUAUACGGUUGCAAGAUAA 
4-AAGACUGGAUCACCAUAAA 
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Figure 4.30: Western blot to confirm silencing of NRP1 with specific siRNA.  
Protein from the parental cell line CFPac1 (1), cells exposed to transfection reagent only (2), 
NRP1 siRNA (3) or Control siRNA (4) were collected at 48 and 72 hours transfection. Lysates 
were then probed for neuropilin-1 (NRP1) or proliferating cell nuclear antigen (PCNA). The 
double band of NRP1 represents the membrane-bound form (130-135 kDa) and a soluble form 
(90 kDa). 
 
 
Chapter 4 
141 
 
 
  
S
ui
t2
 - 
N
R
P
1 
si
R
N
A
S
ui
t2
 - 
C
on
tr
ol
 s
iR
N
A
S
ui
t2
 - 
TR
S
ui
t2
- P
C
L
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Suit2 - NRP1 siRNA
Suit2 - Control siRNA
Suit2 - TR
Suit2- PCL
***
li
g
h
t 
u
n
it
s
/u
g
 p
ro
te
in
 
Figure 4.31: The effect of NRP1 gene silencing on the expression of the firefly luciferase 
reporter gene from VVL15.  
Suit2 cells were seeded in a 24 well plates and transfected 24 hours later with NRP1 siRNA, 
control siRNA, transfection reagent only or mock-transfected. Cells were infected 48 hours 
later with VVL15 at an MOI = 0.1. Cells were lysed 48 hours post-infection and 
bioluminescence was quantified. Experiments were performed in triplicate and results 
represent the data from two separate experiments. Results are presented as mean ± SEM. TR= 
Transfection reagent only, PCL= parental cell line, *** = P ≤ 0.001. 
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Figure 4.32: The effect of NRP1 gene silencing on the expression of the firefly luciferase 
reporter gene from VVL15.  
CFPac1 cells were seeded in a 24 well plates and transfected 24 hours later with NRP1 
siRNA, control siRNA, or transfection reagent only. Cells were infected 48 hours later with 
VVL15 at an MOI = 0.1. Cells were lysed 48 hours post-infection and used to quantify 
bioluminescence with a luminometer. Experiments were performed in triplicate and results 
represent the data from two separate experiments. Results are presented as mean ± SEM. 
TR= Transfection reagent only, PCL= parental cell line, *** = P ≤ 0.001. 
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4.15 The effect of VEGF on Akt phosphorylation status in PDAC cells 
 
The biology of VEGF receptor signalling is most well characterised in endothelial cells and it is 
known that VEGF acts via PI3K to phosphorylate Akt (78). However it has also been 
demonstrated that VEGF can increase Akt phosphorylation through NRP1 and via VEGFR1 in 
cancer cell lines (200, 201). The PI3K-Akt signalling pathways has additionally been shown to 
be important for viral infection and survival (157). We were interested to determine whether 
there was any difference between endogenous Akt phosphorylation in our PDAC cell lines. 
MiaPaca2-VEGF-165 and MiaPaca2-Vector Control cells were starved overnight and protein 
collected for western blotting with Fadu cell extracts used as a positive control. There was no 
clear difference in baseline Akt phosphorylation status (S473) in our cell lines (Figure 4.33). 
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Figure 4.33: Western blot of Akt phosphorylation status (S473) in uninfected 
MiaPaca2-Vector Control (VC) and VEGFA-165 cell lines.  
Cells were starved overnight before protein was collected and used for immunoblotting. Fadu 
was used as a positive control. pAkt = phospho Akt, tAkt = total Akt, MW kDa=Molecular 
Weight in Kilodaltons. 
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4.16 The effect of Akt inhibition on Vaccinia virus transgene expression  
 
Although there was no difference in baseline Akt phosphorylation in our MiaPaca2 model we 
were interested to determine the effect of Akt inhibition on Vaccinia virus, as it had been shown 
previously that the infectivity of myxoma virus, another poxvirus, is dependent on Akt 
activation (158). MiaPaca2 and Suit2 cell lines were treated with Akt inhibitor VIII (202) at 5 or 
10 µM or with the PI3K inhibitor Wortmannin for two hours prior to infection. Cells were then 
infected with VVL15 and lysed 24 and 48 hours later to measure bioluminescence.  A highly 
significant and dose-dependent reduction in transgene expression after Akt inhibition was seen 
in both MiaPaca2 and Suit2 compared to DMSO-treated controls (Figure 4.34 A&B). This 
confirms that as with other viral species, Akt signalling plays an important role in infectivity. 
Wortmannin, an inhibitor of PI3K was used as it is known that PI3K can lead to 
phosphorylation of Akt, although Wortmannin does target other kinases (203). We found a 
limited effect on Vaccinia virus transgene expression at the dose used in our studies, with no 
effect on transgene expression in MiaPaca2 at 48 hours and a slight increase in Suit2 at this time 
point. This is consistent with the work of McNulty et al. who found that even at higher doses 
Wortmannin does not affect the plaque size of IHD-J strain Vaccinia virus (204). 
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Figure 4.34: The effect of Akt and Wortmannin on Firefly luciferase expression 
from VVL15.  
MiaPaca2 (A) and Suit2 (B) were pre-treated with Akt inhibitor VIII and 
Wortmannin for 2 hours prior to infection with VVL15 at MOI = 1 pfu/cell. Cells 
were lysed and bioluminescence quantified with a luminometer (Perkin Elmer Victor) 
at 24 and 48 hours post-infection. Experiments were performed in triplicate and 
results represent the data from two separate experiments. Results are presented as 
mean ± SEM. An unpaired, two-tailed students T Test was used to compare the 
difference to the mean of DMSO treated cells. * = P ≤ 0.05, *** = P ≤ 0.001. 
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4.17 The effect of Akt inhibiton on VEGF production 
 
Akt has been shown to regulate VEGF production in both normoxia and hypoxia (39, 205). This 
regulation may be relevant in PDAC cells as Akt, in addition to its importance for viral infection 
outlined by Cooray et al, may indirectly slow viral internalisation by limiting VEGF production. 
Suit2 cells were treated with Akt inhibitor VIII (5 µM) or DMSO for 2 hours prior mock 
infection or  infection with VVLister at an MOI = 1 pfu/cell. Akt inhibition resulted in a 
reduction in VEGFA productions as measured by ELISA after 2 hours of treatment and this was 
sustained at 24 hours after infection (Figure 4.35). Therefore, a reduction in Akt signalling may 
have an additional inhibitory effect on Vaccinia virus life cycle by reducing Vaccinia virus 
internalisation.  
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Figure 4.35: The production of VEGF during infection with Vaccinia virus and treatment 
with Akt InhibitorVIII.  
Suit2 cells were pre-treated with Akt inhibitor VIII and then infected with VVL15 at an MOI = 
1 pfu/cell. Supernatent was collected prior to treatment and a VEGFA-specific ELISA used to 
quantify the level of secreted VEGFA prior to treatment and at 24 and 48 hours after. DMSO = 
dimethyl sulfoxide, AktVIII = Akt Inhibitor VIII (5 µM).   
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4.18 The effect of Akt inhibition on VEGF internalisation measured using qPCR 
 
To verify that Akt inhibition can affect Vaccinia virus internalisation, an internalisation assay 
was performed after Akt inhibitor treatment. Suit2 cells were treated with Akt Inhibitor VIII at 5 
or 20 µM or with DMSO for 2 hours prior to infection with VVLister (MOI= 10 pfu/cell) at 4 
°C for 1 hour. Internalisation was allowed to occur at 37 °C for 15 and 60 minutes after which 
cells were treated with pronase to remove un-internalised virions. There was a significant 
reduction in Vaccinia virus internalisation at 15 minutes post-infection with 20 µM, (the highest 
dose) of inhibitor (47% reduction vs DMSO, P = 0.009) and a trend with the lower dose (). At 
60 minutes post-infection there was a 30% and 35% reduction in Vaccinia virus internalisation 
after treatment with Akt inhibitor VIII at 5 µM (P = 0.042) and 20 µM (P = 0.032) respectively. 
The effect of Akt inhibition at 60 minutes post-infection appears to be saturated suggesting that 
Akt is involved in one mode of Vaccinia virus entry but other forms are unaffected.  
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Figure 4.36: The effect of Akt inhibition on the rate of viral internalisation.  
Suit2 cells were pre-treated for 2 hours with Akt inhibitor VIII at 5 or 20 µM and then 
infected with VVLister at an MOI = 10 pfu/cell for 1 hour at 4°C. Cells were warmed to 
37°C to allow internalisation of attached viral particles. At 15, 30 and 60 minutes cells 
were treated with pronase (1 mg/ml) for 30 minutes at 4 °C and washed to remove 
uninternalised virus. Cellular and viral DNA was extracted simultaneously and 40 ng used 
for quantitative real-time PCR using the VLTF-1 primer and probe set. Each sample was 
assayed in triplicate for qPCR and each combination and time point were performed in 
biological duplicates. An unpaired two-tailed students T-test was used for statistical 
analysis and results are presented as mean +/- SEM. *** =P < 0.001, * = P <  0.05. 
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4.19 The effect of Akt inhibition on Vaccinia virus cytotoxicity 
 
To verify if Akt inhibition has an effect on the oncolytic efficacy of Vaccinia virus we 
performed a MTS assay in the presence of this inhibitor. Suit2 cells were treated with 5 or 20 
µM of Akt inhibitor VIII prior to infection with serial dilutions of Vaccinia virus and MTS 
reagent was added to assess cell viability at 3 days post-infection. There was a highly significant 
and dose-dependent effect of Akt inhibition on Vaccinia virus cytotoxicity (Figure 4.37). The 
EC50 value at 3 days after infection for DMSO treated cells was 93.6 pfu/cell versus 43.0 
pfu/cell and 19.7 pfu/cell after treatment with 5 µM (P<0.0001) and 20 µM (P<0.0001) of Akt 
inhibitor VIII. This effect may be mediated in part by the reduction in VEGF produced after Akt 
inhibition but will almost certainly be caused by pleiotropic effects of Akt inhibition on the viral 
life cycle and also the host cell.   
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Figure 4.37: The effect of Akt Inhibition on Vaccinia virus cytotoxicity.  
Suit2 cells were pretreated with Akt inhibitor VIII (5 µM or 20 µM) for 2 hours and then 
infected with serial dilutions of VVLister. The infected cells were assayed with MTS reagent 
at day 3 post-infection at 37 °C with 5% CO2 for 2 hours. Viable cells were determined as a 
percentage of the uninfected controls and non-linear regression analysis was used to draw a 
dose–response curve (A) and determine the EC50 value (B). Each assay contained six 
replicates and results are presented as mean ± SEM of two independent experiments. An 
unpaired, two-tailed students T Test was used to compare the difference to the mean EC50 
values. *** = P ≤ 0.0001. 
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4.20 The effect of VEGF on Vaccinia virus transgene expression in vivo 
 
VEGF facilitates Vaccinia virus entry and results in increased transgene expression and 
replication in vitro. To see determine whether this finding was reproducible in vivo and could 
therefore be partly responsible for the tropism of Vaccinia virus, the MiaPaca2 cell model was 
used to establish tumour xenografts. MiaPaca2-VEGF-165 and MiaPaca2-Vector Control cell 
lines were used to establish xenografts in the right flank of Balb/c mice (n = 5 per group). Mice 
were injected with 1x10
7
 pfu of VVL15 intravenously via the tail vein and subsequently imaged 
12 to 132 hours later after the administration of D-luciferin. There was an increase in mean 
bioluminescent signal in MiaPaca2-VEGF-165 compared to vector control cells (Figure 4.38). 
This was statistically significant at 2.5 (P = 0.0019), 3.5 (P = 0.031), and 5.5 (P = 0.018) days 
post-infection and there was a trend towards statistical significance at 1.5 (P = 0.055) and 4.5 (P 
= 0.067) days post-infection. 
 
 A representative image at 2.5 days after infection is shown in Figure 4.39. This shows a clear 
difference between MiaPaca2-VEGF-165 and MiaPaca2-Vector Control xenografts. The 
bioluminescent signal seen in the oral region of some mice appears to be caused by oral contact 
by the mouse with an infected tumour or at the tail vein injections site as this occurs less 
commonly if animals are separated after infection. This does not seem to interfere with their 
eating or drinking habits. 
 
Tumours were collected at the end of the experiment (5.5 days post-infection) to verify that the 
bioluminescent signal corresponded with positive immunohistochemistry for Vaccinia virus. A 
representative image, at low (100x) and high magnification (200x), of immunohistochemistry 
with an anti-Vaccinia polyclonal antibody and serial sections stained with haematoxylin and 
eosin (H&E) is displayed in Figure 4.40 A and B. This shows the characteristic foci of Vaccinia 
virus infection; Strong central staining and finger like projections of infection spreading out in 
all directions. The serial H&E sections show karyolysis in the central area of infection. This 
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finding confirms that VEGF does facilitate Vaccinia virus infection and is a relevant mechanism 
in vivo. 
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Figure 4.38: The effect of VEGFA on the tumour tropism of VVL15.  
5x10
6
 Miapaca2-VEGF-165 (solid line) and Miapaca2-Vector Control (dashed line) cells 
were injected into the right flank of balb/c nude mice. VVL15 at an MOI of 1x10
7
 pfu/mouse 
was injected once via the tail vein at day 0. The bioluminescence for each tumour was 
measured 12 hours after virus infection and every 24 hours after until 5.5 days post-infection 
using the IVIS imaging system. Results are presented as mean bioluminescent intensity ± 
SEM. A repeated measures two way ANOVA with a bonferroni correction was used to 
compare the two groups (n = 5 per group). 
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Figure 4.39: Representative image of the effect of VEGF on bioluminescence from 
VVL15.  
5x10
6
 Miapaca2-VEGF-165 and Miapaca2-Vector Control cells were injected into the right 
flank of balb/c nude mice. VVL15 at an MOI of 1x10
7
 pfu/mouse was injected once via the tail 
vein and this image was taken at 60 hours post-injection using the IVIS imaging system.  
Colour metric scale is the same for both images. 
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Figure 4.40: Immunohistochemistry for Vaccinia viral proteins and H&E staining.  
MiaPaca2-VEGF-165 tumour xenografts were collected at day 6 post intravenous injection of 
VVL15. Images are representative of loci of viral infection found in tumours.  Images were 
taken with 20x/0.5 and 10x/0.32 objectives on a Zeiss Axioplan microscope fitted with a Zeiss 
AxioCam MRc camera.  
100 µM 
100 µM 
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4.21 The effect of hVEGF production on vascularity in the MiaPaca2 xenograft model 
 
VEGF facilitates Vaccinia virus infection in vitro and in vivo, however it is possible that other 
mechanisms may be important in animal models. Our original hypothesis was that VEGF would 
increase vascularity of tumours and therefore help improve the systemic distribution. MiaPaca2-
VEGF-165 and MiaPaca2-Vector Control xenografts were stained for Pecam-1 a marker of 
murine endothelial cells (206). Two sections were taken from the centre of each tumour with a 
200 µM distance between. The percentage of Pecam-1-positive cells was scored across the 
entirety of each section and the mean percentage of positive cells compared between the two 
groups. There is a greater than 90% homology between murine and human VEGFA with a high 
level of conservation at both N and C terminal regions. Thus we expected to see an increase in 
vascularity in the MiaPaca2-VEGF-165 xenografts. There was an increase in Pecam-1 positive 
cells and it was significantly greater than MiaPaca2-Vector Control cells, P = 0.0037 (Figure 
4.41). A representative image of Pecam-1 staining from the MiaPaca2-VEGF-165 and 
MiaPaca2-Vector Control xenografts is shown in Figure 4.42. Although these results show there 
is increased vascularity in the presence of VEGF which could account for some of its effect on 
Vaccinia virus in vivo, they do not give any indication as to the permeability of these vessels, 
which may also be important for Vaccinia virus spread.  
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Figure 4.41: Quantification of Pecam-1 staining in MiaPaca2-VEGF-165 and MiaPaca2-
Vector Control tumour xenografts in Balb/c nude mice.  
Images were taken at 20x magnification to provide complete coverage of tumour sections, 
approximately 15-25 images per tumour. Quantification was performed on two sections 
separated by 200 µM for each tumour. There were five tumours per group. Data are presented 
as percentage area of Pecam-1 positive cells per tumour. **=P<0.01 A two-tailed, unpaired 
students t-test was used to compare the mean percentage of CD31 positivity. Results are 
presented as mean ± SEM. Please refer to Materials and Methods, section 2.8.3, for detailed 
explanation of the quantification procedure.  
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Figure 4.42: Representative images of CD31/Pecam-1 staining in MiaPaca2-VEGF-165 
and MiaPaca2-Vector Control tumour xenografts in Balb/c nude mice.  
Images were taken with 20x/0.5 objectives on a Zeiss Axioplan microscope fitted with a Zeiss 
AxioCam MRc camera.  
MiaPaca2-VEGF-165 
MiaPaca2-Vector Control 
No Primary Antibody 
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5 Construction of VV-ODD, a hypoxia targeting Vaccinia virus 
5.1 Schema for VV-ODD 
 
Having confirmed that Vaccinia virus is a potential vector targeting hypoxic tumours, we next 
sought how to improve the potency of this virus. One strategy is to arm the virus with a 
therapeutic gene however tight regulation of gene expression is required in order to minimise 
off target effects. Previously this has been achieved by limiting the tropism of recombinant 
viruses to cancer cells and by using conditional promoters to target therapeutic gene expression. 
In order to restrict gene expression to hypoxic conditions we designed a Vaccinia virus 
expressing a luciferase reporter gene regulated by hypoxia as a proof of principle. Limiting 
therapeutic gene expression to hypoxia offers an additional level of regulation that could 
enhance the therapeutic ratio as any off target effects in normoxic normal tissue would be 
minimised.  
 
There are three levels of hypoxic regulation in this construct. Firstly it contains an IRES 
sequence to initiate protein translation, which is relatively more preserved than 5‟ methyl cap-
dependent translation in hypoxia (207). Secondly the Luciferase reporter gene is fused to the 
oxygen degradation domain (ODD) of the HIF1 gene. This results in the hydroxylation, 
ubiquitination and consequent proteolytic degradation of the reporter gene in the presence of 
oxygen (208). Thirdly the 3‟-untranslated region (UTR) from the VEGF gene is included as this 
has been shown to increase mRNA stability in hypoxia (209). The construct contains an 
unmodified red fluorescent protein (RFP) selection marker driven directly from the Vaccinia 
virus P7.5 promoter, and an SV40 poly A tail and is inserted into the TK region of the Lister 
strain virus (Figure 5.1). The shuttle plasmid has been designed so that elements including the 
transgene can be easily removed and replaced. 
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All PCR fragments were produced using Novagen KOD polymerase (Merck KGaA, Darmstadt, 
Germany) and all gene-specific primers were obtained from Sigma-Aldrich (St Louis, MO, 
USA). PCR primers for gene-specific reverse transcription from Suit2 DNA are shown in Table 
5.1. All other PCR primers to amplify fragments and introduce restriction enzyme sites (RES) 
are shown in table 5.2.  
 
The EMCV IRES bicistronic vector was used in a PCR reaction to produce a PCR fragment 
with SacI and AscI 5‟ and an RsrII, AsiSI, SacII and SacI RES 3‟ to the EMCV IRES sequence. 
pGem-Luc (Promega, Wisconsin, USA) was used as the source of the luciferase reporter gene. 
Gene-specific primers were designed to produce a PCR fragment with RsrII RES 5‟ and an FseI 
and AsiSI RES 3‟ to the luciferase coding sequence and to delete the stop codon. Suit2 cell 
mRNA was extracted using Trizol reagent (Invitrogen, Carlsbad, California, USA) and cDNA 
produced using superscript II reverse transcriptase (Invitrogen). This Suit2 cDNA was used as 
the source of the HIF1alpha ODD and gene specific primers were designed with a FseI RES 5‟ 
and a stop codon, NdeI and AsiSI RES 3‟ to the ODD coding sequence. These were designed so 
that the ODD sequence remained in frame with the Luciferase reporter gene. Suit2 cDNA was 
used as the source of the VEGFA 3‟UTR, gene specific primers were designed to amplify the 
130 bp sequence as published by Claffey et al (209). Primers were designed to introduce an 
NdeI RES 5‟ and a MluI and AsiSI RES 3‟ to the coding sequence. The SV40 polyA sequence 
was produced using gene-specific primers to introduce a MluI RES 5‟ and an AsiSI 3‟ to the 
coding sequence. All fragments were run on agarose gels with ethidium bromide to verify size 
and gel purified using the GFX PCR DNA purification kit (GE Healthcare Life Sciences, 
Bucks, UK). All fragments were subcloned into pTopo-CR-II blunt cloning vector (Invitrogen, 
Carlsbad, California, USA). All fragments were then cut from the pTOPO subcloning vector 
and gel purified. These were then sequentially ligated into the shuttle vector pSC65RFP.  
 
The pSC65RFP Vaccinia shuttle vector constructed by Dr L Chard, developed originally from 
pSC65, which contains RFP driven from the p7.5 Vaccinia virus promoter in between the TK 
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left and right arm was used to create the pSC65RFP-ODD shuttle plasmid. The BamHI site after 
RFP was cut with its restriction enzyme and a short polylinker, produced by annealing two 
oligonucleotides (Sigma-Aldrich), was then used to insert a SacI and SacII restriction site to 
allow site-directed, sticky-end cloning. This was then cut using the relevant RE and 
dephosphorylated with calf intestinal phosphatase (NEBiolabs, Ipswich, MA, USA) and then 
run on an agarose gel with ethidium bromide and gel-purified.  
 
Once completed the shuttle plasmid pSC65RFP-ODD was sequenced, using conventional 
Sanger sequencing by the QMUL Genome Centre, using 16 specific primers covering the TK 
left arm to the TK right arm. Vector NTI Software (Invitrogen, Carlsbad, CA, USA) was used to 
verify that the sequence was correct. 
 
The recombinant hypoxia-targeting Vaccinia virus was produced by homologous recombination 
of the pSC65RFP-ODD shuttle plasmid with the Lister strain Vaccinia virus in CV1 cells. Cells 
were seeded in 6 well plates and the next day infected with VVLister at an MOI = 0.05 for one 
hour then removed. Cells were transfected two hours later with 1 µg of pSC65RFP-ODD using 
Effectene transfection reagent (Qiagen Inc, Valencia, CA, USA). When CPE was first visible 48 
hours later, cell were collected and freeze thawed three times to release infectious virions. Serial 
dilutions of this were used to infect confluent CV1 cells which were then overlaid with a 50:50 
mix of 2% low melting point (LMP) agrose and DMEM with 20%FCS. Wells were then 
observed for plaques that were positive for RFP using a fluorescent microscope. These were 
picked using a pipette tip, placed into 200 µL of DMEM and freeze-thawed three times. Serial 
dilutions were used to infect CV1 cells and overlaid with LMP agarose and DMEM mix and 
RFP-positive plaques picked again when visible. This process was repeated until all plaques at 
all serial dilutions used were RFP-positive to produce purified VV-ODD which was then used 
to produce a primary expansion as outlined in the methods. 
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Figure 5.1: Schematic of VV-ODD.  
The construct was inserted into the Vaccinia virus thymidine kinase region (J2R) to express the 
red fluorescent protein and firefly luciferase fused to the ODD from a single Vaccinia virus 
promoter. Three un-translated regions were included. TK L=Thymidine kinase gene left arm, 
TK R=Thymidine kinase gene right arm, RFP ORF=Red fluorescent protein open reading 
frame, EMCV IRES=Encephalomyocarditis virus internal ribosomal entry site, VEGF-
3‟UTR=Vascular endothelial growth factor three prime un-translated region, SV40-
polyA=Simian virus 40 polyadenylation sequence. 
 
VV-ODD 
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Table 5. 1: Sequence of reverse transcription (RT) primers used first strand synthesis of 
the ODD sequence and VEGF 3’UTR from Suit2 mRNA. 
Primer Name Primer Sequence (5‟-3‟) 
RT Primer-ODD-Forward CAGTGCATTGTATG 
RT Primer-ODD-Reverse AAGTGAACCATCATG 
RT Primer-VEGF 3 'UTR-Forward CCAGCACGGTCCCTC 
RT Primer-VEGF 3 'UTR-Reverse AAGATCATGCCAGAG 
 
 
 
 
Table 5. 2: Sequence of primers used to produce fragments for the construction of VV-
ODD  
Primer Name Sequence (5'-3') 
Forward-SacI-AscI-EMCV AAGAGCTCGGCGCGCCCCCTAACGTTACTGGCCGAA 
Reverse-EMCV-RsrII-AsisI-Sac2 AGAGCTCTTCCGCGGGCGATCGCCGGTCCGATTATCATCGTGTTTTTCAA 
Forward-Luciferase-RsrII GTTTCGGACCGATGGAAGACGCCAAAAAC 
Reverse-Luciferase-FseI-AsisI CAAAGCGATCGCAGGCCGGCCCAATTTGGACTTTCCGCCC 
Forward-ODD-FseI GTTTGGCCGGCCACAACAAACAGAATGTGTCC 
Reverse-ODD-NdeI-AsisI CAAAGCGATCGCCATATGTCATGATGATGTGGCACTAG 
Forward-VEGF 3'UTR-NdeI GTTTCATATGTAGACACACCCACCC 
Reverse-VEGF 3'UTR-AsisI-MluI CAAAGCGATCGCACGCGTAACATTAGCACTGTTAA 
Forward-SV40 PolyA-MluI GTTTACGCGTTCGACATGATAAGATAC 
Reverse-SV40 PolyA-AsisI CAAAGCGATCGCGGATCTACCACATTTG 
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5.2 The use of Internal Ribosomal Entry Sites to drive protein translation in normoxia 
and hypoxia 
Protein translation by internal ribosomal scanning has been shown to be preserved in times of 
cellular stress such has nutrient deprivation and hypoxia (210). The VEGFA gene 5‟ UTR 
contains an IRES sequence and is reported to be involved in hypoxic regulation of the protein 
(211). To see if the VEGF 5‟UTR would function as an IRES in the context of Vaccinia virus 
infection, biscistronic vectors were created by Dr L Chard. They were all driven from a T7 
promoter and contain the chloramphenicol acetyltransferase (CAT) and firefly luciferase 
reporter genes (fLuc).  
Four bicistronic vectors were made (Figure 5.2): 
 
A. CAT/fLuc with no IRES sequence to show baseline leaky scanning from the upstream 
promoter.  
B. CAT/EMCV IRES/fLuc containing the encephalomyocarditis virus (EMCV) IRES a 
commonly used and well characterized IRES 
C. CAT/VEGF IRES/fLuc containing the VEGF 5‟UTR 
D. CAT/VEGF IRES(AS)/fLuc containing the VEGF 5‟UTR in the 3‟-5‟ direction which 
should not function as an IRES. 
 
Suit2 and MDA-231cells were transfected with one of the four bicistronic vectors and exposed 
to normoxic or hypoxic conditions for 16 hours. Cells were then infected with VTF7-3, a 
recombinant Vaccinia virus expressing the T7 RNA polymerase (212). Cells were lysed 24 
hours after infection and assayed for luciferase expression and CAT expression. Results are 
presented as light units per nanogram of CAT in MDA-231 (Figure 5.3) and Suit2 (Figure 5.4). 
MDA-231 cells were found to be relatively resistant to Vaccinia virus gene expression and 
therefore fLuc/CAT ratios are much lower than the permissive cell line Suit2. The EMCV IRES 
functions in this cell line but there was a reduction, in fLuc expression, of approximately one 
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third under hypoxic conditions. In contrast the EMCV IRES does maintain protein translation in 
hypoxia in Suit2 cells with a significant increase, in fLuc expression, of almost 50 percent 
versus normoxia. The results of the VEGF IRES are less clear. There is a small but highly 
statistically significant increase in hypoxia using the VEGF IRES in the Suit2 cell line 
compared to normoxia. However there are also smaller but significant increases in the 
fLuc/CAT ratio in the CAT/fLuc (A) and CAT/VEGF-IRES (AS)/fLuc (B) vectors. This 
suggests that any difference is more likely to be due to the effect of hypoxia on Vaccinia virus 
or on the T7 RNA polymerase machinery. As the EMCV IRES did preserve protein translation 
in hypoxia this was used as the IRES sequence for VV-ODD. 
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Figure 5.2: Schematic diagram of the bicistronic vectors used to analyse the ability of 
internal ribosomal entry sites to preserve protein translation in hypoxia.  
A=CAT/LUC, B=CAT/EMCV-IRES/fLuc, C=CAT/VEGF-IRES/fLUC, D=CAT/VEGF-
IRES-AS/fLUC. CAT = Chloramphenicol Acetyl Transferase, fLUC = firefly luciferase, 
EMCV = encephalomyocarditis virus internal ribosomal entry site, VEGF-IRES = vascular 
endothelial growth factor internal ribosomal entry site, VEGF IRES-AS = vascular endothelial 
growth factor internal ribosomal entry site in the anti-sense direction. 
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Figure 5.3: The use of a bicistronic vector to assess the efficacy of internal ribosomal entry 
sites in maintaining protein translation in hypoxia in MDA-231.  
MDA-231 cells were transfected with the bicistronic vectors then infected with a Vaccinia virus 
expressing a T7 promoter. At 16 hours post-infection the expression of luciferase was measured 
with a bioluminescence assay and CAT with an enzyme-linked immunosorbent assay. CAT = 
Chloramphenicol Acetyl Transferase, fLuc = firefly luciferase, EMCV = encephalomyocarditis 
virus internal ribosomal entry site, VEGF-IRES = vascular endothelial growth factor internal 
ribosomal entry site, VEGF IRES AS = vascular endothelial growth factor internal ribosomal 
entry site in the anti-sense direction, H=hypoxia. An unpaired, two-tailed students T test was 
used to compare the mean bioluminescence and results are presented as mean ±SEM. *** = 
P≤0.001. 
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Figure 5.4: The use of a bicistronic vector to assess the efficacy of internal ribosomal entry 
sites in maintaining protein translation in hypoxia in Suit2.  
Suit2 cells were transfected with the bicistronic vectors then infected with a vaccinia virus 
expressing a T7 promoter. At 16 hours post-infection the expression of luciferase was measured 
with a bioluminescence assay and CAT with an enzyme-linked immunosorbent assay. CAT = 
Chloramphenicol Acetyl Transferase, Luc = firefly luciferase, EMCV = encephalomyocarditis 
virus internal ribosomal entry site, VEGF-IRES = vascular endothelial growth factor internal 
ribosomal entry site, VEGF-AS = vascular endothelial growth factor internal ribosomal entry 
site in the anti-sense direction. An unpaired, two-tailed students T test was used to compare the 
mean bioluminescence and results are presented as mean ±SEM. *** = P≤0.001. 
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5.3 The efficacy of bioluminescence from VV-ODD and VVL15 
 
Suit2 cells were used to compare the efficacy of bioluminescence from VV-ODD against the 
non-hypoxia-targeting virus VVL15. Cells were infected with either virus at an MOI = 1 
pfu/cell, then exposed to normoxia or hypoxia for 24 hours. Evidence of increased 
bioluminescence was seen in this initial experiment and will be outlined in subsequent figures. 
However, the bioluminescent intensity from VV-ODD was 30 times lower than that seen in 
VVL15 (Figure 5.5). This may be a consequence of luciferase expression being transcribed 
through the IRES sequence rather than directly from the Vaccinia promoter or due to reduced 
luciferase protein efficacy once the ODD element was fused to it. In subsequent experiments 
VV-ODD was compared in normoxia and hypoxia and with VVL15. 
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Figure 5.5: Comparison of bioluminescence from the oxygen sensitive VV-ODD and 
VVLI5  
Suit 2 cells were infected with VV-ODD and VVL15 at an MOI = 1. Cell were then lysed at 24 
hours post-infection and assayed for bioluminescence. An equal number of cells were seeded for 
each replicate and results are presented the mean bioluminescence ± SEM. 
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5.4 VV-ODD a hypoxia targeting Vaccinia virus shows efficacy in multiple cell lines 
 
To verify the hypoxia targeting strategy, two PDAC cells lines and one breast cancer (BC) cell 
line were infected with VV-ODD. Suit2, MiaPaca2 (PDAC) and HeLa (BC) cells were infected 
with VV-ODD at an MOI=0.1pfu/cell and exposed to normoxia or hypoxia for 48 hours. 
Bioluminescence was measured using the Perkin Elmer Victor luminometer and normalised to 
RFP to give a ratio of hypoxia-targeting transgene expression over non-hypoxia-targeting. 
Values were normalised to the ratio of fLuc/RFP in each cell line and consequently the mean 
ratio in normoxia for each cell line is 1. There was a 10.2, 6.3 and 7.8 fold increase in 
bioluminescence in hypoxia in MiaPaca2, Suit2 and HeLa cell respectively, P < 0.0001 (Figure 
5.6). This suggests that the hypoxia-targeting Vaccinia virus could be broadly applicable to 
multiple cell lines. However, this result does not show the individual contribution of each level 
of hypoxic regulation to the overall effect. 
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Figure 5.6: An example of the efficacy of VV-ODD in three different cell lines.  
MiaPaca2, Suit2 and Hela cells were infected with VV-ODD at an MOI = 0.1 pfu/cell or mock 
infected. Cells were then incubated at the indicated oxygen concentrations for forty eight hours. 
Cells were then lysed and the luciferase activity and red fluorescence from VV-ODD was 
measured. Measurements were taken in duplicate from biological duplicates and normalised to 
the ratio in normoxia. The results are the combination of two independent experiments and 
presented as mean ± SEM. *** = P ≤ 0.001 Students two tailed T-test. 
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5.5 A time-, dose- and oxygen concentration-dependent effect of VV-ODD 
 
To show a time-dependent effect of VV-ODD, cells were infected with an MOI = 0.1 pfu/cell 
and exposed to normoxia or hypoxia. A time-dependent relationship with increasing relative 
difference between normoxic and hypoxic bioluminescence was seen in MiaPaca2 (Figure 5.7), 
Suit2 (Figure 5.8) and HeLa cells (Figure 5.9). The statistical significance was P < 0.0001 for 
all time points. In HeLa cells and Suit2 cells a 72 hour time point was not performed as in these 
cells lines significant cytopathic effect was seen. 
 
To show a dose-dependent effect MiaPaca2 and Suit2 cells were infected with VV-ODD at an 
MOI=0.1, 1.0 and 5.0 pfu/cell and cells lysed at 24 hours post-infection (Figure 5.10 and Figure 
5.11 respectively). An increase was seen from 0.1 to 1.0 pfu/cell indicating a dose-dependent 
effect. There was a further increase at 5 pfu/cell in Suit2 but the system appears to be saturated 
at this dose.  
 
An oxygen-dependent increase was also noted when MiaPaca2 cells were infected with an 
MOI=0.1 pfu/cell. Infected cells were exposed to 0.1%, 1.0% and 5.0% oxygen for 24 hours. A 
small but significant increase in the bioluminescent ratio was seen in 5.0% oxygen compared to 
normoxia. However, more significant increases were seen at 1.0 and 0.1% oxygen (Figure 5.13). 
This is reassuring as this mimics the kinetics of HIF in different oxygen concentrations (213). 
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Figure 5.7: A time-dependent effect of luciferase expression from VV-ODD in MiaPaca2 
cells.  
Cells were infected with VV-ODD at an MOI=0.1 pfu/cell or mock infected. Cells were 
incubated at the indicated oxygen concentrations for 24, 48 and 72 hours. Cells were lysed and 
the luciferase activity and red fluorescence from VV-ODD was measured. Measurements were 
taken in duplicate from biological duplicates and normalised to the ratio in normoxia. The 
results are the combination of two independent experiments and presented as mean ± SEM. *** 
= P ≤ 0.001 Students two tailed T-test. 
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Figure 5.8: A time-dependent effect of luciferase expression from VV-ODD in Suit2 cells.  
Cells were infected with VV-ODD at an MOI=0.1 pfu/cell or mock infected. Cells were 
incubated at the indicated oxygen concentrations for 24 and 48 hours. Cells were lysed and the 
luciferase activity and red fluorescence from VV-ODD was measured. Measurements were 
taken in duplicate from biological duplicates and normalised to the ratio in normoxia. The 
results are the combination of two independent experiments and presented as mean ± SEM. *** 
= P ≤ 0.001 Students two tailed T-test. 
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Figure 5.9: A time-dependent effect of luciferase expression from VV-ODD in Hela cells.  
Cells were infected with VV-ODD at an MOI = 0.1 pfu/cell or mock infected. Cells were 
incubated at the indicated oxygen concentrations for 24 and 48 hours. Cells were lysed and the 
luciferase activity and red fluorescence from VV-ODD was measured. Measurements were 
taken in duplicate from biological duplicates and normalised to the ratio in normoxia. The 
results are the combination of two independent experiments and presented as mean ± SEM. *** 
= P ≤ 0.001 Students two tailed T-test. 
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Figure 5.10: A dose-dependent effect of luciferase expression from VV-ODD in MiaPaca2 
cells.  
Cells were infected with VV-ODD at an MOI=0.1, 1.0 or 5.0 pfu/cell. Cells were incubated at 
1% oxygen concentrations for 24 hours. Cells were lysed and the luciferase activity and red 
fluorescence from VV-ODD was measured. Measurements were taken in duplicate from 
biological duplicates and normalised to the ratio in normoxia. The results are the combination of 
two independent experiments and presented as mean ± SEM. *** = P≤0.001 Students two tailed 
T-test. 
 
Chapter 5 
180 
 
 
  
Suit2
0.1 1.0 5.0
0
2
4
6
8
**
***
***
Normoxia
1% Oxygen
MOI (pfu/cell)
li
g
h
t 
u
n
it
s
/r
fp
 
Figure 5.11:  A dose-dependent effect of luciferase expression from VV-ODD in Suit2 
cells.  
Cells were infected with VV-ODD at an MOI = 0.1, 1.0 or 5.0 pfu/cell. Cells were incubated 
at 1% oxygen concentrations for 24 hours. Cells were lysed and the luciferase activity and red 
fluorescence from VV-ODD was measured. Measurements were taken in duplicate from 
biological duplicates and normalised to the ratio in normoxia. The results are the combination 
of two independent experiments and presented as mean ± SEM. *** = P ≤ 0.001 Students two 
tailed T-test. 
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Figure 5.12: The effect of oxygen concentration on luciferase expression from VV-
ODD.  
MiaPaca2 cells were infected with VV-ODD at an MOI = 0.1 pfu/cell or mock-infected. 
Cells were then incubated at the indicated oxygen concentrations for forty eight hours. 
Cells were then lysed and the luciferase activity and red fluorescence from VV-ODD was 
measured. Measurements were taken in duplicate from biological duplicates and 
normalised to the ratio in normoxia. The results are the combination of two independent 
experiments and presented as mean ± SEM. * = P ≤ 0.05, ** = P ≤ 0.01. NS = not 
significant. Mann Whitney U test. 
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5.6 The effect of hypoxia mimetics and an inhibitor of proteasomal degradation on VV-
ODD transgene expression 
 
HeLa cells were infected with VV-ODD at an MOI = 1.0 pfu/cell and treated with the hypoxia 
mimetic Dimethyloxallyl Glycine (DMOG) at increasing concentrations for 48 hours. DMOG is 
a hypoxia mimetic that inhibits prolyl hydroxylase-dependent hydroxylation of the ODD (214). 
No cytotoxicity was seen at the concentrations used in HeLa cells. Cells were lysed at 48 hours 
after infection and a western blot for HIF-1α, the Luciferase-ODD fusion protein and the 
loading control B-actin was performed. As the concentration of DMOG increased stabilisation 
of HIF-1α was seen and increased levels of the Luciferase-ODD fusion protein were seen 
(Figure 5.13). The amount of Luciferase-ODD fusion protein present was quantified and is 
presented in Figure 5.14. 
 
An alternative hypoxia mimetic Cobalt Chloride (CoCl2) and the proteasomal inhibitor MG132 
were also used to show the hypoxia-targeting ability of VV-ODD (213). These compounds were 
found to be cytotoxic on prolonged exposure so were used in a luciferase assay for 6 hours only. 
Hypoxia, at an oxygen concentration of 0.1% was used as a positive control. MiaPaca2 cells 
were infected with VV-ODD at an MOI = 0.1 pfu/cell or mock infected and then exposed to 
CoCl2 (100 µM) and MG132 (10 µM). A significant increase was seen after treatment with both 
compounds showing that the ODD is functional in this fusion protein (Figure 5.15). However 
this assay may not utilise the 5‟ and 3‟ elements of the VV-ODD luciferase construct as these 
compounds are not known to have any effect on ribosomal scanning or mRNA stability unless 
indirectly through HIF-1α stabilisation and target gene transcription. 
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Figure 5.13: The effect of DMOG on VV-ODD fLuc stability.  
Western blot of Hela cells infected with VV-ODD at MOI = 1 pfu/cell and then exposed to 
Dimethyloxallyl Glycine for 48 hours at the indicated concentrations or DMSO as control. 
Dimethyloxallyl Glycine is a cell-permeable competitive inhibitor of the HIF proyl 
hydroxylase enzymes and will stabilise luciferase expressed from VV-ODD. Membranes were 
probed for Hif1α, Luc-ODD and β-Actin. DMOG= Dimethyloxallyl Glycine, Luc-
ODD=Luciferase/Oxygen degradation domain fusion protein. 
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Figure 5.14: Quantification of the effect of DMOG on VV-ODD fLuc stability.  
Quantification of Western blot of HeLa cells infected with VV-ODD (MOI = 1) and then 
exposed to DMOG at the indicated concentration (mM) for 48 hours. The optical density 
measurements are the ratio of Luciferase/Oxygen degradation domain fusion protein to that of 
the loading control Beta-Actin. Ratios were normalised to untreated cells. DMOG= 
Dimethyloxallyl Glycine, DMSO= Dimethyl sulfoxide. 
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Figure 5.15: The effect of hypoxia mimetics and a proteasomal inhibitor on luciferase 
expression from VV-ODD.  
MiaPaca2 cells were infected with VV-ODD at an MOI = 0.1 pfu/cell for twenty four hours or 
mock infected. They were then exposed to normoxia, 1% oxygen, the hypoxia mimetic Cobalt 
Chloride (CoCl2) at 100 µM or the proteasomal inhibitor MG132 (10 µM) for six hours. Cells 
were lysed and the luciferase activity and red fluorescence from VV-ODD was measured. 
Measurements were taken in duplicate from biological duplicates and the results normalised to 
the ratio in normoxia. The results are the combination of two independent experiments and 
presented as mean ± SEM. * = P ≤ 0.05 Students two tailed T-test. 
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6 Discussion and Future Plan 
6.1 Vaccinia Virus and Hypoxia 
Wild-type Vaccinia virus has been well characterized and much of the molecular biology, 
genomic sequence, viral life cycle and immunology have been reported. Vaccinia virus has 
many inherent properties that make it an appealing candidate agent for oncolytic virotherapy. 
Vaccinia virus has a fast and efficient replication cycle with rapid cell-to-cell spread, a natural 
tropism for tumours, a strong lytic ability, large cloning capacity, is safe in humans and has 
good stability (167, 168, 215, 216). As outlined in the introduction, many tumours contain areas 
of hypoxia and these hypoxic regions contribute to the resistance of tumours to conventional 
therapy. Some oncolytic viruses have been shown to also be less effective in a hypoxic 
microenvironment. We have now demonstrated that hypoxia does not significantly affect viral 
gene expression, viral replication, cytotoxicity and it even enhances the tumour-killing activity 
in some PDAC cell lines by vaccinia virus.  
 
We have demonstrated here that the Lister strain Vaccinia virus shows comparable efficacy in 
infection, replication and transgene expression in normoxia and hypoxia. It is important to 
highlight that hypoxic cells used in these experiments had been exposed to reduced oxygen 
concentration for at least 16 hours prior to infection. This is more likely to reflect cellular 
adaptation to hypoxia and model clinical Vaccinia virus infection than shorter exposure times 
that have been used for the study of other oncolytic viruses (101, 188). In addition, we found 
that effective tumour cell lysis was maintained after infection of hypoxic PDAC cell lines and in 
half of the cell lines tested there was a statistically significant improvement in viral cytotoxicity. 
In the metastatic cell line CFPac1 and the primary tumour cell line MiaPaca2 a 3.3-fold and 23-
fold decrease in the EC50 value was seen, respectively, after 6 days of infection. This has 
implications for translational applications given that tumour lysis is the ultimate goal of 
oncolytic therapy and PDAC has been shown to contain areas of hypoxia (67). 
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Many groups have tried to target hypoxic fractions of tumours using hypoxia-specific promoters 
often containing hypoxia response elements (HRE) that facilitate HIF-1α binding and 
downstream gene transcription (176). Unfortunately such promoters are invariably less powerful 
drivers of gene expression than constitutive viral promoters and result in lower levels of gene 
expression and viral replication relative to wild-type viruses (174, 217). Our results show that 
Vaccinia virus has the capacity to infect and replicate in hypoxic tumour cells without the need 
for such approaches.  
 
Conner et al. showed that Oncolytic Vesicular Stomatitis virus (VSV) has comparable viral 
replication in normoxic HeLa cells versus those exposed to 1% O2 for 2 hours prior to infection 
and only a slight reduction of virus-induced CPE on semi-quantitative analysis (188). It is a 
welcome finding that other oncolytic viruses are not affected by oxygen availability, this differs 
from adenovirus which is a commonly used oncolytic virus and has been shown to be attenuated 
in hypoxia (101, 103). However, our results suggest a several-fold, statistically significant 
improvement, rather than non-inferiority, in the oncolytic potential of Vaccinia virus in some 
pancreatic cell lines exposed to hypoxic conditions. Conner et al concluded that their results 
suggest an advantage of RNA viruses over DNA viruses in targeting hypoxic tumour cells 
because of a greater reduction of DNA synthesis in hypoxic cells (188). Vaccinia virus is a 
double-stranded DNA virus but like VSV replicates in the cytoplasm and encodes its own 
polymerases. Therefore our findings do not support their conclusion and suggest that the 
intracellular location of the viral life cycle could be an important factor in its potential as an 
oncolytic agent. 
 
In contrast to Connor et al, Minami et al have found reduced replication of wildtype VSV in 
murine epidermal fibroblasts after exposure to hypoxia due to an increase in GADD34 (218). 
GADD34 is a cellular protein induced at times of cellular stress such as hypoxia and nutrient 
deprivation and was found to inhibit viral replication by inhibiting the mTOR pathway. 
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GADD34 was able to dephosphorylate and reverse the inhibitory effects of tuberous sclerosis 
complex 2 (TSC2) on the mTOR pathway, which regulated viral protein synthesis.  
 
We have found similar replication of wildtype Lister strain Vaccinia virus in Panc1, MiaPaca2 
and Suit2 cells in both normoxia and hypoxia. In Suit2, a permissive cell line, high titres were 
seen in both normoxia and hypoxia by 48 hours.  However, at later time points up to four fold 
higher titres were seen in normoxic conditions. Interestingly this did not affect cytotoxicity in 
this cell line suggesting that either titres of 100pfu/cell are sufficient to cause cell lysis or that 
replication is not the rate-limiting step in cell death. In MiaPaca2 cells, an increase in 
cytotoxicity was found in hypoxic conditions but no significant increase in viral replication was 
seen, further supporting the idea that other factors affect cell lysis in addition to the burden of 
intracellular virions produced. 
 
It is clear, however, that the effect of hypoxia on viral replication is specific to each virus. For 
example, in contrast to the observations for VSV, Aghi et al found that increased GADD34 in 
hypoxic conditions could significantly improve replication of the recombinant herpes simplex 
virus (HSV) G207 in the U87 glioma cell (219). This virus is deleted for the viral gamma 34.5 
protein which normally stops the inhibition of protein translation during viral infection. The 
cellular GADD34 protein compensates for the deletion of this gene and so replication of the 
recombinant virus is increased in hypoxia relative to normoxia. The replication of wildtype 
HSV is similar in normoxia and hypoxia because of the presence of the γ34.5 gene and its 
replication is significantly higher than the recombinant virus. Therefore they suggest deletion of 
γ34.5 is a reason for the improved specificity of this virus in vivo. We have found that the 
cytotoxicity of both wildtype and a TK deleted recombinant Vaccinia virus (VVL15) can be 
increased, relative to normoxia, in some cell lines when exposed to 1% oxygen and is a 
beneficial property inherent to both wildtype and recombinant viral strains.  
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Viral infection induces innate anti-viral mechanisms that inhibit cellular protein synthesis and 
limit viral replication. This is similar to the effect of hypoxia on cells, which can also inhibit 
protein translation (184). Consequently viruses that have acquired mechanisms to subvert 
cellular protein synthesis for virus production during infection may be those most adaptable to 
hypoxic conditions. For example the oncolytic parvovirus, Minute virus of mice, has been 
shown to replicate poorly in hypoxia because it is unable to counteract the shutdown of protein 
translation (220). Protein kinase R (PKR) is a cellular protein involved in the anti-viral response 
and on viral infection it phosphorylates eIF2α inhibiting protein translation. Vaccinia virus 
however has two proteins E3L and K3L which act as pseudo-substrates, inhibiting the function 
of PKR (221). In our experiments we found that viral protein production was maintained in the 
CFPac1 and MiaPaca2 cell lines exposed to hypoxia. E3L and K3L mutant Vaccinia viruses 
have been produced (222) and assessing viral replication and cytotoxicty in hypoxia using these 
viruses would show if they are important for the oncolytic efficacy of Vaccinia virus in hypoxia.  
 
This research shows the effect of 1% oxygen on Vaccinia virus replication and cytotoxicity. 
However, tumours are exposed to a range of oxygen tensions both acutely during temporary 
occlusion of the vasculature but also chronically when tumour cells are further than the 
diffusible distance of oxygen from a vessel. The effect of other forms and ranges of hypoxia on 
Vaccinia virus may be different and requires further investigation. Good transgene expression 
was seen at 0.1% oxygen using the hypoxia-targeting virus VV-ODD, suggesting that even 
lower concentrations of oxygen may not adversely affect Vaccinia virus. It is also unknown if 
the increase in cytotoxicity we have seen in hypoxia is HIF-1α dependent and further studies 
using RNAi strategies or HIF-null cells could be carried out to investigate this. 
 
We were able to show a significant increase in bioluminescence from the recombinant virus 
VVL15 in MiaPaca2 cells after 4 hours of infection. This prompted us to look for a factor that 
regulates an early stage of the Vaccinia virus life cycle that could be affected by hypoxia. We 
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found that VEGF facilitates Vaccinia virus entry, however there are likely to be other factors 
regulated by hypoxia that affect both early and later stages of the Vaccinia virus life cycle and 
may contribute to the increased cytotoxicity found in MiaPaca2 and CFPac1 cell lines. For 
example, using an RNAi approach in a Drosophila model, AMP Kinase was recently identified 
as being involved in Vaccinia virus entry through the control of actin dynamics (223). 
Previously it has been shown that hypoxia can activate AMPK (224) and this may be another 
factor increasing viral cytotoxicity in hypoxia which could be confirmed by assessing AMPK 
activity in CFPac1 and MiaPaca2 cells exposed to hypoxia.  
 
Our findings could also be relevant to others working more broadly on poxvirus biology. 
MiaPaca2 is a cell line relatively resistant to Vaccinia virus in normoxia with an EC50 of 
183.4pfu/cell but becomes 23 fold more sensitive in hypoxia. This model could be used, through 
comparative gene expression and proteomic studies, to identify other host factors that are 
involved in the Vaccinia virus life cycle. 
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6.2 VEGF Facilitates the Vaccinia Virus Life Cycle 
 
During the course of our investigation into the effect of hypoxia on Vaccinia virus we observed 
that increased cytotoxicity of the Lister strain virus was only found in those cell lines where 
there was a hypoxic induction of VEGF. Using VEGF gene silencing in Suit 2 (a cell line with a 
high endogenous VEGF level) and over expressing VEGF in MiaPaca2 (a cell line with a low 
endogenous VEGF level) we were able to show a functional relationship in PDAC cells in vitro 
and in vivo. Using these models we found that VEGF can affect Vaccinia virus replication, 
transgene expression and cytotoxicity. The cytotoxicity of Vaccinia virus was increased by 
over-expression of VEGF in MiaPaca2 cells and resulted in a 4.6 fold decrease in the EC50 
value. This is not as great as the effect seen with hypoxia indicating that VEGF is only one of 
the factors modulated by hypoxia affecting Vaccinia virus efficacy. We were also able to 
increase viral cytotoxicity by the addition of exogenous rhVEGF-165 and decrease efficacy by 
VEGF gene silencing. However, the effect of VEGF gene silencing on the cytotoxicity of the 
Lister strain Vaccinia virus in Suit2 cells, although statistically significant, was small. Suit2 is a 
permissive cell line and supports high titres of Vaccinia virus replication, this suggests that the 
effect of VEGF on viral cytotoxicity may have more relevance to those cell lines that are more 
resistant to Vaccinia virus infection. This supports our hypothesis that once viral replication 
reaches moderate titres (~100pfu/cell) the maximal level of viral replication is no longer the 
main determinant of Vaccinia virus cytotoxicity.    
 
Significantly we found that infection of MiaPaca2-VEGF-165 cells with the fLuc expressing 
virus VVL15 results in significantly higher bioluminescence at 4 hours post-infection compared 
to controls (P < 0.01). This mirrors the effect we had seen after exposure of VVL15 infected 
parental MiaPaca2 cells to hypoxia at this time point. It was apparent in our study, using both a 
quantitative PCR assay and fluorescent confocal microscopy to image internalisation of VVL-
488, that VEGF facilitates the entry of the Lister strain Vaccinia virus. We did not find any 
effect of VEGF on viral attachment to cells, mRNA transcription or EEV release.  
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The innate interferon response, Ras pathway activity and the availability of cellular nucleotides 
are three cellular factors that are involved in pox virus tropism (225). Tumours produce higher 
levels of VEGF and other pro-angiogenic cytokines than normal tissue and hypoxia is an 
important regulator of VEGF production in this context (79).We propose that VEGF is an 
additional factor that is responsible for the tropism of Vaccinia virus for tumour cells by 
increasing the rate of viral internalisation. However, Vaccinia virus enters host cells by a 
number of mechanisms and it has been shown that cell entry is influenced by the form of virus 
used (IMV vs. EEV), the cell type infected and the strain of Vaccinia virus (128, 226, 227). Our 
virus preparations are prepared from lysed, infected CV1 cells after cytopathic effect is seen and 
will be predominately composed of IMVs. We have shown that VEGF affects the tropism of the 
Lister strain virus in PDAC cells but to ascertain whether this mechanism is more widely 
applicable to Vaccinia virus as a species and other cell types will require further investigation.  
 
Primary infection with Vaccinia virus in a pathological context can occur through the 
respiratory tract. Vermeer et al have shown that EGF and the viral homologue VGF are 
important for Vaccinia infection of normal human bronchial epithelium (139).We were 
interested in whether VEGF affected Vaccinia virus infection in these non transformed cells so 
we used exogenous rhVEGF-165 to stimulate NHBE cells and found that viral replication was 
increased. This suggests that VEGF may have a wider role in the tropism of Vaccinia virus for 
different cell types. However internalisation of Vaccinia virus in NHBE cells was not directly 
analysed. Given that NHBE cells are likely to express more VEGFR1 and VEGFR2 than PDAC 
cells the mechanism may be different (193, 200).  
 
Our finding that VEGF facilitates poxvirus infection is not surprising given that a number of 
poxviruses produce homologues to VEGF. VEGF-E was first described in the Orf virus, a 
member of the poxvirus family. VEGF-E is a 25 kDa protein that forms homodimers and binds 
to VEGFR2 and NRP1 but not VEGFR1 or VEGFR3 (89). It acts as a bridging molecule 
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between VEGFR2 and NRP1, which is thought to facilitate VEGF signalling and is important in 
Orf virus pathogenesis (92, 228). Subsequently it has been found that the genomes of other 
parapoxviruses, Bovine Papular Stomatitis Virus and Pseudocowpox virus all contain VEGF 
homologues (229). In contrast, there has been no reports of VEGF homologues in Vaccinia or 
any other orthopoxviruses but it is thought that the evolution of poxviruses has predominately 
been through gain and loss of eukaryotic genes from host cells. We have demonstrated that 
VEGF is able to increase viral internalisation, although this does not discount further 
mechanisms of action. VEGF secretion induced by hypoxia can also protect pancreatic cells 
from pro-apoptotic stimuli (230). Many viruses have mechanisms to inhibit virus-induced 
apoptosis, which facilitates maximal viral replication and also allows latent viral infection to 
occur (157). Future work could involve examining the effect of VEGF on the apoptotic fraction 
of virally infected cells by Annexin V or BrdU fluorescence-activated cell sorting analysis. 
 
In vivo we were able to show that VEGF increases the bioluminescence of VVL15 in human 
xenografts in nude mice. Our group has found that bioluminescence is an effective surrogate for 
viral replication in vivo. VEGF improves Vaccinia virus replication in this mouse model, 
although viral recovery from tumours was not performed. In our mouse model of pancreatic 
cancer, VEGF may increase the rate of internalisation of Vaccinia virus as we have found in 
vitro but it also possible that it improves delivery to the tumour. VEGF increases vascular 
permeability and was originally named vascular permeability factor (73). The increased tumour 
targeting seen in vivo in this study may also be caused by better perfusion of the tumour with 
Vaccinia virus because of the more extensive vasculature which we have demonstrated in 
xenografts of MiaPaca-VEGF-165 compared to MiaPaca2-Vector Control. In addition more 
permeable tumour vasculature in VEGF-expressing stable cell lines could facilitate increased 
extravasation of this relatively large virus (200-250nm) at the site of tumours. The proportion of 
EEV re-entering the vasculature after subsequent rounds of viral replication could also be 
increased if surrounding vessels have been rendered more permeable by increased VEGF and 
would facilitate long-range spread of viral particles. We have not determined if these vessels are 
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more permeable and future work will involve the use of FITC dextran to see determine whether 
Vaccinia virus infection occurs more readily adjacent to areas of permeable vasculature in 
tumours. 
 
VEGF has traditionally been thought to act in a paracrine fashion, being produced by tumour 
cells and ligating VEGF receptors on endothelial cells, so our finding that VEGF acts directly 
on PDAC cell in vitro was unexpected. However VEGF has been found to act in an autocrine 
factor through VEGFR1 and NRP1 on breast, colorectal and pancreatic cancer cell lines and 
seems to modulate cellular chemotaxis (198, 231, 232). Although we detected relatively low 
levels of VEGFR1 and no VEGFR2 a role cannot be excluded. An RNAi approach to silence 
and VEGF receptor expression could be performed to exclude any effect on Vaccinia virus 
internalisation. This would be preferable to VEGF receptor-blocking antibodies as others have 
shown that VEGF can act in an intracrine fashion on perinuclear VEGFR1 (201).  
 
PDAC cells do express NRP1, which is a co-receptor for VEGF, which facilitates the binding of 
VEGF isoforms to VEGFR2. Previously, NRP1 was thought not to be involved directly in 
signalling, but to act as a co-receptor for VEGFR1 and VEGFR2, as it has a transmembrane but 
no intracellular domain itself (233). However, more recently it has been shown that it is a fairly 
promiscuous receptor and is involved in cell signalling by acting as a co-receptor with αVβ3 
integrin or with C-Met (234-236). Interestingly, endocytic cycling of NRP1 has been shown to 
differ depending on the ligand. Studies to date on NRP1 and endocytosis have concentrated on 
endothelial cells. Salikhovaet et al showed that Nrp1 underwent clathrin-dependent endocytosis 
in response to VEGFp165 treatment, whereas its other ligand semaphorin 3C (sema3C) induced 
lipid raft-dependent endocytosis (237). Vaccinia virus uptake has been shown to occur at the 
site of lipd rafts, suggesting that NRP1 may act as a receptor or be involved in viral uptake 
(144). NRP1 has already been implicated in the entry and pathogenesis of another virus human 
T cell leukaemia virus (HTLV) (238). In this context NRP1 forms a ternary complex with 
HTLV-Env proteins, NRP1 and the hypoxia inducible gene Glucose transporter 1 (Glut1). 
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We effectively used NRP1 gene silencing to knockdown NRP1 protein expression however, 
NRP1 gene silencing actually increased Lister strain Vaccinia virus transgene expression by 
approximately twenty percent. Class 3 semaphorin family members have been shown to inhibit 
lammelipodia formation via NRP1, which can be blocked by heparin-binding forms of VEGF 
(239-241). It is tempting to speculate that VEGF may alter the balance of signalling via NRP1 
with other ligands, semaphorins and plexins, resulting in a change in actin dynamics that favour 
virus internalisation. The possibility that NRP1 acts as a receptor or co-receptor for Vaccinia 
virus appears unlikely given our results but needs to be formally excluded by looking for NRP1 
and Vaccinia virus co-localisation using fluorescent confocal microscopy. Investigating the role 
of class 3 semaphorins on Vaccinia virus infectivity could be performed, by overexpressing and 
silencing NRP1, in a similar manner to the viral assays described here for VEGF. This offers an 
intriguing possibility to augment Vaccinia virus potency as strategies to augments VEGF 
activity are unlikely to be approved by new drug regulatory agents whereas blocking of 
semaphorin activity prior to Vaccinia virus may be more acceptable. 
 
VEGF may act via a non-receptor mediated effect as it interacts with cell surface GAGs via its 
heparin binding domain and alter their distribution or availability at the cell surface. GAGs have 
been implicated in Vaccinia virus pathogenesis and virus infectivity can be partially blocked by 
heparin and heparan sulphate (125, 227). One hypothesis could be that VEGF is able to bind 
heparin and heparans on the cell surface and block the inhibitory effects of GAGs on Vaccinia 
virus entry, thereby augmenting Vaccinia virus infectivity via a non signalling-dependent 
mechanism. We have confirmed that GAGs inhibit Lister strain infectivity (data not shown) but 
have been unable to use GAGs reproducibly in the internalisation assays outlined in this thesis 
to confirm if they antagonise the effects of VEGF. Further work to establish an assay to test this 
contention could use a self-quenching rhodamine B-labelled Vaccinia virus, a potentially more 
sensitive tool, to assess the interaction of GAGs and VEGF on virus membrane fusion with 
target cells ((242) & personal communication B Moss). 
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Akt is a central protein involved in actin dynamics, which acts downstream of NRP1, VEGFR2 
and VEGFR1 (78, 243). Akt has recently been described as an important determinate of the 
susceptibility to infection by myxoma virus, a member of the Leporipoxvirus genus of 
poxviruses (158). Although we have been unable to clarify the receptor implicated in the effect 
of VEGF on Vaccinia virus internalisation, we have shown that Akt phosphorylation does affect 
Vaccinia virus infection. Inhibition of Akt reduces Vaccinia virus internalisation, transgene 
expression and cytotoxicity in a dose-dependent manner. Others have shown that Akt is 
phosphorylated early during Vaccinia virus infection and is also involved in later stages of the 
viral life cycle (159, 204). In addition we also show that Akt inhibition reduces VEGF 
production in the context of viral infection and may also affect the internalisation of Vaccinia 
virus in this manner. 
 
During the course of the project, data have been published suggesting that one of the forms of 
cell entry used by Vaccinia virus is fluid phase endocytosis or macropinocytosis (146). Whether 
VEGF affects this mode of cell entry either by stimulating VEGF signalling pathway, acting as 
a scaffold for Vaccinia internalisation complex or reducing the inhibitory effect of GAGs is not 
clear. Mercer et al have shown that the Western Reserve (WR) strain Vaccinia virus induced 
membrane blebbing and the IHD-J strain induces filiopodia formation. They are both sensitive 
to inhibitors of actin polymerization and depolymerization (cytochalasin D and jasplakinolide) 
and myosin II (blebbistatin) but have different sensitivities to the effect of pH or GAGs on virus 
entry (226). Unlike WR IMVs, infection by IHD-J IMVs was not inhibited by genistein 
(tyrosine kinase inhibitor), nor by wortmannin (PI(3)-kinase inhibitor). Given these differences 
between strains, a full screen of inhibitors on the entry of the Lister strain Vaccinia virus needs 
to be performed to ascertain which mode of cell entry VEGF affects. Inhibitors of 
macropinocytosis, kinases and inhibitors of actin polymerization and depolymerisation could be 
used in an initial screen and then validated with siRNA gene silencing or transfection with 
dominant-negative proteins. Arginine rich cell penetrating peptides, originally identified from 
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the HIV tat protein, and now Vaccinia virus has been shown to use macropinocytosis as a mode 
of cell entry (244). Teesalu et al recently showed that the arginine-containing C-terminal of 
VEGF, which is not by definition arginine-rich, is important for cellular internalisation of NRP1 
(245) and raises the possibility of a role for VEGF in macropinocytosis. 
 
The results from this study to date are firstly that hypoxia does not significantly affect the 
efficacy of oncolytic Vaccinia virus. Furthermore, this study has highlighted a wider role for 
VEGF in the tropism of Vaccinia virus. These results are useful for the field of Vaccinia virus 
oncolytic therapy but may also have implication of Vaccinia virus based cancer vaccines and 
more general poxvirus pathogenesis. Although it has been demonstrated that increased 
internalisation of viral particles occurs in the presence of VEGF and that Akt inhibition can 
reverse this, the mode of internalisation and the signalling pathway through which it acts is 
unclear and requires further investigation. 
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6.3 The Hypoxia-Targeting Oncolytic Virus VV-ODD 
 
This section outlines the structure and function of a novel hypoxia-targeting oncolytic Vaccinia 
virus. Other viral vectors have been constructed to target hypoxia using a hypoxia-responsive 
adenovirus for cancer therapy with a hypoxia-responsive adeno-associated virus for 
cardiovascular disease (176, 246). However, both these approaches utilise an HRE to drive 
expression in hypoxia. The use of an HRE results in a significantly reduced gene expression 
compared to endogenous viral promoters and because of Vaccinia‟s reliance on viral 
polymerases cannot be used in this vector. To produce VV-ODD, a construct was designed that 
incorporated three levels of hypoxic regulation; transcriptional regulation using the VEGF 
3‟UTR, translational regulation using an IRES sequence and post-translational regulation using 
the HIF-1α ODD. 
 
A bicistronic vector system was used to compare the function of the EMCV IRES and the 
VEGF 5‟UTR on transgene expression, in normoxia and hypoxia, using a CAT and luciferase 
reporter assay. Contrary to published reports, we found limited evidence that the 5 „UTR of the 
VEGFA gene functioned as an IRES sequence. There was a less than a two-fold difference 
between the fLuc/CAT ratio containing the VEGF 5‟UTR and the control vector in both 
normoxia and hypoxia. Given that eukaryotic promoters would not drive a transgene located in 
the Vaccinia virus genome our results further suggest that the predominant feature of the 5‟ 
UTR is a cryptic promoter rather than an IRES. Our findings also support the more extensive 
report by Bert et al that shows the VEGF 5‟UTR contains a cryptic promoter and has only 
minimal function as an IRES sequence in comparison the EMCV IRES (247). The EMCV IRES 
clearly functions as an IRES sequence in the context of viral infection using a T7 polymerase 
expressing Vaccinia virus to drive reporter gene expression. In the permissive PDAC cell line 
Suit2, there is an 84% increase in hypoxia of protein translation from the IRES compared to 
normoxia. Consequently the EMCV IRES was selected as the IRES sequence for VV-ODD.  
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When the bioluminescence from VV-ODD was compared to that of VVL15 there was a 30-fold 
decrease in bioluminescent signal using our virus. VVL15 contains an unmodified firefly 
luciferase reporter gene driven directly from the Vaccinia virus promoter with no intervening 
IRES sequence. It is unclear from our results if the decrease observed was caused by reduced 
enzymatic activity of the luciferase ODD fusion protein or reduced protein translation from the 
IRES in comparison to 5‟ methyl cap-dependent translation. Simple plasmid vector studies 
could be performed to compare the enzymatic activity of a modified versus unmodified 
luciferase protein. This highlights that the functionality of all new transgenes after being fused 
to the ODD will need to be reassessed versus control to demonstrate there is still sufficient 
biological efficacy. Future work will incorporate an amino acid spacer in between transgenes 
and the ODD as this has been demonstrated to preserve the biological function of fusion 
proteins (248).  
 
It is equally as likely that the IRES, although functioning well in hypoxia, may not be sufficient 
for sufficient transcription of downstream genes. Our lab and others have found that the 
downstream sequence appears to be significantly more poorly expressed compared to the 
upstream sequence (249). Although IRES sequences allow the expression of multiple 
transgenes, in this context where highly efficient transgene expression is required, it does not 
add value in our vector design. The shuttle vector for this virus has been designed so that this 
sequence can be easily removed, making production of future generations of VV-ODD without 
an IRES sequence straightforward.  
 
VV-ODD was used to infect two PDAC cell lines and HeLa cells to see if the concept of a 
hypoxia-targeting virus was feasible. We have demonstrated, using a reporter gene assay, that in 
all cell lines tested we are able to show a virus dose, time and oxygen-dependent effect. 
Significantly more luciferase expression is seen in cells infected with VV-ODD exposed to 
hypoxia at 24-72 hours post-infection and at MOIs from 0.1 – 5.0 pfu/cell. We have shown that 
the function of this construct mirrors the kinetics of HIF-1 when exposed to different oxygen 
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concentrations. Significantly more luciferase expression was seen at 0.1% oxygen versus 5.0% 
oxygen using VV-ODD. In the absence of a closed system for manipulation of cells in hypoxia, 
DMOG was used to inhibit PHD enzymes and stabilise the Luciferase-ODD fusion protein for 
Western blotting. We were able to demonstrate a dose-range effect with increasing 
concentrations on DMOG (0.01-1.0 mM) causing stabilisation of both HIF-1α and the 
Luciferase-ODD fusion protein. Using our reporter gene assay we were also able to show that 
another hypoxia mimetic (CoCl2) and an inhibitor of proteasomal degradation (MG132) are able 
to increase bioluminescence from VV-ODD. In summary, we have shown through the use of 
different oxygen concentrations, hypoxia mimetics and inhibitors of HIF-1α degradation that the 
principle of our hypoxia-targeting Vaccinia virus is valid.  
 
Our construct also contains a 3‟UTR that has been reported to increase mRNA stability (209). 
We have used the smallest AU-rich region from the UTR in our construct but have not formally 
tested the contribution of this to our results. Future work will assess the requirement for this 
sequence by constructing reporter constructs expressing luciferase with or without the VEGF 
3‟UTR under the control of a Vaccinia virus promoter. Co infection/transfection studies with 
such reporter plasmids and the wildtype Lister strain Vaccinia virus in cells exposed to 
hypoxia/normoxia, both with and without an inhibitor of transcription (actinomycin D) would 
quantify the requirement for this sequence in future generations of viruses. 
 
I have outlined above how the requirements for the IRES sequence and 3‟UTR in future 
constructs will be assessed and subsequently modified. However, there maybe additional 
modifications that need to be introduced. Firstly our Vaccinia virus constructs contain two viral 
early termination sequences. These are strings of nucleotides (TTTTTNT) that signal 
termination of mRNA transcription by the Vaccinia virus ternary polymerase complexes when 
driven from an early promoter of Vaccinia virus (250). Two such sequences are present in our 
construct in the ODD sequence and the 3‟UTR. Point mutations are possible that will remove 
these features without affecting the function of either sequence. Currently it is possible that 
Chapter 6 
201 
 
truncated fusions proteins are produced when transcription is driven from the early promoter. 
This means that a fraction of the luciferase reporter protein produced on infection with VV-
ODD is not regulate by hypoxia and may result in increased baseline bioluminescence. 
Removing these early termination sequences may reduce any “leak” in this system and help 
improve specificity.  
 
Recently it has been found the stabilisation of HIF-1α can also be caused by S-nitrosylation at 
Cysteine 533, independent of conventional hydroxylation by PHD enzymes (251). Li et al 
demonstrated that tumour-associated macrophages, after tumour irradiation, were a source of 
nitric oxide (NO) that stabilised HIF-1α in normoxia. This would be undesirable for our 
hypoxia-targeting virus and NO production is likely in the context of viral infection in vivo. In 
line with Li et al we have mutated the Cysteine to Serine in our fusion protein shuttle plasmid 
so that future generations of viruses would not be susceptible to this form of stabilisation. This 
is an important modification to make before any in vivo experiments are performed. In vivo 
experiments using systemically delivered VV-ODD and then luciferase imaging after 
hydralazine administration or carbogen inhalation to induce or reverse tumour hypoxia 
respectively will be required to validate the concept in vivo (252). 
 
Although we have constructed a virus that is effectively able to target transgene expression to 
hypoxia it will also result in transgene expression in systems where the pathways for HIF-1α 
proteasomal degradation are disrupted. Such examples include loss of the VHL protein or PHD 
enzyme function. These mutations are often associated with malignancy and the loss of VHL is 
central to the pathogenesis of clear cell renal cell carcinoma (253). This system is unlikely to 
result in complete loss of transgene expression in normoxia and will increase the function of the 
transgene in hypoxia. Complete loss of transgene expression in normoxic cancer cells is 
undesirable and we anticipate that a combination of this construct and the dose delivered will 
result in a balance that will improve specificity and may reduce toxicity in translation 
applications. 
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A hypoxia-targeting virus would be a useful tool in the development of a clinically feasible 
oncolytic Vaccinia virus therapy. As initial clinical trial results show evidence of biological 
efficacy using replication-competent Vaccinia viruses, future generations of viruses will contain 
transgenes to improve efficacy. The principle, as demonstrated by VV-ODD, could be applied 
in several ways. Firstly, to create a conditionally replicating Vaccinia virus by applying this 
principle to a critical viral protein such as the viral ribonulceotide reductase (254). 
Alternatively, the luciferase reporter gene in VV-ODD could be replaced by a therapeutic 
transgene. Pro-drug converting enzymes such as NADPH:cytochrome P450 reductase are 
important in activating the bioreductive chemotherapy tirapazamine. Attempts to use adenovirus 
to target hypoxia in such a gene therapy approach have shown some specificity but limited 
efficacy (255) presumably as adenovirus replicate poorly in hypoxia. In contrast he VV-ODD 
concept could be used to deliver high levels of NADPH:cytochrome P450 reductase to hypoxic 
tumours. Hypoxia reduces the sensitivity of cells to radiotherapy and we are interested in using 
this concept to restore radiosensitivity to hypoxic tumours. Given the proximity of major vessels 
and other organs to the pancreas, the radiation doses delivered to patients with locally advanced 
PDAC are limited to 40-50Gy. Other tumour types, such as head & neck and prostate cancer, 
have shown significant responses when doses of radiation reach 80Gy. Even with more targeted 
delivery such as intensity-modulated radiotherapy (IMRT) and stereotactic radiotherapy, doses 
are still limited, as is access to this technology. Using the VV-ODD concept, transgene delivery 
specifically to tumour cells may allow us to restore radiosensitivity by augmenting cell death 
pathways or by restoring the oxygen enhancement ratio.  
 
Hypoxia may be an important problem for viral therapy but offers possibilities to improve 
specificity (185). I have outlined the principle and demonstrated the function of the hypoxia-
targeting virus VV-ODD. This could be used in many ways to treat the hypoxic component of 
pancreatic cancer and other tumour types with hypoxic regions although, like other oncolytic 
viruses, treatment is still limited by the ability to reach tumours. However, given the advantages 
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of Vaccinia virus for systemic delivery we believe that the concept of VV-ODD will be useful 
in the development of a clinically relevant oncolytic viral therapy. 
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